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Abstract 
 
 
Background 
Elevated blood pressure (BP) and body mass index (BMI) are associated with abnormalities of 
cardiac structure and dysfunction in cross-sectional studies. However the consequence of 
elevated BP and BMI over the adult life course on cardiac structure and function is unknown.  
 
Methods 
Participants in the Medical Research Council National Survey of Health and Development 
(MRC NSHD) 1946 birth cohort (n=1653) underwent investigations including 
echocardiography and BP and BMI measurement at age 60-64y. BP had been measured 
previously at ages 36, 43 and 53y and BMI had previously been measured at ages 20, 26, 36, 
43 and 53y. The relationships between BP, treatment for hypertension (HTT) and BMI and 
echocardiographic determinants of cardiac structure and function at age 60-64y were 
investigated. 
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Results 
Increased BP from age 36y onwards was associated with increased left ventricular mass index 
(LVMI) and poorer diastolic function (E/e’). This was independent of BP at age 60-64y for BP 
measured at age 53y. Faster rises of BP across mid-life were associated with greater increases 
in LVMI and E/e’. HTT was associated with increased LVMI and E/e’ after adjustment for BP 
at age 60-64y. Associations with systolic function were inconsistent.  
Increased BMI and overweight from the age of 20y onwards was associated with increased 
LVMI and poorer diastolic function. On including BMI/overweight at ages 60-64y, the 
associations remained for some ages (e.g. for ages 26y and 43y for LVMI and from age 36y 
onwards for E/e’). Earlier age at first detection of overweight was associated with increased 
LVMI and diastolic dysfunction. Associations with systolic function were inconsistent. 
 
Conclusions 
Increased adult life course BP and BMI are associated with increased LVMI and diastolic 
dysfunction. Increased rate of change in BP is associated with detrimental effects to cardiac 
structure and function as is HTT. Earlier age of first detection of overweight is associated with 
increased LVMI and diastolic dysfunction. Earlier interventions to prevent rapid rises in BP 
and the development of obesity may be key in preventing future abnormalities in cardiac 
structure and function.  
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Chapter 1 
Introduction  
 
Life course epidemiology 
 
The life course approach 
A life course approach to epidemiology investigates long-term biological, behavioural and 
psychosocial processes that link adult health and disease risk to physical and social exposures 
occurring in gestation, childhood, adolescence, earlier in adulthood or across generations.1 
The life course approach has been extensively used in epidemiology and has helped in the 
examination of biologic, genetic, social, and environmental determinants of health across the 
life course, leading to landmark insights into the relationship of early life  (e.g. fetal 
development2 or childhood socioeconomic position3) and later adult disease. 
Recently some studies have employed a life course perspective to understand the early life 
determinants of cardiovascular disease. In particular, there has been a recent focus on 
applying life course methodology to blood pressure and its effects on future cardiovascular 
disease.4-7  
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History of the life course approach 
Although the term “life course epidemiology” was coined in 1997, the idea that events 
occurring over the life course have effects in later life has been prevalent in the world of 
medicine for some time.8 
In the 19th century the major focus was on infectious diseases which contributed significantly 
to mortality, especially mortality in children.9  Towards the beginning of the 20th century there 
was a growing shift in emphasis onto early life influences on adult public health.10 This trend 
affected public health policies on both sides of the Atlantic with the development of health 
services specifically targeted to the well-being of babies and children.11 
A lot of work was carried out in the first half of the 20th century with the aim of studying 
growth and development; and pioneering work was carried out in the 1920’s on what we 
would now recognise as the critical or sensitive period hypothesis. Work done on animals led 
to the formulation of a theory that there were critical periods in development during which 
exposures to deleterious agents had more of an influence than at other less-critical times.12  
In the 1930s, a series of child health and nutrition studies were undertaken which looked at 
another mechanism of life course epidemiology – the accumulation hypothesis.13, 14 This 
hypothesis postulates that the accumulation of deleterious environmental influences in 
childhood rather than exposures at critical periods could affect adult health. 
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Following World War 2, the accumulation hypotheses found more supporters. World War 2 
army recruits were investigated to show that the accumulation of insults to health, starting 
in infancy, had an effect on adult health.15  
However, post World War 2 there was also a shift in thinking away from trying to modify the 
early-life environment for better adult health. This was a consequence of a perception arising 
in the 1930s that in spite of improving child health, adult death rates had not fallen.16 This 
shift in emphasis accelerated from the 1950s onwards with adult cohort studies which 
identified the risks to health associated with a multitude of factors which we would today 
class as classic cardiovascular risk factors (cigarette smoking, obesity, high blood pressure, 
high cholesterol and physical inactivity). Two such studies which have played major role in 
our understanding of adult cardiovascular risk were the Framingham cohort studies and Doll 
and Hill’s study on UK doctors linking smoking to cardiovascular disease and lung cancer.17, 18 
Another war led to a rekindling of interest in the possible childhood or early adulthood origins 
of cardiovascular diseases which were, at that time thought to be diseases of mid and late 
adult life. Autopsies of young soldiers killed in the Korean War demonstrated the presence of 
coronary atherosclerosis, till then thought to be a disease of middle-aged and elderly men.19  
Subsequent studies, notably the Pathobiological Determinants of Atherosclerosis in Youth 
study emphasized the early origins of fatty streaks and atherosclerosis20 and the life course 
approach came to the forefront again in the 1990s with what is often termed the Barker 
hypothesis. Barker investigated the role of in-utero factors on adult heart disease leading to 
his seminal fetal origins of coronary disease paper in 1995.2 This was followed by a number 
of studies linking both fetal (under-nutrition) and childhood (nutritional and socioeconomic 
status) characteristics with later adult cardiovascular disease.21-24 The role of childhood 
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obesity with increased incidence of later metabolic syndrome and increased premature 
cardiovascular death was also explored at this time.25  
Since the introduction of the term “life course epidemiology” in 1997,8 there has been an 
expansion of the context in which the life course approach has been used both in terms of its 
application in age groups other than the fetal period and in terms of diseases other than 
cardiovascular disease. An illustrative example in respiratory disease is shown in Figure 1.1. 
 
 
Figure 1.1. Life course model depicting life course effects on adult lung disease (after Kuh 
et al).1  
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There has been a general move towards placing chronic disease aetiologies within a life 
course framework with the World Health Organization recommending it in its non-
communicable disease and health promotion programme.27 The life course approach has 
expanded to use in the study of musculoskeletal function, health behaviours, reproductive 
health and the development of certain cancers.28-30  
Very recently there has been a resurgence of interest in investigating the effect of risk factor 
changes over time (i.e. risk factor history) on subsequent cardiovascular disease with studies 
estimating the impact of changes in risk factors in mid-life on cardiovascular outcomes in late 
adulthood.4-7 These studies have again brought to the fore the utility of the life course 
approach by providing evidence that elevated blood pressure at various stages in earlier life 
is associated with future cardiovascular morbidity and mortality in older age. However, what 
must be remembered when modelling risk factors across the life course, is that these risk 
factor trajectories can have their own life course predictors,1 something that I will expand 
upon in the next few sections.   
 
 
 
Life course and cardiovascular risk factors 
Using a life course approach to understand the effects of cardiovascular risk factors would 
seem to be a logical thing to do. Identifying deleterious trends early may help prevent future 
morbidity and mortality and using a life course approach could lead to the discovery of 
sensitive time periods where intervention is likely to be most effective. A life course approach 
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to cardiovascular risk factors has been used in the literature which I will now discuss in more 
detail, focusing particularly on blood pressure and body mass index/being overweight.   
 
 
Life course and blood pressure  
The life course approach to adult blood pressure has most widely been applied to 
investigating the influence of fetal growth and childhood growth on later adult blood 
pressure. There have been fewer studies that have looked longitudinally at the effect of other 
risk factors on later adult blood pressure.  
The fetal origins hypothesis introduced the concept that low birth weight was associated with 
higher blood pressure later in life. There was a proliferation of studies after that reaffirming 
the relationship (see Huxley et al31 for a systematic review), although there were also 
dissenters.24 Even when the effects of a variety of possible confounders e.g. social class,32 
alcohol intake,33 maternal age34 and maternal blood pressure35 were taken into account, birth 
weight was shown in the majority of studies to have an independent relationship with adult 
blood pressure.  
The exact mechanisms and causal pathway through which birth weight affects adult blood 
pressure have not been fully elucidated. Animal models have demonstrated that exposure to 
various environmental or nutritional factors during a sensitive period in early life can cause 
permanent defects at maturity (e.g. transient immunization of neonatal rats against growth 
hormone releasing factor results in permanent impairment of growth hormone secretion and 
thus growth rate)36 and it has been postulated by Harding37 that low birth weight may reflect 
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fetal under-nutrition which may cause permanent fundamental structural and physiological 
changes. These then become manifest in adulthood in the form of hypertension, insulin 
resistance, and increased predisposition to cardiovascular mortality. The role of maternal 
nutritional status may also need to be taken into account in relation to some adult chronic 
diseases, although it may not have a major role to play in adult blood pressure.38, 39 It remains 
unclear whether poor maternal nutritional status acts by directly reducing fetal growth or 
through another mechanism.40, 41 
The role of later growth in childhood on adult blood pressure has also been examined, to 
determine if there is a critical or sensitive period during growth in childhood that leads to 
elevated blood pressure in later adult life, with it being shown that weight at 1 year of age is 
not a predictor of adult blood pressure if current weight is known.42 Some have argued that 
rather than poor fetal growth, a period of “catch-up growth” in infancy and early childhood is 
more detrimental and increases the risk of future type 2 diabetes mellitus and obesity.41, 43, 
44 Whether catch-up growth can predict adult blood pressure has also been tested with no 
association being demonstrated.45 Poor childhood growth may be associated with raised 
adult blood pressure, although this may be due to related nutritional and socioeconomic 
issues.46 
Although childhood and early adulthood weight has been shown to predict blood pressure in 
mid-life, earlier childhood weight does not seem to have an additional predictive value when 
current adult weight is known.47 One of the difficulties in determining if childhood or early 
adult weight has a predictive value over and above later adult weight is the phenomenon of 
“tracking” which describes the relative stability of a certain characteristic over time.48 This 
means that those individuals with a higher blood pressure than the population mean at a 
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younger age are likely to continue along that blood pressure trajectory such that at an older 
age they would have higher blood pressures compared to the population mean at that later 
age.49-51 The same concept is applicable to BMI as well with obese children more likely to 
become obese adults.52 Due to tracking, it is very difficult to determine in observational 
studies if earlier measures of a risk factor (e.g. blood pressure) independently influence future 
disease or whether their influence is mediated through being on a faster-rising risk factor 
trajectory compared to the population mean i.e. tracking.  
The life course approach to blood pressure risk factors has been applied sparingly to older 
adults, but when it has (investigating the effect of BMI across life on blood pressure at age 
45y), there has been a positive association.53   
 
Life course and being overweight/obesity 
Cardiovascular disease has been in decline since the 1960s in the USA and other parts of the 
developed world although there is some evidence that this decline is slowing if not 
reversing.54 However, rising levels of obesity in both developed and developing countries has 
led to an “obesity epidemic”55 with childhood obesity tripling over the last 30 years in the 
USA.56 As a result, it has been suggested that there is likely to be a rise in deaths due to 
cardiovascular diseases.57 
Applying a life course approach to obesity could be beneficial as it might allow targeted 
intervention at an appropriate stage. Alternatively, since once an individual becomes obese, 
it is very difficult to achieve permanent weight reduction, it could consequently be argued 
that measures to prevent obesity need to be implemented as early as possible.58, 59 Identifying 
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a sensitive or critical period early on in childhood could help focus timings of interventions to 
check the increasing trend in obesity.  
Many studies have investigated the association between birth weight and adult body mass 
index (BMI), showing a positive relationship.60-63 The reasons are unclear, although proposed 
explanations range from increased fetal nutrition to hyperinsulinaemia.64, 65 However studies 
looking at maternal under-nutrition and future adult body mass index have shown conflicting 
results with some studies showing an association between maternal under-nutrition and 
adult obesity,66 while others have not shown such associations.67 
The associations of weight in childhood and adolescence and later adult BMI are complex due 
to a number of possible confounding factors. Breast-feeding and catch-up growth appear to 
have a role. Breast-fed infants are less likely to be obese while those with rapid catch-up 
growth go on to develop increased BMI.68, 69 The role of tracking has to be taken into account 
as described earlier.  
 
 
 
 
Life course methodology 
Life course methodology is complex and has evolved (and continues to evolve) with time.70, 
71 The influence of risk factors across the life course is generally viewed in terms of either 
“sensitive periods” or “accumulation of injuries”. The sensitive period approach has also been 
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referred to as “biological programing” or a “latency model approach”.72, 73 This approach has 
formed the basis of the fetal origins approach described earlier.2 The accumulation hypothesis 
looks at the cumulative effect of a long-standing burden of exposure to a risk factor – longer 
exposure is likely to be worse although there may be a plateau in effect after a certain level 
of exposure has been reached.26, 74, 75 The accumulation of exposure to risk factors can occur 
independently or they can be clustered (accumulation model with risk clustering) (Figure 
1.2).26  
 
Figure 1.2. Life course accumulation models. Model (a) depicting accumulation of 
exposures over time to several risk factors; model (b) showing an accumulation model 
with risk factor clustering (after Kuh et al).26 
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The complexities inherent in teasing out effects of a risk factor recorded at multiple time 
points has led to a variety of statistical approaches – starting off with simple linear regressions 
of a risk factor with an outcome some years down the line, to more sophisticated models e.g. 
area under the curve or investigating the effect of different rates of change (trajectories) in 
risk factors.26, 76, 77 The methods relevant to this thesis are described in more detail in the 
methods chapter (chapter 3).  
 
Another important limitation of life course studies is the number of study members lost to 
follow up; this number of course increases the greater the duration of the study. Some of the 
loss is due to death and ill health (precluding participation) and it is possible that as such the 
analysis is biased towards healthier individuals – the so called immortal time bias.78 However 
it is likely that a differential loss of participants is likely to bias to null especially given the 
characteristics of those attending clinic79 and the fact that those with high (and low) BMIs in 
our study had increased mortality risk.80 
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Echocardiography 
 
The history of echocardiography 
Echocardiography is the ultrasound examination of the heart. The first ultrasound assessment 
of cardiac anatomy was made nearly 60 years ago by Elder and Hertz in Sweden in 1954.81 In 
the 1960s Joyner and Reid carried out an anatomical and physiological cardiac examination,82 
while a pericardial effusion was detected on ultrasonography by Feigenbaum in the mid-
sixties.83 Echocardiographic techniques have advanced with time with each new technique 
being rapidly applied in clinical practice. Initially confined to M-mode, echocardiography 
evolved to incorporate 2-dimensional (2-D) scanning in the 1970s84 followed by the clinical 
use of Doppler echocardiography towards the end of that decade.85, 86 The 1980s saw the 
introduction of a number of new techniques, namely colour flow imaging,87 tissue Doppler 
imaging88 and trans-oesophageal echocardiography.89 More recently we have had strain90 
and 3-D echocardiography91, 92 along with the introduction of hand-held ultra-portable 
ultrasound machines.93 
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Echocardiographic techniques – the physics of echocardiography 
Basic Physics 
Echocardiography utilizes ultrasound waves which are acoustic (sound) waves with a 
frequency of more than 20000 Hertz. Sound waves can be defined by seven characteristics 
(Figure 1.3) –  
Frequency – the number of cycles per second (1 cycle/second = 1 Hertz – 1 Hz) 
Period – the time taken to complete 1 vibration cycle; period = 1/frequency. Period is usually 
measured in seconds.  
Wavelength – the length of one complete cycle (measured in mm or cm or m) 
Velocity – the velocity of a wave through a medium is equal to                             frequency X 
wavelength. The average velocity of sound waves in soft tissue is 1540 m/sec. 
Amplitude – the maximum deviation of the wave from the cycle mean position. It is usually 
measured in centimetres or metres. 
Power – the rate at which energy is transferred by the wave measured in Watts (W). 
Intensity – the power density of the wave derived by calculating                         Power/Cross-
sectional Area. It is measured in W/m2. 
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Figure 1.3. Physics of an ultrasound wave 
 
Ultrasound imaging 
Echocardiography is carried out using a transducer which produces and detects ultrasound 
waves (Figure 1.4). Transducers consist of piezoelectric crystals with modern transducers 
containing up to 3000 separate elements. When an alternating current is applied across the 
crystals they deform and vibrate. These vibrations give rise to the ultrasound waves by 
causing intermittent compression and expansion (aka rarefaction) of the transmitting 
medium media (gel, tissue, blood etc.). The conversion of electrical energy to mechanical 
energy in this way is called the “piezoelectric effect”. Since crystals cannot transmit and 
receive simultaneously, the electrical energy is applied in brief repeated pulses to each crystal 
in the transducer (transmission mode) and the frequency of these pulses is termed the pulse-
repetition frequency (PRF). The transmission of an ultrasound wave depends on the acoustic 
impedance of the transmitting medium. When the wave meets a change in impedance (e.g. 
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due to a change in material density) some of the energy is reflected and returns to the crystals. 
On receipt of the reflected wave, mechanical energy is converted into electrical energy by the 
transducer when it is in ‘listening’ mode. By measuring the time between when the 
ultrasound wave was sent and received, the depth of the interface giving rise to the 
impedance mismatch, can be estimated and an image built up.  
 
 
 
Figure 1.4. A typical transducer.94 
 
In clinical practice, the transducer frequency for trans-thoracic echocardiography is typically 
between 2 to 2.5MHz (a higher frequency produces better resolution but has a shallower 
depth of penetration). Fundamental and harmonic imaging are two types of imaging that 
depend on the frequency of the reflected waves sent to the transducer. In fundamental 
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imaging the waves sent and received by the transducer are of the same frequency, whereas 
in harmonic imaging the frequencies of reflected waves are multiples (harmonics) of the initial 
wave. Harmonic imaging results in better delineation of tissue interfaces such as the 
endocardial border of the heart.  
 
Doppler echocardiography 
Christian Doppler first described the Doppler principle in 1842 in a paper that he presented 
in Prague before the Royal Bohemian Society of Sciences entitled "Über das farbige Licht der 
Doppelsterne” (Concerning the coloured light of the double stars and certain other stars of 
the heavens).95-97 He explained that the pitch (analogous to frequency) of a sound was 
affected by motion – with the pitch rising with motion towards the listener and decreasing 
with movement away (Figure 1.5). 
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Figure 1.5. Cartoon illustrating the Doppler principle 
(After Engineering Toolbox.com and The Physics Classroom)98, 99 
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This principle is applied in echocardiography when interrogating the interaction between 
ultrasound waves and moving red blood cells (i.e. blood flow in the heart) or moving tissue 
(Tissue Doppler). The Doppler shift is the change in frequency due to motion of the reflecting 
material away or towards the transducer.100 Mathematically, the relationship of the 
frequency shift (∆F) and velocity of the moving object or interface can be determined.  
 
∆𝐹 =  
2 × 𝐹0 × 𝑣 × 𝑐𝑜𝑠 𝜃
𝑐
  
 
where F0 is the emitted frequency, v is the velocity of movement of blood towards the 
transducer, c is the velocity of sound in the medium and 𝜃 is the angle between the 
interrogating beam and blood flow (Figure 1.6). 
This dependence on cos 𝜃 means that for practical purposes the angle (termed the “Doppler 
angle”) between the interrogating beam and the blood flow must be as close to zero as 
possible. Usually, in the aorta angles <20⁰ can be achieved,101  elsewhere (e.g. the carotid 
artery) angles <60⁰ may be considered acceptable.  
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Figure 1.6. Cartoon of Doppler interrogation of blood flow through the aorta (Ft, 
frequency of ultrasound emitted by probe; Fs, frequency of reflected ultrasound; LV, left 
ventricle; LA, left atrium; ϴ, the angle between the interrogating beam and blood flow)              
(After Kapadia et al.)102 
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There are five clinically relevant Doppler techniques – pulsed wave Doppler, continuous wave 
Doppler, colour flow imaging, tissue Doppler and power Doppler imaging.  
 
Pulsed wave Doppler 
Short bursts (pulses) of ultrasound are transmitted into the body. While targets at multiple 
points along the beam may reflect the transmitted ultrasound pulses, the probe “listens” only 
for a brief, fixed interval after transmission of the pulse. As a result, only signals from a specific 
distance are received and analysed resulting in “range resolution”. Different ranges or depths 
can be evaluated by changing the interval between transmission of the pulse and reception 
of the reflected wave. A technical limitation of the pulsed Doppler technique is the maximum 
velocity that can be accurately resolved.103 To accurately represent a frequency it must be 
sampled using a PRF at twice the frequency of interest. This is termed the Nyquist limit; 
frequencies above this limit cannot be characterised correctly as they undergo aliasing. With 
aliasing, blood flow is represented both above and below the baseline, i.e. seemingly both 
moving towards and away from the transducer. The upper limit of the frequency that can be 
detected by a given pulse is the Nyquist limit (fDOP) and it is defined as half of the PRF - the 
number of pulses that can be transmitted from the transducer in 1 second):  
𝑓𝐷𝑂𝑃 =
𝑃𝑅𝐹
2
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Continuous wave Doppler 
Instead of sending out pulses, in continuous wave Doppler there is a continuous transmission 
and reception of ultrasound signals. There are 2 technologies that can achieve this – some 
transducers have 2 distinct elements: one for transmission and one for reception; other 
transducers have phased array technology where one crystal is used for transmitting and the 
other simultaneously for receiving. Due to the lack of pulses in continuous wave Doppler, 
range resolution is not possible and thus it is impossible to know from where along the sample 
beam any recorded velocity signal arises. However, one of the advantages of continuous wave 
Doppler is that it does not suffer from aliasing.  
 
Colour Flow Imaging 
Colour flow imaging utilises pulsed wave Doppler techniques superimposed on a 2-
dimensional or M-mode template.104 Each pixel in the colour flow image represents a region 
of interest in which flow characteristics have to be measured. However doing an exhaustive 
velocity spectrum analysis for each pixel would be time consuming and as such only mean 
frequencies and variance (frequency spread) are calculated. For each pixel, the strength of 
the returning echo is calculated and it is painted a shade of grey based on pre-determined 
velocity thresholds. With repetitive sampling an average velocity and variance are calculated. 
A colour-reject threshold is used to display velocities above the threshold in colour, with the 
brightness of the colour depending on the magnitude of the velocity. Colour flow imaging 
does suffer from some limitations. The size of a jet of colour flow can be difficult to quantify 
as a 3-dimensional entity cannot be fully captured when represented in a 2-dimensional 
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format. As colour flow imaging utilises pulse Doppler techniques, it too suffers from aliasing 
and a mixing of colours when there is turbulent blood flow. 
 
Tissue Doppler  
The Doppler principle is also applied to the movement of tissue (Figure 1.7).105 The gain and 
reject settings are adjusted to record the motion of the myocardium rather than the blood 
pool. Two things must be factored into analysis – the lower velocity of tissue compared to 
blood and that tissue is a stronger reflector of Doppler signal compared to blood. Once tissue 
velocity has been derived, displacement, strain (a measure of deformation that occurs when 
force is applied to tissue) and strain rate can also be calculated.90, 106   
 
Figure 1.7. Tissue Doppler interrogation  
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Power Doppler  
Power Doppler imaging is an additional colour flow imaging technique that overcomes some 
of the limitations of colour flow imaging.107 Colour flow images are created using phase and 
frequency information of the autocorrelation signal created by the computer of the 
ultrasound machine. However amplitude of the autocorrelation signal is not used to create 
the colour flow image. Amplitude reflects the power of the autocorrelation signal and when 
it is integrated with the colour flow image a power Doppler image is produced. The most 
important benefit of this technique is improved flow sensitivity and a decrease in background 
signal noise.108  
 
 
The role of echocardiography  
Validation of accuracy 
Echocardiography has revolutionised cardiology practice. After its introduction, clinicians for 
the first time had a tool that could offer non-invasive information on cardiac structure and 
function in clinic or at the bed-side. Over time, echocardiography has become the dominant 
imaging modality due to its portability and versatility, with its use having expanded into 
emergency departments, operating theatres and intensive care units where it has 
revolutionised practice.109-114 Echocardiography has a long history and is well validated in 
being able to measure cardiac structures accurately when compared with in-vivo anatomy.115, 
116 Echocardiography has been the tool that has been used to derive normative measures of 
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cardiac structures and has also been validated for its use in determining haemodynamic 
parameters.117-119 This has led to its integral role in delineating cardiac structure and function 
to aid in the management of patients with hypertension, heart muscle disease, valve disease, 
heart failure, congenital heart disease, arrhythmias and all forms of structural heart 
disease.106, 117, 120 It is also being applied in the setting of new technologies e.g. transcatheter 
interventions for valve disease.121  
 
Prognostic value 
Information obtained through echocardiography has also been shown to have prognostic 
benefit. Echocardiographically determined left ventricular mass has been shown to be an 
independent risk factor for future cardiovascular morbidity and mortality.122, 123 The 
prognostic implications of echocardiographic changes in left ventricular mass in those on anti-
hypertensive treatment have also been elucidated in the literature.124 Echocardiography has 
also been used for prognostic purposes in heart failure in symptomatic and asymptomatic 
patients with preserved or abnormal left ventricular function.125 Echocardiography has played 
a key role in determining the prognosis of patients with both systolic and diastolic 
dysfunction,126-131 with the prognostic value of ejection fraction also being demonstrated.132-
136 Echocardiography has played a pivotal role in determining which heart failure patients 
would gain a prognostic benefit from device therapy.137, 138 It has also been used to determine 
cardiovascular risk139 and prognosis post-myocardial infarction in a number of studies.140-143 
Echocardiography is the preferred measurement tool in valve lesions and has demonstrated 
prognostic accuracy in a variety of valvular conditions.144, 145 Echocardiography is also a tool 
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in the armamentarium when determining prognosis for certain cardiomyopathic 
conditions146-150 and arrhythmic processes.151, 152 
 
Weaknesses 
While echocardiography is a widely available, cheap and quick tool to assess cardiac structure 
and function, it does have its limitations. Chief among these is the fact that image quality is 
dependent on patient body habitus. Obesity, lung disease, deformed chest walls and breast 
implants all preclude optimal image acquisition. Operator skill and experience also has a role 
to play in obtaining images of the best quality. Reproducibility of measurements (both intra-
reader and inter-reader) varies with some studies suggesting a variability of +/- 10% for 
ejection fraction measured by Simpson’s biplane method.153 Volume and mass measurements 
may be made more accurately and with better reproducibility by cardiac magnetic resonance 
imaging or by cardiac computed tomography scanning.153-155 Artefact can play a role in 
decreasing image quality (e.g. from mechanical heart valves) and accurate haemodynamic 
measurements require proper alignment of the Doppler probe.156  
Finally it must be remembered that echocardiography is a 2 or sometimes 1-dimensional 
representation of a 3-dimensional structure and the interpretation of images and 
measurements needs to be made with this in mind. 3-dimensional echocardiography is a 
newer technique which has recently entered clinical practice and has shown reasonably good 
validity against cardiac magnetic resonance.157 
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Echocardiographic measures used in this thesis 
Measures of cardiac structure and function used in this thesis have been presented and 
critically discussed in the methods chapter (chapter 3). 
 
Life course echocardiography 
There have been few studies that have utilized echocardiography when looking at the life 
course influences of risk factors on future cardiac structure and function. A systematic review 
and meta-analysis of such studies is presented in chapter 2.   
Using echocardiography in the context of a life course approach, i.e. life course 
echocardiography, would allow a better appreciation of the pathological consequences of 
earlier risk factor exposure and risk factor history on subsequent cardiac structure and 
function. Such improved mechanistic understanding would allow the design of appropriate 
trials to test the effect of earlier targeted interventions.  
 
 
References 
 
 
 (1)  Kuh D, Ben-Shlomo Y. A life course approach to chronic disease epidemiology, 2nd 
edition. 2nd ed. Oxford University Press; 2004. 
51 | P a g e  
  
 (2)  Barker DJ. Fetal origins of coronary heart disease. BMJ 1995 July 15;311(6998):171-
4. 
 (3)  Galobardes B, Smith GD, Lynch JW. Systematic review of the influence of childhood 
socioeconomic circumstances on risk for cardiovascular disease in adulthood. Ann Epidemiol 
2006 February;16(2):91-104. 
 (4)  Berry JD, Dyer A, Cai X et al. Lifetime risks of cardiovascular disease. N Engl J Med 
2012 January 26;366(4):321-9. 
 (5)  Allen N, Berry JD, Ning H, Van HL, Dyer A, Lloyd-Jones DM. Impact of blood 
pressure and blood pressure change during middle age on the remaining lifetime risk for 
cardiovascular disease: the cardiovascular lifetime risk pooling project. Circulation 2012 
January 3;125(1):37-44. 
 (6)  Bibbins-Domingo K, Pletcher MJ. Blood pressure matters, even during young 
adulthood. J Am Coll Cardiol 2011 November 29;58(23):2404-5. 
 (7)  Gray L, Lee IM, Sesso HD, Batty GD. Blood pressure in early adulthood, 
hypertension in middle age, and future cardiovascular disease mortality: HAHS (Harvard 
Alumni Health Study). J Am Coll Cardiol 2011 November 29;58(23):2396-403. 
 (8)  Kuh D, Ben-Shlomo Y. A life course approach to chronic disease epidemiology, 1st 
edition. 1st ed. Oxford University Press; 1997. 
 (9)  Newman G. Infant mortality: a social problem. London: Methuen 1906. 
 (10)  Fisher I. Report on national vitality, its wastes and conservation. National 
Conservation Commission, Washington: Government Printing Office; 1909. 
 (11)  Smith GD, Kuh D. Commentary: William Ogilvy Kermack and the childhood origins 
of adult health and disease. Int J Epidemiol 2001 August;30(4):696-703. 
 (12)  Stockard C. Hormones and structural development. The Beaumonth Fondation 
Lecture, Wayne County Medical Society 1927. 
 (13)  Boyd Orr J. Food health and income. London: Macmillan 1937. 
 (14)  McGonigle G, Kurby J. Poverty and public health. London: V Gollancz 1936. 
 (15)  Ciocco A, Klein H, Palmer C. Child health and the selective service physical 
standards. Pub Health Rep 1941;56:2365-75. 
 (16)  Sydenstricker E. Health and enviornment. New York and London: McGraw-Hill 
1933. 
 (17)  Doll R, Hill A. Mortality in relation to smoking: ten years' observations of British 
doctors. Br Med J 1964 May 30;1(5395):1399-410. 
52 | P a g e  
  
 (18)  Dawber T, Meadors G, Moore FEJ. Epidemiological approaches to heart disease: 
the Framingham Study. Am J Public Health Nations Health 1951 March;41(3):279-81. 
 (19)  Enos W, Holmes R, Beyer J. Coronary disease among United States soldiers killed in 
action in Korea; preliminary report. J Am Med Assoc 1953 July 18;152(12):1090-3. 
 (20)  Strong JP, Malcom GT, Oalmann MC, Wissler RW. The PDAY Study: natural history, 
risk factors, and pathobiology. Pathobiological Determinants of Atherosclerosis in Youth. 
Ann N Y Acad Sci 1997 April 15;811:226-35. 
 (21)  Barker DJ. Mothers, babies and disease in later life. London: BMJ Publishing Group; 
1994. 
 (22)  Bobak M, Hertzman C, Skodova Z, Marmot M. Own education, current conditions, 
parental material circumstances, and risk of myocardial infarction in a former communist 
country. J Epidemiol Community Health 2000 February;54(2):91-6. 
 (23)  Smith GD, McCarron P, Okasha M, McEwen J. Social circumstances in childhood 
and cardiovascular disease mortality: prospective observational study of Glasgow University 
students. J Epidemiol Community Health 2001 May;55(5):340-1. 
 (24)  Huxley R, Neil A, Collins R. Unravelling the fetal origins hypothesis: is there really 
an inverse association between birthweight and subsequent blood pressure? Lancet 2002 
August 31;360(9334):659-65. 
 (25)  Vanhala M. Childhood weight and metabolic syndrome in adults. Ann Med 1999 
August;31(4):236-9. 
 (26)  Kuh D, Ben-Shlomo Y, Lynch J, Hallqvist J, Power C. Life course epidemiology. J 
Epidemiol Community Health 2003 October;57(10):778-83. 
 (27)  Aboderin I, Kalache A, Ben-Shlomo Y, et a. Life course perspectives on coronary 
heart disease, stroke and diabetes: key issues and implications for policy and research. 
Geneva: World Health Organization; 2002.  
 (28)  Richardson A, Cheung HT. Current concepts: I. The relationship between age-
related changes in gene expression, protein turnover, and the responsiveness of an 
organism to stimuli. Life Sci 1982 August 16;31(7):605-13. 
 (29)  Upmark M, Lundberg I, Sadigh J, Bigert C. Conditions during childhood and 
adolescence as explanations of social class differences in disability pension among young 
men. Scand J Public Health 2001 June;29(2):96-103. 
 (30)  Huang Z, Hankinson SE, Colditz GA et al. Dual effects of weight and weight gain on 
breast cancer risk. JAMA 1997 November 5;278(17):1407-11. 
 (31)  Huxley RR, Shiell AW, Law CM. The role of size at birth and postnatal catch-up 
growth in determining systolic blood pressure: a systematic review of the literature. J 
Hypertens 2000 July;18(7):815-31. 
53 | P a g e  
  
 (32)  Elford J, Whincup P, Shaper AG. Early life experience and adult cardiovascular 
disease: longitudinal and case-control studies. Int J Epidemiol 1991 December;20(4):833-44. 
 (33)  Barker DJ, Bull AR, Osmond C, Simmonds SJ. Fetal and placental size and risk of 
hypertension in adult life. BMJ 1990 August 4;301(6746):259-62. 
 (34)  Whincup PH, Cook DG, Shaper AG. Early influences on blood pressure: a study of 
children aged 5-7 years. BMJ 1989 September 2;299(6699):587-91. 
 (35)  Churchill D, Perry IJ, Beevers DG. Ambulatory blood pressure in pregnancy and 
fetal growth. Lancet 1997 January 4;349(9044):7-10. 
 (36)  Cella SG, Locatelli V, Mennini T et al. Deprivation of growth hormone-releasing 
hormone early in the rat's neonatal life permanently affects somatotropic function. 
Endocrinology 1990 October;127(4):1625-34. 
 (37)  Harding JE. The nutritional basis of the fetal origins of adult disease. Int J Epidemiol 
2001 February;30(1):15-23. 
 (38)  Stein Z, Susser M. The Dutch famine, 1944-1945, and the reproductive process. I. 
Effects on six indices at birth. Pediatr Res 1975 February;9(2):70-6. 
 (39)  Roseboom TJ, van der Meulen JH, Ravelli AC et al. Blood pressure in adults after 
prenatal exposure to famine. J Hypertens 1999 March;17(3):325-30. 
 (40)  Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CR. Glucocorticoid exposure 
in utero: new model for adult hypertension. Lancet 1993 February 6;341(8841):339-41. 
 (41)  Edwards CR, Benediktsson R, Lindsay RS, Seckl JR. Dysfunction of placental 
glucocorticoid barrier: link between fetal environment and adult hypertension? Lancet 1993 
February 6;341(8841):355-7. 
 (42)  Whincup PH, Bredow M, Payne F, Sadler S, Golding J. Size at birth and blood 
pressure at 3 years of age. The Avon Longitudinal Study of Pregnancy and Childhood 
(ALSPAC). Am J Epidemiol 1999 April 15;149(8):730-9. 
 (43)  Hales CN, Ozanne SE. The dangerous road of catch-up growth. J Physiol 2003 
February 15;547(Pt 1):5-10. 
 (44)  Cettour-Rose P, Samec S, Russell AP et al. Redistribution of glucose from skeletal 
muscle to adipose tissue during catch-up fat: a link between catch-up growth and later 
metabolic syndrome. Diabetes 2005 March;54(3):751-6. 
 (45)  Law CM, Shiell AW, Newsome CA et al. Fetal, infant, and childhood growth and 
adult blood pressure: a longitudinal study from birth to 22 years of age. Circulation 2002 
March 5;105(9):1088-92. 
 (46)  Hardy R, Wadsworth ME, Langenberg C, Kuh D. Birthweight, childhood growth, and 
blood pressure at 43 years in a British birth cohort. Int J Epidemiol 2004 February;33(1):121-
9. 
54 | P a g e  
  
 (47)  Holland FJ, Stark O, Ades AE, Peckham CS. Birth weight and body mass index in 
childhood, adolescence, and adulthood as predictors of blood pressure at age 36. J 
Epidemiol Community Health 1993 December;47(6):432-5. 
 (48)  Twisk JW. The problem of evaluating the magnitude of tracking coefficients. Eur J 
Epidemiol 2003;18(11):1025-6. 
 (49)  Rosner B, Hennekens CH, Kass EH, Miall WE. Age-specific correlation analysis of 
longitudinal blood pressure data. Am J Epidemiol 1977 October;106(4):306-13. 
 (50)  de SM, Fayers P, Shinebourne EA. Blood pressure survey in a population of 
newborn infants. Br Med J 1976 July 3;2(6026):9-11. 
 (51)  Andre JL, Deschamps JP, Petit JC, Gueguen R. Change of blood pressure over five 
years in childhood and adolescence. Clin Exp Hypertens A 1986;8(4-5):539-45. 
 (52)  Power C, Lake JK, Cole TJ. Measurement and long-term health risks of child and 
adolescent fatness. Int J Obes Relat Metab Disord 1997 July;21(7):507-26. 
 (53)  Li L, Law C, Power C. Body mass index throughout the life-course and blood 
pressure in mid-adult life: a birth cohort study. J Hypertens 2007 June;25(6):1215-23. 
 (54)  Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 
1990-2020: Global Burden of Disease Study. Lancet 1997 May 24;349(9064):1498-504. 
 (55)  Ebbeling CB, Pawlak DB, Ludwig DS. Childhood obesity: public-health crisis, 
common sense cure. Lancet 2002 August 10;360(9331):473-82. 
 (56)  Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM. Prevalence of high body 
mass index in US children and adolescents, 2007-2008. JAMA 2010 January 20;303(3):242-9. 
 (57)  Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics--2012 
update: a report from the American Heart Association. Circulation 2012 January 3;125(1):e2-
e220. 
 (58)  Serdula MK, Mokdad AH, Williamson DF, Galuska DA, Mendlein JM, Heath GW. 
Prevalence of attempting weight loss and strategies for controlling weight. JAMA 1999 
October 13;282(14):1353-8. 
 (59)  Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH. Predicting obesity in young 
adulthood from childhood and parental obesity. N Engl J Med 1997 September 
25;337(13):869-73. 
 (60)  Braddon FE, Rodgers B, Wadsworth ME, Davies JM. Onset of obesity in a 36 year 
birth cohort study. Br Med J (Clin Res Ed) 1986 August 2;293(6542):299-303. 
 (61)  Charney E, Goodman HC, McBride M, Lyon B, Pratt R. Childhood antecedents of 
adult obesity. Do chubby infants become obese adults? N Engl J Med 1976 July 1;295(1):6-9. 
55 | P a g e  
  
 (62)  Curhan GC, Willett WC, Rimm EB, Spiegelman D, Ascherio AL, Stampfer MJ. Birth 
weight and adult hypertension, diabetes mellitus, and obesity in US men. Circulation 1996 
December 15;94(12):3246-50. 
 (63)  Fall CH, Osmond C, Barker DJ et al. Fetal and infant growth and cardiovascular risk 
factors in women. BMJ 1995 February 18;310(6977):428-32. 
 (64)  Plagemann A, Harder T, Rake A et al. Perinatal elevation of hypothalamic insulin, 
acquired malformation of hypothalamic galaninergic neurons, and syndrome x-like 
alterations in adulthood of neonatally overfed rats. Brain Res 1999 July 31;836(1-2):146-55. 
 (65)  Plagemann A, Rake A, Harder T, Melchior K, Rohde W, Dorner G. Reduction of 
cholecystokinin-8S-neurons in the paraventricular hypothalamic nucleus of neonatally 
overfed weanling rats. Neurosci Lett 1998 December 11;258(1):13-6. 
 (66)  Ravelli GP, Stein ZA, Susser MW. Obesity in young men after famine exposure in 
utero and early infancy. N Engl J Med 1976 August 12;295(7):349-53. 
 (67)  Stanner SA, Bulmer K, Andres C et al. Does malnutrition in utero determine 
diabetes and coronary heart disease in adulthood? Results from the Leningrad siege study, a 
cross sectional study. BMJ 1997 November 22;315(7119):1342-8. 
 (68)  Ong KK, Ahmed ML, Emmett PM, Preece MA, Dunger DB. Association between 
postnatal catch-up growth and obesity in childhood: prospective cohort study. BMJ 2000 
April 8;320(7240):967-71. 
 (69)  Hediger ML, Overpeck MD, Kuczmarski RJ, Ruan WJ. Association between infant 
breastfeeding and overweight in young children. JAMA 2001 May 16;285(19):2453-60. 
 (70)  Locke C, Lloyd-Sherlock P. Qualitative life course methodologies: critical reflections 
from development studies. Dev Change 2011;42(5):1131-52. 
 (71)  Lynch J, Smith GD. A life course approach to chronic disease epidemiology. Annu 
Rev Public Health 2005;26:1-35. 
 (72)  Ben-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: 
conceptual models, empirical challenges and interdisciplinary perspectives. Int J Epidemiol 
2002 April;31(2):285-93. 
 (73)  Hertzman C, Power C, Matthews S, Manor O. Using an interactive framework of 
society and lifecourse to explain self-rated health in early adulthood. Soc Sci Med 2001 
December;53(12):1575-85. 
 (74)  Hallqvist J, Lynch J, Bartley M, Lang T, Blane D. Can we disentangle life course 
processes of accumulation, critical period and social mobility? An analysis of disadvantaged 
socio-economic positions and myocardial infarction in the Stockholm Heart Epidemiology 
Program. Soc Sci Med 2004 April;58(8):1555-62. 
56 | P a g e  
  
 (75)  Naess O, Claussen B, Thelle DS, Davey SG. Cumulative deprivation and cause 
specific mortality. A census based study of life course influences over three decades. J 
Epidemiol Community Health 2004 July;58(7):599-603. 
 (76)  De Stavola BL, Nitsch D, dos SS, I et al. Statistical issues in life course epidemiology. 
Am J Epidemiol 2006 January 1;163(1):84-96. 
 (77)  Mishra G, Nitsch D, Black S, De SB, Kuh D, Hardy R. A structured approach to 
modelling the effects of binary exposure variables over the life course. Int J Epidemiol 2009 
April;38(2):528-37. 
 (78)  Hazzard WR, Ettinger WH, Jr. Aging and Atherosclerosis: Changing Considerations 
in Cardiovascular Disease Prevention as the Barrier to Immortality is Approached in Old Age. 
Am J Geriatr Cardiol 1995 July;4(4):16-36. 
 (79)  Stafford M, Black S, Shah I et al. Using a birth cohort to study ageing: 
representativeness and response rates in the National Survey of Health and Development. 
Eur J Ageing 2013 June;10(2):145-57. 
 (80)  Strand BH, Kuh D, Shah I, Guralnik J, Hardy R. Childhood, adolescent and early adult 
body mass index in relation to adult mortality: results from the British 1946 birth cohort. J 
Epidemiol Community Health 2012 March;66(3):225-32. 
 (81)  Edler I, Hertz CH. The use of ultrasonic reflectoscope for the continuous recording 
of the movements of heart walls. 1954. Clin Physiol Funct Imaging 2004 May;24(3):118-36. 
 (82)  Joyner C, Reid J. Applications of ultrasound in cardiology and cardiovascular 
physiology. Prog Cardiovasc Dis 1963 March;5:482-97. 
 (83)  Feigenbaum H, Waldhausen J, Hyde L. Ultrasound diagnosis of pericardial effusion. 
JAMA 1965 March 1;191:711-4. 
 (84)  Tajik AJ, Seward JB, Hagler DJ, Mair DD, Lie JT. Two-dimensional real-time 
ultrasonic imaging of the heart and great vessels. Technique, image orientation, structure 
identification, and validation. Mayo Clin Proc 1978 May;53(5):271-303. 
 (85)  Holen J, Aaslid R, Landmark K, Simonsen S. Determination of pressure gradient in 
mitral stenosis with a non-invasive ultrasound Doppler technique. Acta Med Scand 
1976;199(6):455-60. 
 (86)  Hatle L, Brubakk A, Tromsdal A, Angelsen B. Noninvasive assessment of pressure 
drop in mitral stenosis by Doppler ultrasound. Br Heart J 1978 February;40(2):131-40. 
 (87)  Sahn DJ. Instrumentation and physical factors related to visualization of stenotic 
and regurgitant jets by Doppler color flow mapping. J Am Coll Cardiol 1988 
November;12(5):1354-65. 
 (88)  McDicken WN, Sutherland GR, Moran CM, Gordon LN. Colour Doppler velocity 
imaging of the myocardium. Ultrasound Med Biol 1992;18(6-7):651-4. 
57 | P a g e  
  
 (89)  Seward JB, Khandheria BK, Oh JK et al. Transesophageal echocardiography: 
technique, anatomic correlations, implementation, and clinical applications. Mayo Clin Proc 
1988 July;63(7):649-80. 
 (90)  Heimdal A, Stoylen A, Torp H, Skjaerpe T. Real-time strain rate imaging of the left 
ventricle by ultrasound. J Am Soc Echocardiogr 1998 November;11(11):1013-9. 
 (91)  Zamorano J, Cordeiro P, Sugeng L et al. Real-time three-dimensional 
echocardiography for rheumatic mitral valve stenosis evaluation: an accurate and novel 
approach. J Am Coll Cardiol 2004 June 2;43(11):2091-6. 
 (92)  Kuhl HP, Schreckenberg M, Rulands D et al. High-resolution transthoracic real-time 
three-dimensional echocardiography: quantitation of cardiac volumes and function using 
semi-automatic border detection and comparison with cardiac magnetic resonance imaging. 
J Am Coll Cardiol 2004 June 2;43(11):2083-90. 
 (93)  Sicari R, Galderisi M, Voigt JU et al. The use of pocket-size imaging devices: a 
position statement of the European Association of Echocardiography. Eur J Echocardiogr 
2011 February;12(2):85-7. 
 (94)  Simmons A. Ultrasound in medical diasgnosis.  8-8-2012. 8-8-2012.  
Ref Type: Online Source 
 (95)  Coman IM. Christian Andreas Doppler--the man and his legacy. Eur J Echocardiogr 
2005 January;6(1):7-10. 
 (96)  Bollinger A, Partsch H. Christian Doppler is 200 years young. Vasa 2003 
November;32(4):225-33. 
 (97)  Roguin A. Christian Johann Doppler: the man behind the effect. Br J Radiol 2002 
July;75(895):615-9. 
 (98)  Engineering Toolbox.com. Ultrasonic Doppler and Time of Flight Flow Meters.  7-8-
2012.  
Ref Type: Online Source 
 (99)  The Physics Classroom. Behaviour of waves.  7-8-2012.  
Ref Type: Online Source 
 (100)  Miyatake K, Okamoto M, Kinoshita N et al. Clinical applications of a new type of 
real-time two-dimensional Doppler flow imaging system. Am J Cardiol 1984 October 
1;54(7):857-68. 
 (101)  Huntsman LL, Gams E, Johnson CC, Fairbanks E. Trancutaneous determination of 
aortic blood-flow velocities in man. Am Heart J 1975 May;89(5):605-12. 
 (102)  Kapadia SR, Schoenhagen P, Stewart W, Tuzcu EM. Imaging for transcatheter valve 
procedures. Curr Probl Cardiol 2010 May;35(5):228-76. 
58 | P a g e  
  
 (103)  Bom K, de BJ, Rijsterborgh H. On the aliasing problem in pulsed Doppler cardiac 
studies. J Clin Ultrasound 1984 November;12(9):559-67. 
 (104)  Armstrong W, Ryan T. Feigenbaum's echocardiography. 7 ed. Philadelphia, USA: 
Wolters Kluwer; 2010. 
 (105)  Waggoner AD, Bierig SM. Tissue Doppler imaging: a useful echocardiographic 
method for the cardiac sonographer to assess systolic and diastolic ventricular function. J 
Am Soc Echocardiogr 2001 December;14(12):1143-52. 
 (106)  Douglas PS, Garcia MJ, Haines DE et al. 
ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for 
Echocardiography. A Report of the American College of Cardiology Foundation Appropriate 
Use Criteria Task Force, American Society of Echocardiography, American Heart Association, 
American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm 
Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care 
Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular 
Magnetic Resonance Endorsed by the American College of Chest Physicians. J Am Coll 
Cardiol 2011 March 1;57(9):1126-66. 
 (107)  Rubin JM, Bude RO, Carson PL, Bree RL, Adler RS. Power Doppler US: a potentially 
useful alternative to mean frequency-based color Doppler US. Radiology 1994 
March;190(3):853-6. 
 (108)  Hamper UM, DeJong MR, Caskey CI, Sheth S. Power Doppler imaging: clinical 
experience and correlation with color Doppler US and other imaging modalities. 
Radiographics 1997 March;17(2):499-513. 
 (109)  Poldermans D, Bax JJ, Boersma E et al. Guidelines for pre-operative cardiac risk 
assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009 
November;30(22):2769-812. 
 (110)  Vignon P, Mentec H, Terre S, Gastinne H, Gueret P, Lemaire F. Diagnostic accuracy 
and therapeutic impact of transthoracic and transesophageal echocardiography in 
mechanically ventilated patients in the ICU. Chest 1994 December;106(6):1829-34. 
 (111)  Bergenzaun L, Gudmundsson P, Ohlin H et al. Assessing left ventricular systolic 
function in shock: evaluation of echocardiographic parameters in intensive care. Crit Care 
2011;15(4):R200. 
 (112)  Chew MS. Haemodynamic monitoring using echocardiography in the critically ill: a 
review. Cardiol Res Pract 2012;2012:139537. 
 (113)  Pierard LA, Lancellotti P. Echocardiography in the emergency room: non-invasive 
imaging. Heart 2009 February;95(2):164-70. 
 (114)  Van Dantzig JM. Echocardiography in the emergency department. Semin 
Cardiothorac Vasc Anesth 2006 March;10(1):79-81. 
59 | P a g e  
  
 (115)  Reichek N, Helak J, Plappert T, Sutton MS, Weber KT. Anatomic validation of left 
ventricular mass estimates from clinical two-dimensional echocardiography: initial results. 
Circulation 1983 February;67(2):348-52. 
 (116)  Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left 
ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986 February 
15;57(6):450-8. 
 (117)  Lang RM, Bierig M, Devereux RB et al. Recommendations for chamber 
quantification: a report from the American Society of Echocardiography's Guidelines and 
Standards Committee and the Chamber Quantification Writing Group, developed in 
conjunction with the European Association of Echocardiography, a branch of the European 
Society of Cardiology. J Am Soc Echocardiogr 2005 December;18(12):1440-63. 
 (118)  Vasan RS, Larson MG, Levy D, Evans JC, Benjamin EJ. Distribution and 
categorization of echocardiographic measurements in relation to reference limits: the 
Framingham Heart Study: formulation of a height- and sex-specific classification and its 
prospective validation. Circulation 1997 September 16;96(6):1863-73. 
 (119)  Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilatation and 
the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 
1997 May 8;336(19):1350-5. 
 (120)  Greenland P, Alpert JS, Beller GA et al. 2010 ACCF/AHA guideline for assessment of 
cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 
2010 December 14;56(25):e50-103. 
 (121)  Zamorano JL, Badano LP, Bruce C et al. EAE/ASE recommendations for the use of 
echocardiography in new transcatheter interventions for valvular heart disease. Eur Heart J 
2011 September;32(17):2189-214. 
 (122)  Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left 
ventricular mass and geometry to morbidity and mortality in uncomplicated essential 
hypertension. Ann Intern Med 1991 March 1;114(5):345-52. 
 (123)  Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of 
echocardiographically determined left ventricular mass in the Framingham Heart Study. N 
Engl J Med 1990 May 31;322(22):1561-6. 
 (124)  Devereux RB, Wachtell K, Gerdts E et al. Prognostic significance of left ventricular 
mass change during treatment of hypertension. JAMA 2004 November 17;292(19):2350-6. 
 (125)  Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value 
of systolic and diastolic function for incident congestive heart failure in the elderly: the 
cardiovascular health study. J Am Coll Cardiol 2001 March 15;37(4):1042-8. 
60 | P a g e  
  
 (126)  Nagueh SF, Appleton CP, Gillebert TC et al. Recommendations for the evaluation of 
left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009 
February;22(2):107-33. 
 (127)  Nagueh SF, Appleton CP, Gillebert TC et al. Recommendations for the evaluation of 
left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009 
March;10(2):165-93. 
 (128)  Ward RP, Mansour IN, Lemieux N, Gera N, Mehta R, Lang RM. Prospective 
evaluation of the clinical application of the American College of Cardiology 
Foundation/American Society of Echocardiography Appropriateness Criteria for 
transthoracic echocardiography. JACC Cardiovasc Imaging 2008 September;1(5):663-71. 
 (129)  Franklin KM, Aurigemma GP. Prognosis in diastolic heart failure. Prog Cardiovasc 
Dis 2005 March;47(5):333-9. 
 (130)  Pinamonti B, Zecchin M, Di LA, Gregori D, Sinagra G, Camerini F. Persistence of 
restrictive left ventricular filling pattern in dilated cardiomyopathy: an ominous prognostic 
sign. J Am Coll Cardiol 1997 March 1;29(3):604-12. 
 (131)  Garcia MJ, Smedira NG, Greenberg NL et al. Color M-mode Doppler flow 
propagation velocity is a preload insensitive index of left ventricular relaxation: animal and 
human validation. J Am Coll Cardiol 2000 January;35(1):201-8. 
 (132)  Owens AT, Jessup M. The year in heart failure. J Am Coll Cardiol 2012 July 
31;60(5):359-68. 
 (133)  McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and 
treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and 
Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. 
Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 
2012 July;33(14):1787-847. 
 (134)  Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart 
failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence 
and mortality in a population-based cohort. J Am Coll Cardiol 1999 June;33(7):1948-55. 
 (135)  St John SM, Pfeffer MA, Plappert T et al. Quantitative two-dimensional 
echocardiographic measurements are major predictors of adverse cardiovascular events 
after acute myocardial infarction. The protective effects of captopril. Circulation 1994 
January;89(1):68-75. 
 (136)  Cleland JG, Torabi A, Khan NK. Epidemiology and management of heart failure and 
left ventricular systolic dysfunction in the aftermath of a myocardial infarction. Heart 2005 
May;91 Suppl 2:ii7-13. 
 (137)  Dickstein K, Vardas PE, Auricchio A et al. 2010 Focused Update of ESC Guidelines 
on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis 
and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac 
61 | P a g e  
  
and resynchronization therapy. Developed with the special contribution of the Heart Failure 
Association and the European Heart Rhythm Association. Eur Heart J 2010 
November;31(21):2677-87. 
 (138)  Tanaka H, Nesser HJ, Buck T et al. Dyssynchrony by speckle-tracking 
echocardiography and response to cardiac resynchronization therapy: results of the Speckle 
Tracking and Resynchronization (STAR) study. Eur Heart J 2010 July;31(14):1690-700. 
 (139)  Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and 
future directions. Circulation 2010 April 20;121(15):1768-77. 
 (140)  Sanz G, Castaner A, Betriu A et al. Determinants of prognosis in survivors of 
myocardial infarction: a prospective clinical angiographic study. N Engl J Med 1982 May 
6;306(18):1065-70. 
 (141)  Multicenter Postinfacrtion Research Group. Risk stratification and survival after 
myocardial infarction. N Engl J Med 1983 August 11;309(6):331-6. 
 (142)  Ahnve S, Gilpin E, Henning H, Curtis G, Collins D, Ross J, Jr. Limitations and 
advantages of the ejection fraction for defining high risk after acute myocardial infarction. 
Am J Cardiol 1986 November 1;58(10):872-8. 
 (143)  White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left 
ventricular end-systolic volume as the major determinant of survival after recovery from 
myocardial infarction. Circulation 1987 July;76(1):44-51. 
 (144)  Baumgartner H, Hung J, Bermejo J et al. Echocardiographic assessment of valve 
stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009 
January;22(1):1-23. 
 (145)  Vahanian A, Baumgartner H, Bax J et al. Guidelines on the management of valvular 
heart disease: The Task Force on the Management of Valvular Heart Disease of the 
European Society of Cardiology. Eur Heart J 2007 January;28(2):230-68. 
 (146)  Grun S, Schumm J, Greulich S et al. Long-term follow-up of biopsy-proven viral 
myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 2012 May 
1;59(18):1604-15. 
 (147)  Kindermann I, Barth C, Mahfoud F et al. Update on myocarditis. J Am Coll Cardiol 
2012 February 28;59(9):779-92. 
 (148)  Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA Guideline for the Diagnosis 
and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of 
Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
Developed in collaboration with the American Association for Thoracic Surgery, American 
Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society 
of America, Heart Rhythm Society, Society for Cardiovascular Angiography and 
Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011 December 
13;58(25):e212-e260. 
62 | P a g e  
  
 (149)  Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA guideline for the diagnosis 
and treatment of hypertrophic cardiomyopathy: a report of the American College of 
Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J 
Thorac Cardiovasc Surg 2011 December;142(6):e153-e203. 
 (150)  Maron BJ, Towbin JA, Thiene G et al. Contemporary definitions and classification of 
the cardiomyopathies: an American Heart Association Scientific Statement from the Council 
on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and 
Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary 
Working Groups; and Council on Epidemiology and Prevention. Circulation 2006 April 
11;113(14):1807-16. 
 (151)  Epstein AE, Dimarco JP, Ellenbogen KA et al. ACC/AHA/HRS 2008 Guidelines for 
device-based therapy of cardiac rhythm abnormalities. Heart Rhythm 2008 June;5(6):e1-62. 
 (152)  Zipes DP, Camm AJ, Borggrefe M et al. ACC/AHA/ESC 2006 guidelines for 
management of patients with ventricular arrhythmias and the prevention of sudden cardiac 
death: a report of the American College of Cardiology/American Heart Association Task 
Force and the European Society of Cardiology Committee for Practice Guidelines (Writing 
Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias 
and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006 September 
5;48(5):e247-e346. 
 (153)  Otterstad JE, Froeland G, St John SM, Holme I. Accuracy and reproducibility of 
biplane two-dimensional echocardiographic measurements of left ventricular dimensions 
and function. Eur Heart J 1997 March;18(3):507-13. 
 (154)  Higgins CB. Which standard has the gold? J Am Coll Cardiol 1992 June;19(7):1608-9. 
 (155)  Doherty NE, III, Seelos KC, Suzuki J et al. Application of cine nuclear magnetic 
resonance imaging for sequential evaluation of response to angiotensin-converting enzyme 
inhibitor therapy in dilated cardiomyopathy. J Am Coll Cardiol 1992 May;19(6):1294-302. 
 (156)  Huang SJ, McLean AS. Appreciating the strengths and weaknesses of transthoracic 
echocardiography in hemodynamic assessments. Cardiol Res Pract 2012;2012:894308. 
 (157)  Friedberg MK, Su X, Tworetzky W, Soriano BD, Powell AJ, Marx GR. Validation of 3D 
echocardiographic assessment of left ventricular volumes, mass, and ejection fraction in 
neonates and infants with congenital heart disease: a comparison study with cardiac MRI. 
Circ Cardiovasc Imaging 2010 November;3(6):735-42. 
 
 
 
 
 
63 | P a g e  
  
 
Chapter 2 
 
Cardiovascular risk factors from early life predict 
future adult cardiac structural and functional 
abnormalities: a Systematic Review of the published 
literature 
 
Introduction 
The evaluation of cardiovascular risk in clinical practice is based on current risk factor (RF) 
levels and largely disregards prior RF history and changes in RFs over the totality of the life 
course. There is considerable evidence associating RFs such as body mass index (BMI) and 
blood pressure (BP) in midlife with subsequent cardiovascular morbidity and mortality.1 There 
is also literature cross-sectionally associating current RFs (BP and BMI) with 
echocardiographic changes (left ventricular mass - LVM and left ventricular hypertrophy - 
LVH) and with these changes relating independently to cardiovascular events.2-4 There has 
also been some research relating presence or absence of diabetes to later echocardiographic 
outcomes.5 However, less is known about how earlier-life levels of these RFs, changes in RFs, 
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and duration of and long-term control of RFs like hypertension, obesity and diabetes are 
associated with subsequent cardiac morphology and function as measured through 
echocardiography and this has never been systematically examined.6  
Lifetime RF history can be captured by the life course approach which has been extensively 
used to model RF trajectories in multiple cohorts.7  The life course approach investigates long-
term biological processes that link adult health and disease risk to physical and environmental 
exposures occurring in gestation, childhood, adolescence, earlier in adulthood or across 
generations.8 Although such an approach has not yet been widely applied to the 
cardiovascular domain, after initial early forays by Barker in the mid-nineties (fetal 
undernutrition in middle to late gestation, which leads to disproportionate fetal growth, 
programmes later coronary heart disease),9 there has recently been a renewed recognition 
of this analytical method. This has resulted in a flurry of recent work on larger population 
groups, showing the far-reaching influences of early and mid-adulthood RF levels (e.g. BP) on 
cardiovascular morbidity and mortality many years later.10-13 In spite of this recent utilization 
of a life course approach to future cardiovascular morbidity and mortality, and therefore, 
potentially cardiac structure and function,13, 14 there has been less work directly delineating 
the effects of earlier RFs on future cardiac structure and function as measured through 
echocardiography. Elucidating these echocardiographic changes could give us better insights 
into the mechanisms by which early RF exposures cause future cardiovascular complications 
and thus enable better targeted interventions. For instance, it remains unclear whether 
detrimental changes in cardiac structure and function are caused by exposures or accelerated 
change at particularly sensitive periods in an individual’s life or the overall cumulative burden 
of exposure. To put this in a clinical context, it is unknown, for example, whether being 
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overweight or being diabetic from the age of 20 years onwards is more detrimental to the 
heart in older age, than first becoming overweight or diabetic at the age of 50 years, or 
whether for individuals with the same current BP, the effect on cardiac structure and function 
varies depending on whether there had been a gradual increase in BP over a 30 year period 
or a steeper increase over a shorter period.  
Using a life course approach allows us to determine whether early exposures to RFs like BP 
can lead to LVH in the future, although it must be borne in mind that reverse causality cannot 
be definitely excluded (e.g. LVH leading to hypertension) if baseline LVM is unknown (due to 
a lack of baseline echocardiography). However, identifying such associations remains 
important, as it would allow earlier targeted intervention, before the development of 
abnormality (e.g. LVH). Such approaches (identifying and intervening in those at greatest risk 
early) have been tested recently in the Danish Hypertension Prevention and TROPHY 
studies.15 
Due to the lacunae thus identified in the published literature, we conducted a systematic 
review to determine if increasing lifetime exposure to raised BP, BMI and impaired glycaemic 
control was associated with worse future cardiac structure and function. 
 
Methods 
Criteria for Study Inclusion and search strategy 
Studies eligible for inclusion were observational studies with longitudinal repeated measures 
of one or more of the exposures of interest (BP, BMI and glycaemic control) and at least one 
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echocardiographic examination of participants (looking at cardiac structure and/or function) 
in adulthood. Eligible study samples consisted of individuals who were healthy, non-disabled 
and community-dwelling at the time of measurement of the RFs. 
Outcomes considered were any echocardiographic measure of cardiac structure (e.g. wall and 
chamber dimensions and volumes) or function (e.g. ejection fraction (EF), fractional 
shortening, E/A ratio, and tissue Doppler based measures such as E/e’ ratio). 
Searches of the electronic databases PubMed and EMBASE (January 1966 to December 2011) 
were performed using the following Mesh terms: (longitudinal OR cohort OR life course OR 
lifecourse OR follow up OR tracking) AND (blood pressure measurements OR body mass index 
measurements OR birth weight OR lipids OR glycaemic control) AND (echocardiography).  
Only studies in English were considered. Figure 2.1 summarises the identification of studies.  
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Figure 2.1. Flow of studies through the systematic review (after the PRISMA and MOOSE 
statements).16, 17 
 
After removing duplicates, 1096 study abstracts were screened resulting in the exclusion of 
1060 papers that did not meet inclusion criteria (were cross-sectional studies, hospital-based, 
measured outcomes other than echocardiographic parameters, or the RFs were not analysed 
as continuous variables). The full text of 36 articles were obtained and reviewed for eligibility 
using a standardised inclusion/exclusion form, and 12 were excluded as being ineligible. Of 
the 12 that were excluded, 4 had adopted a “reverse causation” analysis,18-21 1 did not have 
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any echocardiographic measures in adulthood22 and the remainder used a cross-sectional 
analytical approach or did not examine the RFs in a longitudinal manner.23-29  
Any uncertainty about study eligibility was resolved through discussion between my 
supervisors and myself. Details of relevant published results, study populations, 
measurement of RFs and outcomes and details of statistical analysis were extracted from the 
papers using a data extraction form.  
The analyses presented in the papers were too varied to enable a formal meta-analysis of the 
published data. Furthermore, the cardiac outcomes assessed and the ages at which RFs were 
measured were also too heterogeneous to allow an individual level meta-analysis. Hence, no 
attempts were made to contact authors for additional information.  
 
 
Results 
The 24 papers meeting the inclusion criteria used data from 13 different cohort studies. The 
characteristics of included studies are provided in Table 2.1. Table 2.2 describes a summary 
of the associations between the RFs and the cardiac outcomes of interest.  The full main 
findings and statistical methods used are provided in Table 2.3.  
Some studies used more than one method or looked at both cardiac structure and function 
and have thus been included more than once in the tables.  
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Table 2.1.  Characteristics of studies included in the systematic review  
 
Paper: First 
author and 
year 
Study name 
and location 
Analysed sample size 
(at last examination 
round if not further 
qualified) 
Mean Age +/- 1SD 
(Age range)  
in years at last follow  
up (unless otherwise 
mentioned) 
Maximum duration of 
follow up in years and 
maximum number of 
repeated examination 
rounds for the purpose 
of quoted paper 
Repeat measure(s) 
related to 
echocardiographic 
outcome for the purpose 
of quoted paper (not all 
measures may have been 
taken in all rounds) 
Cardiac 
Outcome 
measure(s)  
(non-
longitudinal 
analysis in 
italics) 
 
Cardiac Structure   
Prospective approach  
Urbina30 
1995 
Bogalusa, USA 90 males and 70 
females at first 
echocardiography 
round 
13.3 at first 
echocardiography round 
(9-22) 
4 with 1 follow-up round 
of echocardiography 
BP, weight, height Structure  
Vasan31 
1995 
Framingham, 
USA 
2803 men and 3411 
women at baseline; 
1849 men and 2152 
women at 1st follow up  
20-89 at baseline 8 and 1 BP, BMI Structure  
Vijayakumar32 Hertfordshire  290 men  66.9 +/- 3.2 70 and 2 BP, BMI, glucose and 
insulin 
Structure  
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1995 Cohort, UK 
Kumaran33 
2000 
Mysore, India 435 (237 men and 198 
women) 
49.5 +/- 4.8 49.5 and 1 BP, BMI Structure  
Jokiniitty34 
2001 
Tampere, 
Finland 
97 men at baseline and 
86 men at follow up 
35-45 10 and 1 BP, BMI Structure  
Sundstrom35 
2001 
Uppsala, 
Sweden 
2322 men at baseline; 
1221 at follow-up (475 
qualified for inclusion) 
70-74 20 and 1 BP, BMI, glycaemic control Structure  
Gardin36 
2002 
CARDIA, USA 5115 at baseline; 4243 
at 1st follow-up; 1536 at 
2nd follow-up; 1189 
qualified for inclusion 
(544 men and 645 
women) 
18-30 at baseline 10 and 2 BP, BMI Structure  
Arnlov37 
2005 
Uppsala, 
Sweden 
2330 at baseline; 1227 
at follow-up (505 men 
qualified for inclusion) 
70 20 and 1 BP, BMI, glycaemic control Structure and 
function  
 
Haji38 
2006 
Bogalusa, USA 197 men and 309 
women 
32 +/- 3 23 and 2 to 12 follow-
ups with an average of 6 
BP, BMI, fasting glucose  Structure and 
function 
 
Strand39 
2006 
Oslo, Norway 56 men 42.1 +/- 0.5 at baseline 20 and 1 BP, BMI Structure and 
function  
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Lin40 
2007 
The 
Longitudinal 
Study of Aging, 
China 
193 at baseline; 170 at 
1st follow-up; 144 at 2nd 
follow-up (81 men and 
24 women qualified for 
inclusion) 
71.7 +/- 3.9 
(60-81) 
4 and 2 BP, BMI, glycaemic control Structure and 
function 
 
Toprak41 
2008 
Bogalusa, USA 338 men and 486 
women 
36 
(24-44) 
24 and 1 BP, BMI, glucose Structure  
Ridderstrale42 
2010 
Military 
recruits, 
Sweden 
74 male army recruits 
at baseline, 64 at 
follow-up 
40 20 and 1 BP, BMI,  Structure and 
function 
 
        
Accumulation or Change approach  
Johnson43 
1983 
Bourbon 
County, USA 
837 at baseline; 77 men 
and 51 women 
qualified for final 
inclusion 
16-19 at baseline 5 and 1 BP, BMI Structure and 
function 
 
Lauer44 
1991 
Framingham, 
USA 
451 (152 men and 299 
women) 
68 +/- 6 30 and 16 BP, BMI Structure  
Zureik45 
1995 
Paris, France 177 men 51.6 +/- 2.9 
(47-58) 
2 and 1 BP, BMI Structure  
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Bjorklund46 
2002 
Uppsala, 
Sweden 
2322 men at baseline; 
1221 at follow-up (583 
qualified for inclusion) 
70 20 and 1 BP Structure and 
function 
 
Gardin36 
2002 
CARDIA, USA Refer above      
Lorber47 
2003 
CARDIA, USA 737 men and 881 
women 
18-30 at baseline 10 and 5 BP, BMI, fasting insulin 
levels 
Structure  
Li48  
2004 
Bogalusa, USA 1420 at baseline; 467 at 
6th follow-up (182 men 
and 285 women) 
32.6  
(20-38) 
23 and 2 to 12 follow-
ups with an average of 6 
 
BP, BMI Structure  
Cardiac function  
Johnson43 
1983 
Bourbon 
County, USA 
Refer above      
Arnlov49 
2001 
Uppsala, 
Sweden 
2330 at baseline, 1227 
at 1st follow-up (431 
men qualified for 
inclusion) 
48-51 in the 1st round 20 and 1 Glycaemic control Function  
Bjorklund46 
2002 
Uppsala, 
Sweden 
Refer above      
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Arnlov37 
2005 
Uppsala, 
Sweden 
Refer above      
Cheng50 
2010 
Framingham 
Offspring, USA 
1851 men and 2211 
women 
 
45 +/- 10 at baseline  16 and 4 BP, BMI, fasting glucose Structure and 
function 
 
Longitudinal modelling of cardiac outcomes  
Lieb51 
2009 
Framingham 
Offspring, USA 
1973 men and 2244 
women in long term 
study; 1094 men and 
1511 women in short 
term study 
45  4 to 16 and maximum of 
4 follow-ups 
BP, BMI, diabetic status Structure  
Cheng50 
2010 
Framingham 
Offspring, USA 
Refer above      
Lam52 
2010 
Framingham 
Offspring, USA 
1671 men and 1835 
women in short term 
group; 2187 men and 
2355 women in long 
term group 
52+/-10 for men and 
51+/-10 for women in 
short term group; 46+/-
10 for men and 45+/-10 
for women in long term 
group (25-74) 
4 to 16 and 2-6 follow-
ups 
BP, BMI Structure  
McManus53 
2010 
Framingham 
Offspring, USA 
2102 men and 2301 
women in long term 
group; 1559 men and 
45 4 to 16 and maximum of 
4 follow-ups 
BP, BMI, diabetic status Structure  
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1806 women in short 
term group 
BP, Blood Pressure; BMI, Body Mass Index  
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Table 2.2. Associations of longitudinally analysed RFs with cardiac outcomes 
 
Paper: First author and year Study name and location BP BMI/weight Glucose/glycaemic control Cardiac 
outcome 
Association with 
cardiac outcome 
Cardiac Structure 
Prospective approach 
Urbina30 
1995 
Bogalusa, USA Y Y - LVM BP: +ve  Weight: 
+ve 
Vasan31 
1995 
Framingham, USA Y - - AoRD BP: +ve for DBP 
and MAP, -ve for 
SBP and PP 
Vijayakumar32 
1995 
Hertfordshire  
Cohort, UK 
- Y - LVM, 
IVSD, 
LVPWD 
Weight: +ve 
Kumaran33 
2000 
Mysore, India - Y - LVMI, 
LVH 
Weight: no 
association 
Jokiniitty34 
2001 
Tampere, Finland Y Y - LVMI BP: +ve for PP 
BMI: +ve 
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Sundstrom35 
2001 
Uppsala, Sweden Y Y - LVH BP: +ve                
BMI: +ve 
Gardin36 
2002 
CARDIA, USA Y Y - LVM BP: +ve                        
BMI: +ve 
Arnlov37 
2005 
Uppsala, Sweden Y Y Y E/A, A’, 
LA 
diameter 
BP: -ve for E/A, 
+ve for A with SBP                
BMI: -ve for E/A, 
+ve for A, +ve for 
LA diameter 
Glucose: +ve for E, 
+ve for A with 
insulin/proinsulin, 
+ve for LA 
diameter with 
insulin/proinsulin 
Haji38 
2006 
Bogalusa, USA Y Y - LV 
dilation 
BP: no association      
BMI: +ve  
Strand39 
2006 
Oslo, Norway Y - - LVM, 
LVMI 
BP: +ve for LVM 
with DBP 
BMI: +ve for LVM 
and LVMI 
77 | P a g e  
  
Lin40 
2007 
The Longitudinal Study of Aging, China Y Y Y LVMI, 
LVH 
BP:+ve for LVH 
with PP                     
BMI:+ve for LVMI        
Glucose: +ve for 
LVMI 
Toprak41 
2008 
Bogalusa, USA Y Y Y LVH BP: +ve for 
concentric LVH 
and DBP            
BMI: +ve for 
eccentric LVH            
Glucose: no 
association with 
childhood 
diabetes mellitus  
Ridderstrale42 
2010 
Military recruits, Sweden Y Y Y LVMI BP: +ve with MAP            
BMI: +ve               
Glucose: +ve with 
insulin 
       
Accumulation or Change approach 
Johnson43 
1983 
Bourbon County, USA Y - - FS, IVSD, 
LVPWTD 
BP: +ve with FS, 
IVSD, LVPWTD 
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Lauer44 
1991 
Framingham, USA Y - - LVMI, 
LVH 
BP: +ve 
Zureik45 
1995 
Paris, France Y y - LVMI, 
LVWT 
BP: +ve                             
BMI: no 
association 
Bjorklund46 
2002 
Uppsala, Sweden Y - - LVMI, 
IVSD, 
LVPWT, 
EF 
BP: +ve with LVMI, 
IVSD and LVPWT, 
no association 
with EF 
Gardin36 
2002 
CARDIA, USA Refer above     
Lorber47 
2003 
CARDIA, USA Y y - LVMI, 
LVG 
BP: +ve                       
BMI: +ve 
Li48  
2004 
Bogalusa, USA Y Y - 
 
LVM BP: +ve                       
BMI: +ve 
Cardiac function 
Johnson43 
1983 
Bourbon County, USA Refer above     
Arnlov49 Uppsala, Sweden - - Y EF Glucose: -ve 
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2001 
Bjorklund46 
2002 
Uppsala, Sweden Refer above     
Arnlov37 
2005 
Uppsala, Sweden Refer above     
Cheng50 
2010 
 
 
 
 
 
 
Framingham Offspring, USA Y 
 
Y Y LVIDD, 
LVWT, 
FS 
BP: +ve for LVIDD, 
LVWT and FS with 
SBP and PP, -ve 
for FS and LVIDD 
with DBP                     
BMI: +ve for 
LVIDD and LVWT                     
Glucose: 
Individuals with 
diabetes mellitus 
experienced 
greater age-
associated 
increases in LVWT 
and lesser 
decrease in LVIDD 
(see table 3 for 
details) 
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Longitudinal modelling of cardiac outcomes 
Lieb51 
2009 
Framingham 
Offspring, USA 
Y Y Y LVM BP: +ve                   
BMI: +ve                   
Glucose: Subjects 
in low RF group 
experienced lesser 
increases in LVM 
with time (see 
table 3 for details) 
Cheng50 
2010 
Framingham Offspring, USA Refer above     
Lam52 
2010 
Framingham Offspring, USA Y Y - AoRD BP: +ve for AoRD 
with DBP and PP, -
ve for AoRD with 
SBP and MAP                              
BMI: +ve  
McManus53 
2010 
Framingham 
Offspring, USA 
Y Y - LA 
diameter 
BP: +ve for LA 
diameter with 
SBP, -ve for LA 
diameter with 
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DBP                    
BMI: +ve  
BP, blood pressure; BMI, body mass index; LVM, left ventricular mass; AoRD, aortic root diameter; DBP, diastolic blood pressure; MAP, mean arterial 
pressure; SBP, systolic blood pressure; PP, pulse pressure; IVSD, interventricular septal thickness in diastole; LVPWD, left ventricular posterior wall thickness 
in diastole; LVMI, left ventricular mass index; LVH, left ventricular hypertrophy; LA, left atrium; LV, left ventricle; FS, fractional shortening; LVPWT, left 
ventricular posterior wall thickness; LVG, left ventricular geometry; EF, ejection fraction; LVIDD, left ventricular internal diameter in diastole; LVWT, left 
ventricular wall thickness 
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Table 2.3.  Main findings and statistical methods used 
 
Paper: First 
author and year 
Study name and 
location 
Main findings Statistical methods used 
Cardiac Structure 
Prospective approach 
Urbina30 
1995 
Bogalusa, USA BP: Higher SBP and DBP at the time of first examination 
(average age of 13.3 years, age range 9 to 22 years) 
predicted higher LVM at follow-up 4 years later. 
Weight: Higher adiposity (weight, ponderal index, triceps 
skin fold thickness) at first examination predicted higher 
LVM at follow up in univariable analyses. In multivariable 
analyses only baseline weight was significant in 
determining final LVM consistently across both sexes. 
ANOVA used to look at sex and race differences and 
interactions. Tracking coefficients for anthropometric 
measures, BP and LVM by sex derived and colinearity 
tested for.  
 
Vasan31 
1995 
Framingham, 
USA 
BP: AoRD in individuals aged 20to 89 years positively 
associated with MAP and DBP and inversely associated 
with PP and SBP. Incorporating BP measured 8 years 
previously in the models yielded minimal changes in r2.  
BMI: Analysed in cross-sectional manner. 
Initially univariable regression analyses carried out 
determining correlation coefficients for the RF variables 
with AoRD as the dependent variable. Multivariable 
regression analyses then carried out. 
Vijayakumar32 
1995 
Hertfordshire  
Cohort, UK 
Weight: Higher weight at 1 year associated with lower 
LVM at a mean age of 66.9 years, after adjustment for 
confounding factors. Higher weight at 1 year positively 
associated with IVSD, LVPWD and RWT but not with 
Multiple regression analysis relating weight at 1 year to 
LVMI adjusted for adult BSA, SBP and age. 
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LVIDD, LVIDS and cardiac output before and after 
adjustment for BSA. Higher birth weight non-significantly 
associated with decreasing LVM. 
Kumaran33  
2000 
Mysore, India Weight: Birth weight (when adjusted for sex) was not 
associated with LVMI or with LVH at a mean age of 49.5 
years. Longer length at birth length was associated with 
increasing LVMI, LVH and RWT.  
Linear regression and logistic regression relating birth size 
measures to LVM and LVH, respectively. 
Jokiniitty34 
2001 
Tampere, 
Finland 
BP: Baseline 24h PP in 35 to 45 year old men positively 
associated with LVMI 10 years hence. PP stronger 
predictor of future LVMI than SBP or DBP. Increase in PP 
over the 10 year period correlated with increase in LVMI. 
BMI: The best predictive model for increase in future 
LVMI included increasing BMI. 
5 clusters of baseline BP variables chosen – casual BP, 
daytime IAMB, nocturnal IAMB, 24h IAMB and a 5th cluster 
with all preceding BP variables. Stepwise regression 
analyses performed to identify models predictive of future 
LVMI.  
Sundstrom35 
2001 
Uppsala, 
Sweden 
BP: High SBP and DBP at age 50 years predicted 
prevalence of LVH 20 years later.  
BMI: High BMI at age 50 years predicted increased 
prevalence of LVH 20 years later 
Glycaemic control: Analysed in cross-sectional manner. 
Multiple logistic regression used to adjust for RFs which 
were treated as dichotomous variables. ANOVA used to 
calculate differences in means amongst 4 LVG groups.   
Gardin36 
2002 
CARDIA BP: In a biracial population 28 to 40 years of age, initial 
SBP significantly positively associated with year 10 LVM 
in white men and black women and change in SBP 
positively associated with future LVM in black women.  
Bivariable Pearson correlation coefficients computed for 
change in LVM and each RF. Multiple linear regression 
used to estimate effect of each RF. 
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BMI: Baseline BMI and change in BMI significant positive 
predictors of 10 year future LVM.  
Arnlov37 
2005 
Uppsala, 
Sweden 
BP: Higher SBP and DBP at age 50 years associated with 
decreased E/A ratio after adjustment at age 70 years. 
Higher SBP associated with higher A-wave, but no 
association with DBP. No association between either SBP 
or DBP and LAD. 
BMI: Higher BMI at age 50 years was associated with 
decreased E/A ratio and increased A-wave after 
adjustment. Higher BMI at age 50 years associated with 
greater LAD at age 70 years.  
Glycaemic control: E-wave at age 70 years positively 
correlated to fasting glucose at age 50 years. A-wave at 
age 70 years positively correlated to specific insulin and 
proinsulin levels at age 50 years. LAD at age 70 years 
positively correlated to specific insulin and proinsulin 
levels at age 50 years. 
RFs measured at age 50 years related to echocardiography 
measures at 70 years using partial correlation coefficients.  
Haji38 
2006 
Bogalusa, USA BP:  Childhood BP (mean age 11 +/-3 years) not 
associated with adult LV dilation (mean age 32 +/-3 
years).  
BMI: BMI in childhood positively predicted LV dilation in 
adulthood.  
Cardiac function analysed in cross-sectional manner. 
RFs  measured at first and last examinations used as the 
childhood and adulthood values. Multiple logistic 
regression used with RFs corrected for age, gender and 
race.  
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Strand39 
2006 
Oslo, Norway BP: Baseline DBP in men aged 42.1 +/- 0.5 years 
positively predicted LVM 20 years in the future. SBP was 
not associated with future LVM.  
BMI: Baseline BMI positively predicted LVM and LVMI 20 
years in the future. 
Cardiac function related to subgroups only.  
Univariable regression analysis followed by multivariable 
linear regression analysis.  
Lin40 
2007 
The 
Longitudinal 
Study of Aging, 
China 
BP: Baseline PP positively associated with year 4 LVH in a 
univariable model in individuals with a baseline age of 
71.7 +/-3.9 years.  
BMI: Baseline BMI positively associated with year 4 LVMI 
in a univariable model. 
Glycaemic control: Baseline fasting glucose positively 
correlated with year 4 LVMI. 
Cardiac function analysed in cross-sectional manner. 
Univariable analysis initially carried out followed by 
stepwise multiple regression. 
Toprak41 
2008 
Bogalusa, USA BP: DBP levels in childhood (5 to 18 years, average age 
12 years) significant positive predictor of concentric LVH 
in adulthood (24 to 44 years, average age 36 years, 24 
years after childhood examinations) 
BMI: Higher BMI in adulthood and childhood significant 
determinants of developing eccentric LVH.  
Glycaemic control: Childhood diabetes mellitus was not 
associated with adult cardiac structure.  
ANCOVA was used to evaluate differences between 4 LVG 
groups. Adjusted multinomial logistic regression analyses 
performed to define adult and childhood determinants of 
LVG in adulthood. 
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Ridderstrale42 
2010 
Military recruits, 
Sweden 
BP: MAP at age 20 years positively associated with LVMI 
at age 40 years. 
BMI: Baseline BMI positively associated with follow-up 
LVMI in a univariable model. 
Glycaemic control: Baseline insulin levels positively 
related to follow-up LVMI in those with elevated 
baseline BP in multivariable model 
Cardiac function analysed in cross-sectional manner.  
Longitudinal changes in RFs analysed using two-way 
ANOVA. RFs related to later LVMI by linear and regression. 
   
 
 
 
 
 
 
 
 
Accumulation or Change approach 
Johnson43 
1983 
Bourbon 
County, USA 
BP: Higher sustained 5 year SBP between 16-19 years 
and 21-24 years (follow-up measures used but due to 
high tracking and selection carried out this can be 
BP measured at baseline (16 to 19 years) and selected 
sample (those above 95th, below 5th percentile of SBP at 
baseline and a random sample of the rest) measured again 
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 interpreted as sustained high SBP) associated with 
higher FS and mean velocity of circumferential fibre 
shortening. IVSD, LVPWTD and LVPWTS significantly less 
in those with sustained low SBP versus those in 
intermediate and higher SBP groups. LVIDD and LVIDS 
did not differ among groups. 
BMI: Measures of body size used as correcting factors in 
the analyses.  
5 years later. High, intermediate and low SBP groups 
defined in terms of follow-up SBP and ANOVA used to 
compare echocardiography measures across the three 
groups.  
Lauer44 
1991 
Framingham, 
USA 
BP: Higher 30 year average SBP positively associated 
with LVMI and LVH at follow-up (average age of 68 +/- 6 
years). 30 year average DBP correlated with LVMI but to 
a lesser extent than SBP.  
BMI: Analysed in cross-sectional manner. 
Student’s t test and Pearson correlation coefficients used 
to estimate associations between RFs and LVM. 
Multivariable linear regression analyses carried out.  
Zureik45 
1995 
Paris, France BP: 2 year increases in SBP and DBP associated with 
increases in LVMI and LVWT in men aged 51.6 +/- 2.9 
years at baseline. 
BMI: 2 year BMI changes not associated with change in 
LV measurements.  
Changes in baseline and follow up values assessed using 
Student’s t tests. Pearson correlation coefficients used in 
univariable analysis and multiple linear regression in 
multivariable analysis. 
Bjorklund46 
2002 
Uppsala, 
Sweden 
BP: IVSD, LVPWT, LVMI at age 70 years increased in 
those with sustained hypertension over previous 20 
years. EF not associated with BP.  
Logarithmic transformation for skewed variables. ANOVA 
used to calculate differences in means; potential 
confounders taken into account by ANCOVA.   
Gardin36 
2002 
CARDIA Refer above  
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Lorber47 
2003 
CARDIA BP: In a biracial population 28 to 40 years of age, black 
men and black women with increasing SBP over 10 years 
had higher LVMI at 10 year follow-up. For black women 
the same was true for LVG. 
BMI: Black men, black women and white women with 
increasing BMI over 10 years had higher LVMI.  
Glycaemic control: Analysed in cross-sectional manner. 
10 year trends in BMI and BP assessed with year 10 LVM 
and LVG by fitting for SBP and BMI a separate regression 
line to the 10 year follow-up for each person and 
calculating Pearson correlation coefficients between the 
person-specific slopes estimated from regression models 
and LVMI and LVG. A linear random coefficients model was 
used to obtain the person-specific slopes.   
Li48 
2004 
Bogalusa, USA BP: Higher SBP in childhood and greater cumulative 
burden from childhood to adulthood (AUC over a 23 year 
period) associated with higher LVM at an average age of 
32.6 years (age range 20-38 years). 
BMI: Higher BMI in childhood and greater cumulative 
burden from childhood to adulthood (AUC) associated 
with higher LVM at 23 year follow-up. 
Multiple regression with LVM as outcome and 
standardized risk factor measures since childhood and AUC 
of risk factors as explanatory variables. 
   
 
 
 
 
Cardiac Function 
Johnson43 
1983 
Bourbon 
County, USA 
Refer above  
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Arnlov49 
2001 
Uppsala, 
Sweden 
Glycaemic control: Fasting glucose at age 50 years was 
negatively correlated with EF at 70 years.  
As for Arnlov et al 2005 
Bjorklund46 
2002 
Uppsala, 
Sweden 
Refer above  
Arnlov37 
2005 
Uppsala, 
Sweden 
Refer above  
Cheng50 
2010 
Framingham  
Offspring, USA 
BP:  In individuals with a mean age of 45 +/- 10 years, 
higher SBP, PP and hypertension treatment significantly 
related to both greater LVIDD and LVWT . SBP and PP 
positively associated with FS; DBP negatively associated 
with FS and LVIDD.  
BMI: Higher BMI significantly related to both greater 
LVIDD and LVWT. 
Glycaemic control: Individuals with diabetes mellitus 
experienced greater age-associated increases in LVWT 
and lesser decrease in LVIDD. 
Individuals in low RF group experienced greater changes 
in FS with age compared to those in high RF group.  
Long term changes: Multilevel models used to model 
individual changes in LVM with age over a 16 year period. 
Short term change: Four year echocardiographic changes 
between exams 4-5 and exams 5-6. RFs used from earliest 
of each consecutive pair of exams. Generalised estimating 
equations used to allow for fact that some participants 
contribute twice. To estimate the “overall burden” of RFs, 
high risk and low risk groups were created (based on 
presence/absence of hypertension, obesity and diabetes). 
Median SBP and DBP among the groups used in the 
regression equation. 
    
Longitudinal modelling of cardiac outcomes 
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Lieb51 
2009 
Framingham 
Offspring, USA 
BP: In individuals with a mean age of 45 years, increase 
in SBP was associated with increase in LVMI. 
BMI: Increasing BMI associated with greater increments 
in LVM; association stronger in women. 
Glycaemic control: Subjects in low RF group experienced 
lesser increases in LVM with time. 
 
As for Cheng et al 2010 
Cheng50 
2010 
Framingham  
Offspring, USA 
Refer above  
Lam52 
2010 
Framingham 
Offspring, USA 
BP: In individuals with average ages of 52+/-10 years for 
men and 51+/-10 years for women in short term group 
and 46+/-10 years for men and 45+/-10 years for women 
in long term group (age range 25-74 years), lower SBP 
and higher DBP associated with greater AoRD in 
mutually adjusted short term change models, also 
adjusted for BMI, age and sex. 
In similar models with PP and MAP replacing SBP and 
DBP, lower PP and higher MAP associated with greater 
AoRD. 
In long term change models including the same 
variables, higher DBP was associated with greater AoRD 
and lower SBP with greater AoRD in men.  
As for Cheng et al 2010 
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In similar models with PP and MAP replacing SBP and 
DBP, lower PP and higher MAP associated with greater 
AoRD.  
BMI: Higher BMI associated with greater AoRD in short 
and long term change analyses after adjustment for BP, 
age and sex. 
McManus53 
2010 
Framingham 
Offspring, USA 
BP: In individuals with an average age of 45 years, 
participants with higher RF burden (higher SBP) had a 
greater LAD increase after 16 years. DBP was inversely 
related to LAD size.  
BMI: Participants with a higher RF burden (higher BMI) 
had a greater LAD increase after 16 years.  
Glycaemic control: Analysed in cross-sectional manner. 
As for Cheng et al 2010 
LVM, Left Ventricular Mass; IVSD, Interventricular septal diameter; LVPWD, Left ventricular posterior wall diameter; RWT, Relative wall thickness; LVIDD, 
Left ventricular internal diameter in diastole; LVIDS, Left ventricular internal diameter in systole; BSA, Body Surface Area; LVMI, Left ventricular mass index; 
SBP, Systolic blood pressure; LVH, Left ventricular hypertrophy; BP, Blood pressure; LVPWTD, Left ventricular posterior wall thickness in diastole; LVPWTS, 
Left ventricular posterior wall thickness in systole; ANOVA, Analysis of variance; BMI, Body mass index; AUC, Area Under the Curve; LV, Left ventricle; RF, 
Risk factor; DBP, Diastolic blood pressure; LVG, Left ventricular geometry; MAP, Mean arterial pressure; PP, Pulse pressure; LVWT, Left ventricular wall 
thickness; FS, Fractional shortening; AoRD, Aortic root diameter; LAD, Left atrial diameter; IAMB, Intra-arterial ambulatory blood pressure; EF, Ejection 
Fraction; ANCOVA, Analysis of covariance 
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There was more than 1 paper from 5 studies; Framingham (2 papers), Framingham Offspring 
(4), Bogalusa (4), Uppsala (4) and CARDIA (2). These papers focussed on different RFs and/or 
outcomes and were thus all included in the review.  The range of follow up periods in these 
studies was wide, varying from 2 years to 70 years and the mean age of study members at 
baseline varied from 7 years to 89 years. Most studies were conducted in adult participants, 
although 4 measured RFs in children with follow up into adulthood (Bogalusa, Hertfordshire 
cohort and the studies by Johnson and Kumaran).32, 33, 41, 43 Six studies were in men only 
(Uppsala cohort studies and in the studies by Ridderstrale, Vijayakumar, Jokiniitty, Strand and 
Zureik),32, 34, 35, 37, 39, 42, 45, 46, 49 but the majority had male and female participants. Bogalusa 
and CARDIA had a purposely bi-ethnic study population, while Kumaran’s study was on South 
Asian Indians and Lin’s study on Chinese seniors. The others consisted of European-origin 
population cohorts. 
The longitudinal relationship between RFs and future cardiac structure and function was 
investigated in a variety of ways. Papers from the same study sometimes used different 
approaches while more than one approach was also used in the same paper. Although there 
was some overlap, we have divided the studies into 3 broad groups (depending on the 
approach to data analysis).  
One group of studies related RFs at a single point in time with cardiac structure measured at 
a subsequent time point: 2, 30, 33-42 we have called this the “prospective approach” for the 
purposes of this review. The second group of studies, with regularly repeated measures of 
RFs, calculated summary measures of the RFs over a period of time for each individual, e.g. 
the area under the curve (AUC) or rate of change, and related those to future cardiac structure 
and function.30, 44, 46-48 We have labelled this an “accumulation or change approach”. One 
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study fell into both the “prospective” and “accumulation or change” categories as it carried 
out both types of analysis in the same paper.36 
A third approach, used only in the Framingham Offspring papers, concentrated on 
investigating the short term changes in RFs with concurrent changes in cardiac measures.50-53 
These studies also investigated the associations between baseline RFs and subsequent 
longitudinal changes in cardiac measures over a longer period of time; an approach which did 
not strictly fit our inclusion criteria as it did not utilise repeated measures of the RF and also 
looked at longitudinal change in the outcome measure rather than in the RF. However, given 
the similarity of approach we have included these studies in this review for comparative 
purposes. We have called this approach “longitudinal modelling of cardiac outcomes”. This 
category is dealt with at the end of the results in a separate section. 
Within each of these categories, results from studies with younger participants have been 
presented first followed by studies with older patients.  
 
Cardiac structure  
Blood pressure  
The relationship between BP and cardiac structure was investigated in all 13 cohorts.   
“Prospective approach” 
BP measured at different times across the lifetime has been positively related to subsequent 
left ventricular (LV) wall thickness and mass. 
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Childhood Systolic and Diastolic BP (SBP and DBP) (average age 13.3 years) were positively 
associated with LVM measured 4 years later and LVH measured 19 years later in Bogalusa, 
but SBP was not associated with LV dilation 19 years later. 30, 38, 41 Similar positive associations 
between SBP and mean arterial pressure (MAP) measured in childhood and adolescence and 
future LVM (measured 10-20 years later) were observed in young adults (18-30 years in age). 
36, 42 These studies did not investigate the role of current BP in these associations. 
Vasan found that previous BP did not provide additional information when current BP was 
known when predicting aortic root diameter in a population ranging from 20 years to 89 years 
in age.31 
The association between SBP at older ages and subsequent cardiac structure was considered 
in 4 studies. In one study SBP and DBP at age 50 years were associated with an increased 
prevalence of LVH at age 70 years,35 while in another, DBP at age 42.1 years positively 
predicted LVM 20 years later.39 In a study of elderly Chinese, only baseline pulse pressure (PP) 
was positively associated with LVH 4 years later.40   
“Accumulation or change approach” 
Studies have generally shown a relationship between faster rates of SBP change and higher 
cumulative SBP across the life course and poorer cardiac structure.  
Greater LVM at age 33 years was associated with a greater cumulative SBP burden over the 
prior 23 year period (quantified by AUC),48 while greater wall thickness [(interventricular 
septal thickness in diastole (IVSD) and left ventricular posterior wall thickness in diastole 
(LVPWT)] but not left ventricular internal diameter in diastole (LVIDD) in 21 to 24 year olds 
was associated with sustained higher BP over the preceding 5 years. 43 
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In young black men and black women, a greater increase in SBP over 10 years was positively 
associated with future LVM index (LVMI).47 
Similarly, in older samples,  greater wall thickness was associated with sustained hypertension 
in Uppsala (50 years at baseline, 20 year follow up)46 and faster increases in SBP in a Parisian 
cohort (47-58 years at baseline, 2 year follow up).45 
In the Framingham cohort, average 30-year SBP was calculated which positively correlated 
with LVMI and LVH at follow up when individuals were aged 68 years.44 
 
BMI and weight 
“Prospective approach” 
The relationship between weight at birth or in infancy with later cardiac structure was 
investigated in 2 studies.  Birth weight was not associated with LVMI or left ventricular 
geometry (LVG) at a mean age of 49.5 years, and a longer length at birth showed a weak and 
non-significant association with increasing LVMI, LVG and relative wall thickness (RWT).33 
However, in the study with the longest follow-up, greater weight at 1 year was associated 
with lower LVM, IVSD, LVPWT and RWT, but was not associated with LVIDD at a mean age of 
70 years.32  
Higher BMI or weight in children and young adolescents was related to greater future LVM,30 
LV dilation, eccentric LVH and left atrial diameter (4 years later).38, 41 BMI in young adults was 
also positively associated with LVM 10 and 20 years later.36, 42  
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BMI was related to cardiac structure in 3 older cohorts where it was predictive of future LVMI 
after 4, 10 and 20 years respectively (baseline ages 35-45, 71.7 and 42 years respectively).34, 
39, 40 High BMI at the age of 50 years was also associated with increased prevalence of LVH 
and higher left atrial diameter at 70 years.35, 37 
 
“RF accumulation or change approach” 
Only 3 studies have related summary measures of repeated BMI to cardiac structure. A 
greater cumulative BMI burden (AUC) over a period of 23 years was associated with a higher 
LVM at 33 years.48 Among black men and black and white women, greater increases in BMI 
over a 10 year period, were associated with a greater LVMI at ages 28-40 years.36    
In older individuals (52 year old men), BMI changes were not associated with changes in LV 
structure. However the follow up was only for 2 years.45 
 
Glycaemic control 
All studies considering glycaemic control took a “prospective” approach. Although no 
relationships between childhood glycaemic control and later cardiac structure were evident 
from the analyses, this was not the case for measures of glycaemia in adult life. 
Only 4 studies considered the prospective effect of glycaemic control on cardiac structure.37, 
40-42  Fasting glucose measured in childhood was not associated with LVH 24 years later.41 
However in 20 year olds, baseline insulin levels were associated with LVMI measured 20 years 
subsequently.  
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Relationships between glycaemic control and cardiac structure were evident in older cohorts. 
Proinsulin levels at age 50 years were positively correlated with left atrial diameter at age 70 
years,37 while fasting glucose at baseline was positively correlated with year 4 LVMI in Chinese 
seniors.40 
 
Longitudinal modelling of cardiac outcomes 
The Framingham Offspring Study papers have concentrated on relating baseline RFs to 
longitudinal changes in cardiac measures over 4 year and 16 year periods.50-53 Multilevel 
modelling was used to evaluate the correlates of LVM prospectively over a 4-16 year period.  
Higher baseline SBP was associated with greater increases in LVMI, and higher SBP and PP 
were significantly related to greater increases in LV dimensions and wall thickness as well as 
larger increases in left atrial diameter.51 The relationships between BP and change in aortic 
root diameter were more complex with lower baseline SBP and PP and higher baseline DBP 
and MAP being associated with greater increases in follow-up aortic root diameter.53 
Baseline BMI was also related to changes in cardiac structure with positive associations with 
increases in LVIDD, LV wall thickness50 and LVM, the last association being stronger in 
women.51 Higher BMI was also positively associated with a greater increase in aortic root 
diameter.52 
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Cardiac function 
There were a limited number of studies investigating the effect of RFs on cardiac function.  In 
general the studies did find that BP, BMI and glycaemic control were all predictors of future 
cardiac function. 
A total of 9 studies investigated cardiac function of which 4 were excluded from this section 
as analyses were carried out in a cross-sectional manner or only on a subgroup of the study 
cohort.38-40, 42 Of the 5 papers investigating longitudinal associations, 3 were on the Uppsala 
cohort.37, 43, 46, 49, 50 All studies considered BP and only the Uppsala group investigated BMI 
and glycaemic control. 
Sustained higher SBP over a 5 year period in adolescents and young adults was positively 
associated with fractional shortening and mean velocity of circumferential fibre shortening, 
measured at 21-24 years.43 In the Framingham Offspring cohort, higher baseline SBP was 
associated with faster increases in fractional shortening.50  In older samples, although BP did 
not show a relationship with EF, higher SBP and DBP at age 50 years were associated with 
decreased E/A ratio and higher SBP to higher A-wave 20 years later.37, 46 
In the Uppsala cohort, higher BMI at age 50 was associated with diastolic dysfunction manifest 
as decreased E/A ratio and larger A-wave after adjustment at age 70.37  Fasting glucose at 50 
years was negatively related to EF at age 70, and positively correlated with E-wave,49 and 
specific insulin and proinsulin levels were positively correlated with the magnitude of the A-
wave.37 
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Discussion 
Most studies included in the review show associations between higher SBP and BMI at an 
earlier time-point and poorer cardiac structure measured up to 70 years later. Single 
measures of SBP and BMI measured in childhood, adolescence and early adulthood and 
greater cumulative burden of these RFs predict cardiac measures (LVM, LV wall thickness) in 
adulthood in the few studies that look at this. Overall, there was a lack of studies relating birth 
weight, infant weight or glycaemic control to cardiac structure and a lack of studies 
considering the longitudinal relationship of RFs with cardiac function. 
 
Assessment of bias and justification for exclusions 
Due to the variation in cardiac measures investigated (even for a single cardiac measure such 
as LVM, indexing was done in a variety of ways), the variation in age at measurement of RFs 
and length of follow-up, and the differences in statistical analysis with different levels of 
adjustment for potential confounding variables, it was not possible to perform a meta-
analysis of results. We were thus also unable to formally assess publication bias. By 
systematically reviewing the literature according to published guidelines16, 17 and following a 
pre-specified protocol, we have attempted to include all published results of the main 
associations of interest. However, we did limit our search to two electronic databases using 
the Mesh terms stated above and to studies written in English, and therefore, may have 
missed some relevant studies. 
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Interpretation of the findings  
Ideally, life course studies require RFs to be collected over a substantial period of time and at 
various phases of the life course. The studies that have shown single RF measurements in 
childhood, adolescence or early adulthood to be correlated with adult echocardiographic 
measures may reflect “tracking” of the RF from childhood to adulthood (those with high levels 
of a RF in childhood continue to have high levels in adulthood).54 Few studies investigate this 
possibility and so it remains unclear whether these observations can be interpreted as 
showing a distinct contribution from earlier exposure to RFs. Current SBP seemed to account 
for the effect of SBP measured 8 years earlier in the only study that investigated whether 
prior SBP had a predictive value independent of current SBP.31 The question of whether SBP 
measured earlier in the life course has an independent role (by affecting cardiac measures in 
a particularly sensitive period of the life course) remains unclear.  
Other studies suggest a “cumulative” effect of exposure to obesity and hypertension on later 
echocardiographic results, possibly through an accrual of damage over time worsened by 
prolonged exposure. However, no study has analysed the impact of RF trajectories starting 
from birth and continuing to early, mid and later adulthood on cardiac structure and function 
at an older age. Neither of the two studies investigating very early weight and adult LVM 
found evidence of an association, suggesting that fetal development associated with low birth 
weight in the normal range exerts minimal effect on future LVH.  However, both studies were 
quite small and may have lacked the required statistical power to detect a relatively small 
relationship.   
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While this review focuses on the effect of long-term and longitudinal changes in BP, BMI and 
glycaemic control on cardiac structure and function, the possibility of reverse causality cannot 
be ruled out in those studies without baseline echocardiography. Some studies have explored 
the effects of an echocardiographic diagnosis such as LVH on subsequent levels of BP. These 
studies have shown that increased LVM, in normotensive individuals or subjects with 
optimally controlled blood pressure, predicts the development of future hypertension.18, 21 
Poorer baseline cardiac function in the form of lower EF has also been found to be associated 
with subsequent higher SBP.19 
 
Some studies suggest that 24 hour PP, as opposed to SBP, is more predictive of later LVM.34  
Different BP parameters (SBP, DBP, PP, MAP) reflect the effect of BP in subtly different ways. 
For example, PP depends on stroke volume and arterial stiffness whereas MAP is determined 
by cardiac output and peripheral resistance.55, 56 From the papers reviewed, it is not possible 
to determine which measures are the most useful predictors over the longer term, as 
different measures have not been compared against each other. Consideration of these 
multiple BP measurements in future longitudinal studies may result in better insights into the 
hemodynamic mechanisms acting over the life course to affect cardiac structure and function.  
 
The studies in our review showed associations between poorer glycaemic control and worse 
left ventricular mass, ejection fraction and E/A ratio.37, 40-42 However caution would be needed 
before extrapolating these findings to all population groups due to the small number of 
studies. In addition, the effect of long-term glycaemic control was not measured and although 
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attempts were made to account for the role of confounding factors, it is difficult to tease out 
the effect of glycaemia independent of its effect through BMI.   
 
Implications of the findings 
One of our striking findings was the lack of a standardised approach to analysis. The papers 
in this review were published between 1983 and 2010, and the analytical approaches have 
developed in line with the changing nature of the hypotheses with regard to biological 
mechanisms. Multivariable linear regression, relating the RF at a single time point to a 
subsequent echocardiographic measure, has been used in most studies. However, analyses 
become more complex if the aim is to use repeated measures of the RF.  A few studies have 
attempted to deal with problems of modelling correlated measures of exposure by creating 
a summary measure for each individual e.g. AUC, or rate of change,57 and relating these to 
the outcome.44 However, no studies have as yet attempted to disentangle the effect of 
“cumulative” RF burden from exposures during sensitive periods.58, 59 In the domain of life 
course epidemiology and life course cardiology in particular, there is no standard statistical 
approach to analysis linking a repeated exposure to a subsequent health outcome. The most 
appropriate method will depend on the specific hypothesis under study and hence the 
plurality of techniques used in the included papers.60   
 
Another issue is the added complexity when children are followed up into early adulthood as 
childhood growth may not be adequately captured by changes in childhood BMI.61  Fat mass 
and lean mass may need to be considered separately when analysing cardiac growth in 
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children, but most studies only had measures of BMI and we were thus unable to consider 
this.62, 63 
 
We also found a lack of studies dealing with the longitudinal effects of RFs on cardiac function, 
and the few that did, investigated different aspects of systolic or diastolic function. Many of 
the populations included in the review have been young adults, and as such, the vast majority 
of study participants had normal cardiac function. As a result, it is not possible to make a 
generalised systematic assessment of the findings and this area would benefit from further 
research. Some findings have also been different among blacks and whites in the bi-ethnic 
studies. Further research with more heterogeneous study populations would be helpful in 
making findings more generalizable.  
 
New research on the long-term effect of exposure to poorly controlled BP, BMI and glycaemia 
is warranted to better understand the mechanisms by which they independently, 
cumulatively or interactively affect later cardiac function and structure. The life course 
approach could help identify periods where exposures to RFs may be particularly detrimental 
to cardiac function and structure. This new knowledge would be invaluable to inform policy 
related to cardiovascular disease prevention, enabling earlier targeted intervention to 
individuals at risk.  
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Conclusions 
This systematic review provides some evidence that earlier elevated BP, high BMI and poor 
glycaemic control result in worse cardiac structure and function up to 70 years later. This 
information may be used to inform clinical practice with the caveats that the number of 
studies on which this evidence is based is limited, and the findings are difficult to generalize 
to all population groups. There is a lack of studies investigating either the effect of changes in 
RFs over the life course or the cumulative effect of exposure to RFs on cardiac structure and 
function. Future studies utilizing a life course approach, to identify if there are sensitive 
periods where exposure is particularly detrimental, might suggest time-points when 
prevention may be most beneficial. Ultimately such information would be invaluable from a 
public health and preventive Cardiology perspective.  
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Chapter 3 
Methods 
 
Data collection 
 
Study patients 
The UK Medical Research Council National Survey of Health and Development is a prospective 
birth cohort study of singleton births that occurred in one week of March 1946 in England, 
Scotland, and Wales (5362 births; 2547 women, 2815 men). Follow-up has included over 20 
contacts with the whole cohort between birth and the most recent data collection when the 
participants were between 60-64y of age. At the most recent round of data collection, 3163 
(59%) were included in the target sample; of the original cohort, 718 (13.4%) had died, 594 
(11.1%) had previously withdrawn from the study, 567 (10.6%) lived abroad, and 320 (5.9%) 
had been permanently untraced for more than ten years.  
Study members received postal questionnaires between 2007 and 2008 and were invited for 
clinic visits between October 2007 and February 2011. If study members were unable or 
unwilling to come to one of the six clinical research facilities located around the UK, they were 
offered a slightly less comprehensive examination (which did not include echocardiography), 
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carried out in their own home by a trained nurse.  Of the 3163 people in the target sample, 
information was obtained from the postal questionnaire and/or visits from 2661 (84%). Of 
these, 1690 attended a clinic and 539 had a home visit. 
 Survey members had previously been interviewed in their own homes by trained research 
nurses at ages 36, 43 and 53y. The cohort profile has been described in detail previously.1 2  
 
 
 
Blood pressure measurement 
Brachial blood pressure (BP) was measured in the upper right arm with an appropriately sized 
cuff by a trained research nurse after 5 minutes of rest using an Omron HEM-705  machine 
(Omron Corporation, Tokyo, Japan).3 The measurement was repeated twice with the second 
measurement used for analysis, or the first if the second was unavailable. This was done for 
consistency with previous visits.  An Omron HEM-705 was also used when study members 
were aged 53y, while a Hawksley random zero sphygmomanometer (Hawksley & Sons Ltd, 
Lancin, UK) was used at ages 36 and 43y. BP values obtained with the random zero 
sphygmomanometer were corrected to enable comparison with BP measured with the 
Omron machine using an algorithm described by Stang et al.4 
 
Antihypertensive medication (HTT) 
HTT was recorded on the postal and clinic questionnaires at the most recent data collection. 
In previous years, study members had been asked about medications at the home visits. Drugs 
acting on the cardiovascular system for the last 2 rounds of data collection were classified 
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according to International Classification of Diseases and related Health Problems classification 
(ICD).1, 2 
 
 
Anthropometric measurements  
Height and weight were measured at 36, 43, 53 and 60-64y and self-reported at 20y 
(questionnaire) and 26y (home visit by interviewer).  
In the last round of data collection, standing height in centimetres (to the nearest millimetre) 
was measured using a portable stadiometer with the head in the Frankfort plane. Weight at 
60-64y was measured in Kg (to the nearest 0.1Kg) using Tanita solar weighting scales 
calibrated by Chasmors Limited (London, UK).   
Standing height and weight were measured using the same equipment at ages 36-53y by 
research nurses during home visits. At 36y weight was recorded to the nearest 0.5Kg below 
and standing height to the nearest 0.5cm below. At 43y weight was recorded to the nearest 
0.5Kg below and standing height to the nearest 1mm below. At 53y weight to the nearest 
0.5Kg and standing height to the nearest 0.5cm were recorded. Imperial measurements at 
ages 20y and 26y were converted to metric values. 
Body mass index (BMI), defined as weight (Kg) / height (m)2 was calculated at each age. Those 
with a BMI of >= 25 Kg/m2 were classed as overweight following the World Health 
Organization definition.5  
We constructed an “age at first overweight” variable, which was the first age study members 
were recorded as overweight, provided they were recorded as overweight at all subsequent 
visits (Table 3.1). We were unable to define “duration of overweight” due to there being 
intervals between measurements, as overweight individuals may have been of normal weight 
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between clinic measures. Cohort members who were not persistently overweight (including 
those with missing data) were excluded from these analyses. 
 
 
 
 
 
Table 3.1. Depiction of how age at first overweight was defined. 
Age of first overweight  
(years) 
Ages when documented as being overweight (years) 
N/A Never 
60-64 60-64 
53 60-64 + 53 
43 60-64 + 53 + 43 
36 60-64 + 53 +43 +36 
26 60-64 + 53 + 43 + 36 + 26 
20 60-64 + 53 + 43 + 36 + 26 + 20 
 
 
Waist circumference was also measured but these data were not available for use at the time 
of analysis.  
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Type 2 diabetes mellitus 
Presence of type 2 diabetes mellitus (T2DM) was used as a confounding variable in analyses. 
175 cohort members reported that a doctor had diagnosed them with T2DM. Study members 
who were diagnosed with T2DM on the basis of their clinic blood tests were also included.  
 
 
 
Echocardiographic studies 
Of the 1690 participants who attended a clinic, 1653 [798 men and 855 women, mean age 
63.3y +/- 1.1y (1SD)] underwent echocardiography using GE Vivid I machines (General Electric, 
Fairfield, Connecticut, USA) and 1480 had analysable images (89%). Echocardiographic images 
were obtained from parasternal long axis and short axis, apical 5-chamber, 4-chamber, 3-
chamber, 2-chamber and aortic views along with conventional and tissue Doppler in the 4-
chamber view. Image analysis was carried out by AKG along with two experienced cardiac 
physiologists masked to patient identity using GE EchoPac software. 
A manual of operations was in place before my involvement in the project. I reviewed it and 
made some changes under the guidance of my supervisors. This modified manual of 
operations was followed by echocardiographers for all scans.  I also carried out some scanning 
when echocardiographers were unavailable. 
 
 
 
115 | P a g e  
 
Measures of cardiac structure  
Wall thickness 
Wall thickness measurements were made in accordance with the latest American Society of 
Echocardiography (ASE)/ European Association of Echocardiography (EAE) guidelines on 
chamber quantification.6 2-dimensional (2D) targeted M-mode guided measurements were 
taken. Linear dimensions were taken of the septal wall, LV cavity, and posterior wall along the 
LV minor axis, identified as the largest diameter perpendicular to the septum and posterior 
wall according to the model of a prolate ellipse of revolution. M-mode images can often be 
of insufficient quality and as such criteria were established in the Manual of Operations as to 
acceptable image quality for measurement:  
1) a single dominant line 
2) continuous lines at the point of measurement at least 5 mm in length 
3) an interface with motion characteristics for the specific cardiac structure 
 If the M-mode images were of insufficient quality, 2-Dimensional measurements were taken.  
 
Left ventricular mass  
Left ventricular mass (LVM) in our study has been calculated using the ASE/EAE recommended 
formula for deriving LVM from linear measurements6: 
 
LVM =  0.8 X [1.04 X [(LVIDD +  LVPWTD +  IVSD)3 – (LVIDD)3]] +  0.6 g 
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where LVIDD = LV internal diameter in diastole, LVPWTD = LV posterior wall thickness in diastole and IVSD = 
interventricular septal thickness in diastole 
 
While this formula produces results which have been well correlated with necropsy              (r 
= 0.90, p <0.001),7 it does model the left ventricle (LV) as a prolate ellipse of revolution. As 
such, this formula is valid only for those patients without significantly abnormal LV geometry 
and errors in measurement can be magnified as measurements are cubed. 
LVM is usually indexed (LVMI) to facilitate comparison with others/sexes and the use of 
normal value charts. The best method of indexing LVM remains a topic of debate.8, 9 Body 
surface area (BSA) has been the commonest parameter used for indexing in clinical trials6 and 
this has method been used in this thesis with the Dubois formula being used to calculate 
BSA.10 However, a problem with using BSA is that LV hypertrophy (LVH) will be 
underestimated in obese individuals. To account for this, allometric indexing has also been 
advocated (height2.7).11, 12 LVM was also indexed to height2.7 in this work for some 
comparative analyses.  
 
 
Relative wall thickness 
Relative wall thickness (RWT) was also calculated to allow differentiation of LV remodelling 
patterns (Figure 3.1):  
𝑅𝑊𝑇 =
 2 𝑋 𝐿𝑉𝑃𝑊𝑇𝐷
𝐿𝑉𝐼𝐷𝐷
  
117 | P a g e  
 
where LVIDD = LV internal diameter in diastole and LVPWTD = LV posterior wall thickness in diastole  
 
 
 
Figure 3.1. Comparison of relative wall thickness (RWT). Patients with normal left 
ventricular (LV) mass can have either concentric remodelling (normal LV mass with 
increased RWT >=0.42) or normal geometry (RWT <=0.42) and normal LV mass. Patients 
with increased LV mass can have either concentric (RWT >=0.42) or eccentric (RWT <=0.42) 
hypertrophy. These LV mass measurements are based on linear measurements.6 
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Measures of cardiac structure  
Diastolic function  
Pulsed wave Doppler in the 4 chamber view was used to acquire mitral inflow velocities which 
can help assess LV filling.13 The flow pattern typically consists of two components – the E wave 
and A wave, associated with early filling and atrial contraction respectively (Figure 3.2).  
 
 
Figure 3.2. Normal mitral inflow pattern acquired by pulsed wave Doppler.14 
The mitral E wave velocity primarily reflects the pressure gradient between the left atrium 
(LA) and LV in early diastole, which is largely established by relaxation of the left ventricle 
aspirating blood into itself.15 The A wave results from a pressure gradient established by atrial 
contraction in late diastole. The ratio of the two (E/A) is a normalized index that reflects early 
E wave 
A wave 
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diastolic filling relative to atrial contraction16 and has been widely used as an indicator of 
diastolic function.  
The E and A waves can be influenced by a variety of factors. The E wave can be affected by 
preload and changes in LV relaxation, volumes, elastic recoil and diastolic pressures.17 The A 
wave can be affected by LV compliance (the relationship between LV pressure and volume) 
and LA contractility.18 Another limitation of E and A measurements is that LV filling patterns 
have a “U-shaped” relationship with diastolic function. Diastolic dysfunction is usually 
accompanied by a progressive increase in LV filling pressures. Slowed or prolonged LV 
relaxation causes a decrease in E velocity but at the same time contributes to elevation of LA 
pressure, which in turn tends to increase the E velocity.19 This is usually accompanied by a 
decrease in compliance and, as a result, with time the effects of worsening diastolic function 
on E/A become progressively compensated and then over-compensated by the effects of 
loading and reduced compliance, resulting in an “U–shaped” non-linear relation between E/A 
and the severity of diastolic dysfunction.20 Due to this, subjects with a E/A of 1-2 could have 
normal or abnormal diastolic function – the “pseudonormalization” phenomenon (Figure 
3.3).21  
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LVEDP – Left ventricular end diastolic pressure. 
Figure 3.3. Schematic diagram of the changes in mitral inflow in response to changes in 
the transmitral pressure gradient.21 
 
To overcome this problem of pseudonormalization, other markers of diastolic function have 
to been developed. In this work, I have also utilized tissue Doppler to provide additional 
information on diastolic function. Pulsed wave tissue Doppler imaging in the 4-chamber view 
was used to obtain mitral annular velocities.22 The velocities that are recorded are analogous 
to those obtained with pulsed wave Doppler – e’ represents early diastolic annular velocity 
(analogous to E wave) and a’ represents late diastolic annular velocity (analogous to the A 
wave) (Figure 3.4). e’ progressively reduces as LV long axis relaxation is impaired and it is 
much less susceptible to  the effects of increased preload.18 Velocities at the lateral and septal 
annulus are not interchangeable23 and the ASE/EAE14 have recommend using  the average of 
septal and lateral velocity; this was done in this thesis.  
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s’ - systolic annular motion; e’ and a’ - respective early and late diastolic annular motion 
Figure 3.4. Tissue Doppler recording from the lateral mitral annulus.  
 
The ratio E/e’ is used to provide an estimate of mean LA pressure. E/e’ has been validated in 
a number of clinical situations24 and is related to prognosis.25-27 Currently, it is the favoured 
primary measure of diastolic function, as advocated by the latest (2009) joint EAE/ASE 
guidelines.14, 28 
Another advantage of tissue Doppler, is that unlike pulsed wave Doppler across the mitral 
valve, there is no “U-shaped” relationship between the velocities and diastolic function and 
thus no pseudonormalization of e’/a’ (Figure 3.5).  
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LVEDP – Left ventricular end diastolic pressure; Em - e’; Am - a’.  
Figure 3.5. Schematic diagram of the changes in tissue Doppler mitral annular velocities in 
response to changes in the transmitral pressure gradient.21 
 
Left atrial volume indexed to body surface area (LAVI) was also examined as a marker of 
chronic left ventricular filling pressures.29, 30 Simpson’s biplane method was used to calculate 
the volume of the left atrium.6, 31 Simpson’s algorithm uses the method of discs dividing the 
left atrium into a series of stacked oval discs (height =h, orthogonal minor axis = D1, 
orthogonal major axis = D2). The volume of the left atrium is then calculated as follows: 
𝐿𝑒𝑓𝑡 𝑎𝑡𝑟𝑖𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 =  
𝜋
4  
 𝑋 ℎ  Σ [(𝐷1 ) X (𝐷2 )]   
where h = left atrial height, D1 = orthogonal minor axis, D2 = orthogonal major axis 
 
 
Systolic function  
Systolic function has been measured in this thesis in the form of ejection fraction – EF and 
tissue Doppler velocity of systolic motion of the mitral annulus (average of the lateral and 
septal annulus) – s’.  
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EF is the fraction of blood ejected at each beat: 
𝐸𝐹 =  
𝐿𝑉𝐸𝐷𝑉 − 𝐿𝑉𝐸𝑆𝑉
𝐿𝑉𝐸𝐷𝑉
 
where LVEDV = left ventricular end diastolic volume and LVESV = left ventricular end systolic volume 
 
Simpson’s biplane method of discs was used to calculate the EF using two orthogonal views 
(2 chamber and 4 chamber). Using Simpson’s biplane method can sometimes be problematic 
due to poor endocardial border definition.6 In these situations, linear methods (2-D guided M 
mode) were used. However, a difficulty with using linear measures is that regional wall 
abnormalities may not be reflected in the EF value, or conversely, they may lead to a reduced 
EF not in keeping with global LV function which may be within normal limits.  
While EF does correlate well with prognosis in heart failure of any aetiology,32-35 s’ may be a 
more sensitive marker of systolic dysfunction and is often depressed before there is any 
change in ejection fraction36 and can detect subclinical systolic dysfunction in diabetic 
patients37 and in patients with pre-clinical genetically-proven hypertrophic cardiomyopathy.38 
s’ is also a predictor of cardiovascular events and mortality.39-42 
Other measures of systolic function include endocardial fractional shortening, midwall 
fractional shortening, stress-corrected midwall fractional shortening and active fibre stress. 
These measures were not calculated in this thesis.  
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Quality control for echocardiographers 
Standardized training for echocardiographers had taken place before data collection had 
started (before I was recruited as a PhD student). I arranged training for new 
echocardiographers who were assigned to the data collection team as well as arranging 
refresher training sessions.  
All scans were reviewed by either myself or a member of the data collection team trained in 
image-quality interpretation and the manual of operations. Regular monthly feedback was 
provided to the echocardiographers and more frequent feedback was given if necessary. 
Retraining was planned if problems persisted, but in practice this did not prove necessary. If 
there were any significant clinical abnormalities, the participant was referred for a full 
echocardiogram, which was carried out and reported locally by an experienced Cardiologist.  
I also carried out calibration testing of the Vivid GE machines at all the 6 clinical research 
facilities using a CIRS ultrasound phantom 055A (CIRS Incorporated, Norfolk, VA, USA).  The 
images from the calibration testing of the 2D probe at one of the clinical research facilities is 
given below (Figure 3.6). 
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Figure 3.6. Screenshot of phantom calibration testing of 2D ultrasound probe. 
 
 
Quality control for readers 
Scans were read by me and 2 experienced echocardiographers. I had input into the 
preparation of a standardised image-reading protocol which was used to analyse the images 
offline using GE EchoPac software. A pre-specified analysis protocol was created in EchoPac 
by a GE technician under my guidance to streamline the reporting process.  
Blind duplicate reading reproducibility studies were carried out to establish inter- and intra-
reader variability with excellent reproducibility [intra-class correlation coefficients (ICCs) 
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were >90% for most measurements]. The results for some of the measures analysed in this 
thesis are documented in table 3.2.  
 
Table 3.2. Intra-reader and inter-reader ICCs for Interventricular septal thickness in 
diastole, left ventricular internal diameter in diastole, e’ and E/A. 
Variable Intra-reader ICC 
(reader 1) 
Intra-reader ICC 
(reader 2) 
Intra-reader ICC 
(reader 3) 
Inter-reader ICC 
IVSD 0.916 0.922 0.916 0.932 
LVIDD 0.968 0.969 0.968 0.968 
e’ 0.907 0.911 0.906 0.919 
E/A 0.979 0.979 0.980 0.981 
ICC -Intra-class correlation coefficient; IVSD - Interventricular septal thickness in diastole; LVIDD - Left ventricular 
internal diameter in diastole 
 
 
Bland-Altman plots were also constructed for the reproducibility exercise. The Bland-Altman 
plots for left ventricular internal diameter in diastole (LVIDD) measured by the 3 readers are 
given below (Tables 3.3a-c and Figures 3.7a-c).   
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Reader 1 vs. Reader 2 
Table 3a. Mean, standard deviation, limits of agreement, p for bias and random error for 
left ventricular internal diameter in diastole (cm) measured by reader 1 (AG) and reader 2 
(AO). 
Measurement Results 
 
Mean ± SD (cm) Reader 1  4.62 ± 0.68 vs. Reader 2  4.72 ± 0.79 
Difference ± SD (cm) -0.00 ± 0.25 
Limits of agreement -0.55, 0.54 
p for bias 0.97 
± random error 0.54 
SD - Standard deviation 
 
 
Figure 3.7a. Bland-Altman plot for left ventricular internal diameter in diastole (cm) 
measured by reader 1 (AG) and reader 2 (AO). 
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Reader 1 vs. Reader 3 
 
Table 3.3b. Mean, standard deviation, limits of agreement, p for bias and random error for 
left ventricular diameter in diastole (cm) measured by reader 1 (AG) and reader 3 (KM). 
Measurement Results 
 
Mean ± SD (cm) Reader 1  4.62 ± 0.68 vs. Reader 3  4.68 ± 0.67 
Difference ± SD (cm) -0.03 ± 0.13 
Limits of agreement -0.30, 0.24 
p for bias 0.34 
± random error 0.27 
SD - Standard deviation  
          
 
 
Figure 3.7b. Bland-Altman plot for left ventricular internal diameter in diastole (cm) 
measured by reader 1 (AG) and reader 3 (KM). 
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Reader 2 vs. Reader 3 
 
Table 3.3c. Mean, standard deviation, limits of agreement, p for bias and random error for 
left ventricular internal diameter in diastole (cm) measured by reader 2 (AO) and reader 3 
(KM). 
Measurement Results 
 
Mean ± SD (cm) Reader 2  4.72 ± 0.79 vs. Reader 3  4.68 ± 0.67 
Difference ± SD (cm) -0.00 ± 0.22 
Limits of agreement -0.49, 0.49 
p for bias 0.99 
± random error 0.49 
SD - Standard deviation  
 
Figure 3.7c. Bland-Altman plot for left ventricular internal diameter in diastole (cm) 
measured by reader 2 (AO) and reader 3 (KM). 
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Coding the data 
 
Codes were created for the various possible reasons why a study member did not undergo 
echocardiography and for the reasons for poor image quality. I was involved in coding the 
questionnaires using the above codes.  
 
 
 
 
Data cleaning 
All the echocardiographic measures and BP and heart rate readings were checked and cleaned 
prior to analysis (including those echocardiographic measures which were not used for 
analyses in this thesis). Means and 2 standard deviations were tabulated our measurements 
compared to the published data.6, 14, 28, 31, 43 Outliers (outside 2 standard deviations) were 
individually inspected. This inspection involved reviewing measurements documented in the 
clinic questionnaire (e.g. BP and heart rate) or reviewing echocardiographic images 
themselves and re-measuring. For some of the echocardiographic measures, other related 
measurements were also checked (e.g. left atrial volume was checked if left atrial diameter 
was outside the 2 standard deviation range). 
Normality of the data was checked by visually inspecting the distributions of the 
measurements once they had been cleaned. As the measurements used in this thesis were 
normally distributed no transformations (e.g. logarithmic) were performed. Once cleaned, the 
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variables were renamed with a suffix to indicate that they were the final variables to be used 
in analyses. 
 
 
 
Statistical modelling 
In the context of this thesis I have attempted to relate longitudinal changes in risk factors to 
future echocardiographic outcomes. While the converse approach has been applied in the 
literature (e.g. relating longitudinal changes in repeated echocardiographic measures to a 
single risk factor measurement i.e. changes in left ventricular mass over time in hypertensive 
patients in the Framingham cohort papers),44, 45 there are no birth cohorts that have been 
analysed in the same manner as in this thesis. 
With the repeated measures of risk factors in adult life I have aimed to determine if changes 
in these risk factors over time exert an influence on later cardiac structure and function and 
whether exposure to these risk factors at particular time points is more detrimental than at 
other times (sensitive period hypothesis). The rationale of this approach in a clinical context 
has also been discussed in the introduction of chapter 2.   
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Descriptive analysis 
Data are presented as means with 95% confidence intervals. Data cleaning and checking for 
normality has been described above. 
 
Initial BP and BMI analyses and adjustment for potential confounders 
Initial analyses were carried out using linear regression with the cardiac variable as the 
outcome measure. Similar analyses were carried out for BP and BMI using comparable models 
and adjustments were made for similar confounders. The BP analyses are described initially 
followed by the BMI analyses.  
 
Initial BP analyses 
The predictive power of BP at different ages on subsequent cardiac structure and function 
was tested. Adjustments were initially made for the basic potential confounders age, sex and 
clinic attended. Given that the participants were aged between 60-64y when they underwent 
echocardiography, age was adjusted for. Six national clinics were used in this study and this 
could have led to geographical variations in the echocardiographic measures, so this was also 
accounted for.  
Since some BP measurements were made while participants were on HTT, we assessed the 
impact of treatment on cardiac structure and function. We therefore added HTT at the 
respective age of BP measurement to the models. BP at age 60-64y was then included in the 
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model to determine if previous BP had an independent association with the cardiac outcome. 
This was done to determine if the association could be fully explained by tracking (or not). 
T2DM and BMI being potential confounding variables were then included in the model.  
The regression analysis relating the association of BP at age 36y on cardiac structure at age 
60-64y is diagrammatically represented in Figure 3.8. 
 
 
 
Figure 3.8. Diagrammatic representation of regression analysis of the effect of BP at 36y 
on cardiac structure at 60-64y (as measured by echocardiography) with successive 
adjustments (BP – blood pressure, HTT – hypertension treatment, T2DM – type 2 diabetes 
mellitus, BMI – body mass index) 
 
For the models investigating cardiac function, LVMI was included in the final adjustment to 
determine if the associations were independent of cardiac dysfunction caused by BP-related 
changes in LVMI.  
Residuals were also calculated, graphically plotted and reviewed for the models.  
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Initial BMI analyses 
For the BMI analyses, the effect of BMI and overweight at the different ages on measures of 
cardiac function was examined using linear regression models similar to those used for the 
corresponding BP analyses.   
Initial adjustments were made for age, sex and clinic attended. Subsequent adjustments were 
made for the potential confounders systolic BP (SBP) and T2DM at age 60-64y. The final model 
included BMI at age 60-64y (or overweight at age 60-64y for the overweight models) to 
determine if previous BMI (or overweight) was predictive of cardiac structure independent of 
BMI (or overweight) at 60-64y. For the BMI-cardiac function analyses, adjustment for LVMI 
(for the same rationale as in the BP-cardiac function models) was made prior to final 
adjustment with BMI or overweight at age 60-64y.  
 
Multinomial regression analysis was performed when non-ordered categorical variables were 
included in the regression models. This was done for analyses involving LVH and RWT. 
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Further SBP analyses 
 
The Accumulation Approach for SBP 
The accumulation hypothesis has been previously tested by relating area-under-the-curve 
(AUC) of BP or BMI change to cardiac outcomes.46 We initially investigated the utility of  the 
AUC approach to test the cumulative effect of SBP on future cardiac structure by fitting linear 
regression models including the slope and intercept as predictor variables with an 
echocardiographic variable as the outcome measure. To construct the AUC model, we used a 
slope and intercept previously derived by a colleague which covered SBP change from 36y to 
53y.47 Initially, a multilevel model was constructed for each component of SBP, from which 
individual fitted random intercepts (which represent BP at 36y) were extracted along with 
slopes (which represent changes in BP from 36-53y).47 The AUC was then derived by 
calculating the area covered by the rectangle (A) and triangle (B) obtained by plotting the rate 
of change in SBP from 36-53y (Figure 3.9).  We then included SBP at age 60-64y in the model 
to determine if the effect of AUC from 36-53y was independent of SBP at age 60-64y. Analyses 
indicated that it was the slope, i.e. the rate of change, that largely determined the AUC 
because the majority of participants exhibited increasing BP over the period 36-53y. The 
association between AUC and cardiac outcome was thus driven by the effect of rate of 
change. As such, we decided to examine the rate of change in BP from 36-60/64y to determine 
if there was a sensitive period for BP change (described below).  
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Figure 3.9. The components of the Area under a Curve plot – A and B (see text for details). 
  
 
The Sensitive Period Approach for SBP 
We decided to look at the effect of rate of change in BP on future cardiac structure and 
function to determine if there was a sensitive period among them. To test for a sensitive 
period, the study duration had to be divided into periods. BP had been measured 4 times in 
our cohort, so this allowed division into 3 periods: 36-43y, 43-53y and 53-60/64y. The change 
in SBP for the periods 36-43y, 43-53y and 53-60 to 64y conditional on earlier SBP was 
calculated. This was done by linear regression of each BP measure (from age 43y onwards) on 
the earlier measure(s) for each sex and saving the residuals i.e. for the first regression the 
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time period 36-43y was used, while for the second regression the time period 53-43y was 
used, taking into account what had gone before (BP at 36y) and so forth (Figure 3.10).  
 
 
 
 
 
 
Figure 3.10. Graph illustrating expected BP trajectory over time along with BP of two 
individuals not on the expected trajectory (one above and one below). The residuals are 
also plotted (difference between the observed value and the predicted value). 
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These residuals reflect BP velocity and can be interpreted as the change in BP above or below 
that expected given earlier BP.48 The residuals were then standardised (mean = 0 and 
standard deviation = 1) to allow a comparison of the relative associations between periods. 
Regression models were subsequently fitted including all these standardised changes with 
the echocardiographic measure as the outcome. By deriving change in this way, the 3 
variables (i.e. the rates of change over the 3 periods) could be entered into the regression 
model, as they were uncorrelated (since the derived variables were conditional on past BP 
levels). The coefficients for each period were compared against each other using the Wald 
test (an approximation of the likelihood ratio test estimating whether the coefficient from 
one period is equal to the coefficient from another period).  These models were then adjusted 
for possible confounders with initial adjustment made for age, sex and clinic attended and 
further adjustment for BMI, T2DM and HTT at age 60-64y.  
 
Further BMI analyses 
The effect of age at first overweight on cardiac structure and function was examined using 
the age at first overweight variable described previously. The sequence of adjustments was 
the same as for the BMI/overweight-cardiac structure/function analyses. Tests for linear 
trend across categories of age at overweight were obtained to determine if earlier overweight 
was related to worse cardiac outcome. Tests for deviation from linear trend were also carried 
out by using a likelihood ratio test to assess whether a model including age at first overweight 
as a categorical variable provided a better model fit than a model with age at first overweight 
fitted as a continuous variable (linear trend). Estimated marginal means were also calculated 
for the minimally adjusted models. 
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Chapter 4 
 
Effect of mid-life blood pressure change and 
treatment on subsequent left ventricular 
structure 
 
Introduction  
Blood pressure (BP) is a key risk factor for cardiovascular disease (CVD).1, 2 Higher BP is also 
associated with increased left ventricular mass (LVM)3 and left ventricular hypertrophy (LVH)4 
which are themselves related to subsequent CVD independent of current BP3, 5 and increased 
LVM/LVH is a commonly used measure of hypertension-associated target organ damage.6, 7 
Some studies have suggested that exposure to elevated BP or hypertension from early life 
onwards contributes to increased atherosclerosis and CVD in later life.8-11 Currently, it is 
unclear whether this reflects tracking of BP across the life course, the cumulative burden of 
lifetime exposure to high BP, or the effect of high BP in a sensitive period. The long-term 
influence of hypertension therapy (HTT) has also been little explored, although in the short-
term HTT causes regression of LVM and LVH and reduces CVD.12, 13  
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We therefore examined the effect of longitudinal changes in BP over the 28y period (ages 36y 
to 60-64y) on left ventricular (LV) structure as an indicator of target organ damage at 60-64y 
in the MRC NSHD. We also investigated the impact of HTT on BP-related changes in LV 
structure to explore the possible reversibility of the structural consequences of high BP.  
 
 
Methods 
The methods have been described in detail in the methods chapter (chapter 3). 
 
Echocardiographic studies 
Wall and LV chamber measures were made according to ASE/EAE guidelines.14 LVM was 
indexed to body surface area (LVMI) as described in the methods chapter (chapter 3). 
 
Statistical Analysis 
This has been described in detail in the methods chapter (chapter 3).  
Initially, separate regression models investigated the association between systolic BP (SBP) at 
each of the 4 ages at which it was measured and LVMI at 60-64y, with adjustment for sex, age 
at clinic visit and clinic attended. We tested whether these associations were linear and 
whether they were different for men and women. There was no evidence of a difference in 
association between men and women so in subsequent analyses both genders were pooled 
and adjusted for sex. HTT at the same age as BP measurement was then added to models. 
Additional models assessed whether earlier SBP remained predictive once current SBP was 
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also included. Final adjustments were made by including other possible confounders - BMI 
and T2DM at 60-64y. For the cross-sectional SBP model, we assessed whether any effect of 
HTT could be explained by prior BP.  
To investigate whether rate of change in BP at a particular period of midlife was more strongly 
associated with LVMI, we used a rate of change in BP model described previously in the 
methods chapter (chapter 3).  
The same analyses were repeated for diastolic BP (DBP), pulse pressure (PP) and mean arterial 
pressure (MAP) and for each of the other outcome measures [Interventricular septal 
thickness in diastole (IVSD), left ventricular posterior wall thickness in diastole (LVPWTD) and 
relative wall thickness (RWT)]. Predictors of LVH were analysed using multiple logistic 
regression. 
Sensitivity analyses were carried out to assess whether the associations with SBP remained 
unchanged if those on HTT or those who were hypertensive (SBP>=140 mmHg and/or DBP >= 
90mmHg) were excluded. 
 
 
 
 
Results 
The characteristics of the study sample are shown in Table 4.1.  Those with un-analysable 
echocardiograms had higher BMI (28.8; SD=4.8 vs. 27.5; SD=4.6, p <0.001) and heart rate 
(71.1; SD=13.0 vs. 68.5; SD=11.8, p = 0.0082) than those with analysable scans.  
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Compared to men, women were older, had lower SBP, DBP, fasting triglyceride levels, fasting 
blood glucose levels and higher heart rates, fasting total cholesterol levels and fasting HDL 
cholesterol levels. BMI and prevalence of T2DM were similar between the sexes. 
Men had larger left ventricular internal diameter (measured in diastole – LVIDD), IVSD, 
LVPWTD, RWT, LVM and LVMI.  
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Table 4.1. Echocardiographic and cardiac risk factor characteristics of study participants (Maximum sample had at least 1 echocardiographic 
measure of interest recorded = 1480) (Fasting blood samples used for glucose and lipid measures). Unless otherwise stated data refer to age 
60-64y. 
 
Variable (At age 60-64y unless 
stated otherwise) 
Combined Men Women 
n (%) Mean (SD) n (%) Mean (SD) n (%) Mean (SD) 
Age at echo (y) 1480 63.3 (1.1) 701 63.2 (1.1) 779 63.3 (1.1) 
IVSD (cm) 1480 1.1 (0.2) 701 1.1 (0.2) 779 1.0 (0.2) 
LVPWTD (cm) 1480 1.0 (0.2) 701 1.0 (0.2) 779 0.9 (0.2) 
RWT 1480 0.4 (0.1) 701 0.4 (0.1) 779  0.4 (0.1) 
LVM(g) 1480 181.3 (59.3) 701 209.2 (60.3) 779 156.1 (45.6) 
LVMI-BSA (g/m2) 1480 95.7 (26.6) 701 104.1 (27.9) 779  88.1 (22.9) 
LVMI-ht2.7 (g/m2.7) 1480 44.2 (13.2) 701 46.1 (13.7) 779 42.4 (12.6) 
SBP (mm Hg) 1478 135.7 (17.9) 701 139.0 (17.7) 777 132.8 (17.7) 
SBP in those on HTT (mm Hg) 315 137.5 (17.6) 160 139.2 (18.2) 155 135.8 (16.8) 
SBP in those not on HTT (mm Hg) 1011 135.1 (18.0) 457 138.6 (17.4) 554 132.1 (18.0) 
SBP at 53y (mm Hg) 1393 134.1 (19.1) 657 137.8 (18.9) 736 130.7 (18.7) 
SBP at 43y (mm Hg) 1381 121.5 (14.5) 654 123.0 (14.3) 727 120.1 (14.6) 
SBP at 36y (mm Hg) 1334 118.3 (14.0) 631 121.3 (14.2) 703 115.6 (13.4) 
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DBP (mm Hg) 1478 77.4 (9.7) 701 79.0 (9.8) 777 75.9 (9.3) 
DBP at 53y (mm Hg) 1393 83.4 (11.9) 657 86.2 (11.9) 736 80.9 (11.3) 
DBP at 43y (mm Hg) 1381 78.5 (11.3) 654 80.9 (11.2) 727  76.3 (10.9) 
DBP at 36y (mm Hg) 1333 76.0 (11.7) 630 77.8 (11.7) 703 74.4 (11.4) 
HTT  1332   620  712  
     On medication             315 (24)          159 (26)          156 (22)  
Heart Rate (bpm) 1473 68.5 (11.8) 699 67.2 (12.5) 774  69.7 (11.0) 
BMI  (Kg/m2) 1480 27.5 (4.6) 701 27.7 (4.0) 779 27.4 (5.1) 
Total cholesterol (mmol/L) 1386 5.7 (1.2) 657 5.4 (1.1) 729 6.0 (1.2) 
HDL cholesterol (mmol/L) 1386 1.6 (0.4) 657 1.4 (0.3) 729 1.8 (0.4) 
Triglycerides¶  (mmol/L)  1386 1.1 (0.8) 657 1.2 (0.9) 729 1.0 (0.7) 
Assessed for T2DM 1357  635  722  
     T2DM present              73 (6)            37 (6)          36 (5)  
Glucose (mmol/L) 1407 5.8 (1.2) 667 6.0 (1.2) 740 5.6 (1.2) 
HbA1c 1387 5.8 (0.7) 656 5.8 (0.7) 731 5.8 (0.6) 
¶ Median and interquartile range 
SD - Standard deviation; IVSD - Interventricular septal thickness in diastole; LVPWTD - Left ventricular posterior wall thickness in diastole; RWT - Relative wall thickness; 
LVM - Left ventricular mass; LVMI-BSA - Left ventricular mass indexed to body surface area; LVMI-ht2.7 - Left ventricular mass indexed to height raised to the power 2.7; SBP 
- Systolic blood pressure; HTT - Hypertension therapy; DBP - Diastolic blood pressure; BMI - Body mass index; HDL - High density lipoprotein; T2DM - Type 2 diabetes 
mellitus; Hb A1c - Haemoglobin A1C 
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Higher SBP from 36y onwards was associated with higher LVMI at 60-64y in a minimally 
adjusted model (Table 4.2a). Associations remained unchanged after adjustment for HTT.  
From the age of 43y onwards, individuals on HTT had a higher mean LVMI than those who 
were not on treatment after adjusting for SBP at 60-64y.  
We assessed the predictive value of previous BP over and above BP at 60-64y; SBP at age 53y 
remained associated with LVMI, with only marginal attenuation, whereas associations with 
SBP at ages 36y and 43y were considerably weakened. A model with SBP at 53y and at 60-
64y, or equivalently change in SBP between 53-60-64y, provided an improvement in fit over 
the model with only SBP at age 60-64y (p<0.001), thus indicating that change in SBP between 
53y and 60-64y adds to the cross-sectional SBP association. Further adjustment for BMI and 
presence of T2DM at 60-64y slightly attenuated the associations of SBP and HTT with LVMI 
but the relationship between SBP at 53y and LVMI remained. 
The associations were similar when SBP was substituted with DBP, PP or MAP (Tables 4.2b-d) 
and when LVMI was substituted with IVSD or LVPWTD (Tables 4.2e-f). 
We investigated the possibility that the relationship between HTT at 60-64y and LVMI could 
be explained by high prior BP. Inclusion of SBP at 53y attenuated the effect of HTT on LVMI 
from 11.01 (95% CI: 7.86, 14.15) to 7.83 (95% CI: 4.36, 11.29), while additional inclusion of 
SBP at younger ages had negligible effects. 
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Table 4.2a. Regression coefficients (g/m
2
), 95% confidence intervals and p values estimating the effect of SBP and HTT at 4 time points on 
left ventricular mass indexed to body surface area at 60-64 years. 
 
 
 
 
 
 
 
 
 
 
HTT -  Hypertension therapy; SBP -  Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + SBP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
Age 36 (n = 1205) SBP  0.17 (0.05, 0.28) 0.004 0.17 (0.05, 0.28) 0.004 0.11 (-0.01, 0.22) 0.072 0.10 (-0.01, 0.22) 0.083 
 HTT  - - 0.89 (-13.49, 15.27) 0.903 2.08 (-12.20, 16.37) 0.775 -1.01 (-14.99, 12.97) 0.887 
Age 43 (n = 1237) SBP  0.16 (0.06, 0.26) 0.003 0.15 (0.04, 0.25) 0.005 0.07 (-0.04, 0.18) 0.190 0.07 (-0.03, 0.18) 0.183 
 HTT  - - 15.93 (6.60, 25.27) 0.001 16.15 (6.88, 25.41) 0.001 11.91 (2.73, 21.09) 0.011 
Age 53 (n = 1260) SBP  0.29 (0.22, 0.36) <0.001 0.25 (0.18, 0.32) <0.001 0.22 (0.14, 0.30) <0.001 0.19 (0.11, 0.27) <0.001 
 HTT  - - 10.07 (5.91, 14.22) <0.001 10.19 (6.04, 14.34) <0.001 7.85 (3.67, 12.02) <0.001 
Age 60-64 (n = 1319) SBP  0.20 (0.13, 0.28) <0.001 0.19 (0.10, 0.26) <0.001 - - 0.15 (0.08, 0.23) <0.001 
 HTT  - - 11.01 (7.86, 14.15) <0.001 - - 8.37 (5.15, 11.58) <0.001 
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Table 4.2b. Regression coefficients (g/m2), 95% confidence intervals and p values estimating the effect of DBP and HTT at 4 time points on 
left ventricular mass indexed to body surface area at 60-64 years. 
 
 
 
 
 
 
 HTT - Hypertension therapy; DBP - Diastolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index 
 
 
 
 
 
 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + DBP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
Age 36 (n = 1186) DBP  0.22 (0.07, 0.37) 0.005 0.22 (0.07, 0.37) 0.005 0.18 (0.02, 0.34) 0.027 0.16 (0.01, 0.31) 0.041 
 HTT  - - 0.36 (-14.06, 14.77) 0.961 0.90 (-13.50, 15.29) 0.903 -2.05 (-16.09, 12.00) 0.775 
Age 43 (n = 1237) DBP  0.19 (0.03, 0.35) 0.018 0.16 (0.01, 0.32) 0.043 0.12 (-0.05, 0.28) 0.161 0.09 (-0.07, 0.25) 0.276 
 HTT  - - 15.68 (6.30, 25.06) 0.001 15.75 (6.40, 25.11) 0.001 11.38 (2.14, 20.62) 0.016 
Age 53 (n = 1260) DBP  0.39 (0.27, 0.51) <0.001 0.33 (0.21, 0.45) <0.001 0.31 (0.18, 0.43) <0.001 0.24(0.12, 0.37) <0.001 
 HTT  - - 11.10  (6.94,15.25) <0.001 11.15 (6.99, 15.31) <0.001 8.52 (4.34, 12.70) <0.001 
Age 60-64 (n = 1319) DBP  0.23 (0.10, 0.38) 0.001 0.22 (0.08, 0.37) 0.002 - - 0.20 (0.06, 0.34) 0.005 
 HTT  - - 11.33 (8.17, 14.49) <0.001 - - 8.44(5.22, 11.66) <0.001 
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Table 4.2c. Regression coefficients (g/m2), 95% confidence intervals and p values estimating the effect of PP and HTT at 4 time points on left 
ventricular mass indexed to body surface area at 60-64 years. 
 
 
 
 
 
 
HTT - Hypertension therapy; PP - Pulse pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index 
 
 
 
 
 
 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + PP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
Age 36 (n = 1204) PP  0.08 (-0.07, 0.23) 0.294 0.08 (-0.07, 0.23) 0.294 0.04 (-0.11, 0.19) 0.591 0.04 (-0.10, 0.19) 0.559 
 HTT  - - 2.14 (-12.27, 16.54) 0.771 2.82 (-11.48, 17.13) 0.699 -0.35 (-14.35, 13.65) 0.961 
Age 43 (n = 1237) PP  0.13 (-0.01, 0.27) 0.064 0.14 (-0.002, 0.276) 0.055 0.06 (-0.09, 0.20) 0.432 0.07 (-0.07, 0.21) 0.310 
 HTT  - - 16.81 (7.47, 26.14) 0.001 16.78 (7.50, 26.05) <0.001 12.46 (3.27, 21.65) 0.008 
Age 53 (n = 1260) PP  0.31 (0.20, 0.41) <0.001 0.26 (0.16, 0.37) <0.001 0.22 (0.11, 0.33) <0.001 0.19 (0.08, 0.30) <0.001 
 HTT  - - 11.69  (7.55, 15.83) <0.001 11.68 (7.55,15.81) <0.001 8.92 (4.76, 13.08) <0.001 
Age 60-64 (n = 1319) PP  0.23 (0.13, 0.33) <0.001 0.21 (0.11, 0.31) <0.001 - - 0.16 (0.06, 0.26) 0.001 
 HTT  - - 11.09 (7.93, 14.24) <0.001 - - 8.40 (5.18, 11.62) <0.001 
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Table 4.2d. Regression coefficients (g/m2), 95% confidence intervals and p values estimating the effect of MAP and HTT at 4 time points on 
left ventricular mass indexed to body surface area at 60-64 years. 
 
 
 
 
 
 
HTT - Hypertension therapy; MAP – Mean arterial pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + MAP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
Age 36 (n = 1204) MAP  0.24 (0.09, 0.39) 0.002 0.24 (0.09, 0.39) 0.002 0.17 (0.01, 0.32) 0.035 0.16 (0.01, 0.31) 0.043 
 HTT  - - 0.27 (-14.13, 14.67) 0.971 1.32 (-13.01, 15.66) 0.856 -1.67 (-15.69, 12.34) 0.815 
Age 43 (n = 1237) MAP  0.22 (0.07, 0.36) 0.004 0.19 (0.05, 0.34) 0.010 0.11 (-0.04, 0.27) 0.147 0.10 (-0.05, 0.25) 0.206 
 HTT  - - 15.57 (6.21, 24.93) 0.001 15.78 (6.47, 25.09) 0.001 11.51 (2.30, 20.72) 0.014 
Age 53 (n = 1260) MAP  0.41 (0.30, 0.51) <0.001 0.35 (0.25, 0.45) <0.001 0.31 (0.20, 0.43) <0.001 0.26 (0.14, 0.37) <0.001 
 HTT  - - 10.24  (6.08, 14.40) <0.001 10.36  (6.20, 14.52) <0.001 7.96 (3.78, 12.14) <0.001 
Age 60-64 (n = 1319) MAP  0.28 (0.16, 0.41) <0.001 0.26 (0.15, 0.38) <0.001 - - 0.22 (0.11, 0.34) <0.001 
 HTT  - - 11.14 (7.99, 14.29) <0.001 - - 8.39 (5.18, 11.61) <0.001 
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Table 4.2e. Regression coefficients (cm), 95% confidence intervals and p values estimating the effect of SBP and HTT at 4 time points on 
interventricular thickness in diastole at 60-64 years. 
 
 
 
 
 
 
 
 
 
HTT - Hypertension therapy; SBP – Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index 
 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 +  SBP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
Age 36 (n = 1207) SBP  0.00060 
(-0.0004, 0.0016) 
0.218 0.00060 
(-0.0004, 0.0016) 
0.217 0.000049 
(-0.0009, 0.0010) 
0.921 0.000090 
(-0.0009, 0.0010) 
0.851 
 HTT  - - -0.0038 
(-0.125, 0.117) 
0.950 0.0074 
(-0.113, 0.127) 
0.904 -0.026 
(-0.142, 0.091) 
0.665 
Age 43 (n = 1239) SBP  0.0011 
(0.0002, 0.0020) 
0.014 0.0010 
(0.0002, 0.0019) 
0.122 
0.021 
 
0.002 
0.0004 
(-0.0006, 0.0013) 
0.124 
0.432 
 
0.002 
0.0004 
(-0.0005, 0.0013) 
0.079 
0.348 
 
0.042 
 HTT  - - (0.043, 0.201)  (0.046, 0.202)  (0.003, 0.155)  
Age 53 (n = 1262) SBP   0.0022 
(0.0016, 0.0028) 
<0.001 0.0020 
(0.0014, 0.0026) 
0.055 
<0.001 
 
0.002 
0.0016 
(0.0010, 0.0023) 
0.056 
<0.001 0.0013 
(0.0007, 0.0020) 
0.033 
<0.001 
 
0.064 
 HTT  - - (0.020, 0.090)  (0.021, 0.091) 0.002 (-0.002, 0.068)  
Age 60-64 (n = 1321) SBP   0.0017 
(0.0011, 0.0024) 
<0.001 0.0016 
(0.0010, 0.0022) 
<0.001 - - 0.0012 
(0.0006, 0.0018) 
<0.001 
 HTT  - - 0.083 
(0.056, 0.109) 
<0.001 - - 0.053 
(0.026, 0.079) 
<0.001 
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Table 4.2f. Regression coefficients (cm), 95% confidence intervals and p values estimating the effect of SBP and HTT at 4 time points on left 
ventricular posterior wall thickness in diastole at 60-64 years. 
 
 
 
 
 
 
 
 
 
 
 
HTT - Hypertension therapy; SBP – Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 +  SBP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
Age 36 (n = 1205) SBP  0.00092 
(0.0002, 0.0016) 
0.015 0.00093 
(0.0002, 0.0017) 
0.015 0.000049 
(-0.0003, 0.0923) 
0.208 0.00052 
(-0.0002, 0.0012) 
0.155 
 HTT  - - -0.0097 
(-0.104, 0.084) 
0.840 -0.0008 
(-0.094, 0.092) 
0.986 -0.033 
(-0.121, 0.056) 
0.471 
Age 43 (n = 1237) SBP  0.0014 
(0.0007, 0.0021) 
<0.001 0.0013 
(0.0006, 0.0020) 
0.097 
<0.001 
 
0.002 
0.00080 
(0.0008, 0.0015) 
0.098 
0.029 
 
0.002 
0.00086 
(0.0002, 0.0015) 
0.057 
0.014 
 
0.056 
 HTT  - - (0.035, 0.158)  (0.037, 0.159)  (-0.002, 0.116)  
Age 53 (n = 1260) SBP   0.0018 
(0.0013, 0.0022) 
<0.001 0.0016 
(0.0011, 0.0020) 
0.051 
<0.001 
 
<0.001 
0.0012 
(0.0007, 0.0018) 
0.052 
<0.001 0.00093 
(0.0004, 0.0014) 
0.031 
<0.001 
 
0.026 
 HTT  - - (0.023, 0.079)  (0.025, 0.080) <0.001 (0.004, 0.058)  
Age 60-64 (n = 1319) SBP   0.0015 
(0.0010, 0.0020) 
<0.001 0.0014 
(0.0009, 0.0019) 
<0.001 - - 0.0010 
(0.0005, 0.0014) 
<0.001 
 HTT  - - 0.059 
(0.0396, 0.080) 
<0.001 - - 0.030 
(0.009, 0.051) 
0.004 
157 | P a g e  
 
The relationships between SBP and RWT were similar to those between SBP and LVMI, 
demonstrating associations of midlife SBP with RWT independent of SBP at 60-64y, although 
the association with SBP at 36y was weaker (Table 4.2g).  
SBP from 53y onwards was associated with LVH independent of SBP at 60-64y (OR = 1.22, 
95% CI = 1.05, 1.42) for a 1 SD increase in SBP at 53y adjusted for age, sex, clinic, HTT, SBP at 
60-64y, T2DM and BMI.  
The associations between SBP and LVMI remained unchanged when those on HTT or those 
who were hypertensive (SBP>=140 mmHg and/or DBP >= 90mmHg) were excluded (Tables 
4.2h-i). 
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Table 4.2g. Regression coefficients, 95% confidence intervals and p values estimating the effect of SBP and HTT at 4 time points on relative 
wall thickness at 60-64 years. 
 
 
HTT -  Hypertension therapy; SBP -  Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index 
 
Variable  Model 1 
(age sex, clinic) 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + SBP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
Age 36 (n = 1203) SBP  0.00017 
 (-0.00021, 0.00056) 
0.377 0.00018 
 (-0.00012, 0.00057) 
0.361 0.000040 
 (-0.00036, 0.00044) 
0.840 0.00050 
 (-0.00035, 0.00045) 
0.807 
 HTT  - - -0.015  
(-0.064, 0.034) 
0.559 -0.012 
 (-0.061, 0.037) 
0.637 -0.018 
 (-0.067, 0.031) 
0.465 
Age 43 (n = 1235) SBP  0.00067 
 (0.00031, 0.00103) 
<0.001 0.00066  
(0.00030, 0.00102) 
<0.001 0.00052 
 (0.00014, 0.00090) 
0.007 0.00054  
(0.00016, 0.00092) 
0.005 
 HTT  - - 0.018  
(-0.015, 0.051) 
0.281 0.019 
 (-0.014, 0.052) 
0.259 0.011 
 (-0.022, 0.044) 
0.511 
Age 53 (n = 1259) SBP  0.00057  
(0.00032 0.00082) 
<0.001 0.00053  
(0.00027, 0.00079) 
<0.001 0.00042 
 (0.00014, 0.00070) 
0.003 0.00037 
 (0.00088, 0.00065) 
0.010 
 HTT  - - 0.010 
 (-0.004, 0.025) 
0.171 0.011  
(-0.004, 0.026) 
0.155 0.008  
(-0.007, 0.023) 
0.321 
Age 60-64 (n = 1317) SBP  0.00047 
 (0.00020, 0.00073) 
0.001 0.00045  
(0.00018, 0.00071) 
0.001 - - 0.00037  
(0.00098, 0.00063) 
0.008 
 HTT  - - 0.015  
(0.004, 0.026) 
0.010 - - 0.009  
(-0.002, 0.021) 
0.122 
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Table 4.2h. Regression coefficients (g/m2), 95% confidence intervals and p values estimating the effect of SBP and HTT at 4 time points on 
left ventricular mass indexed to body surface area at 60-64 years (excluding those who are hypertensive BP >=140/90mmHg). 
 
 
 
 
 
 
 
HTT -  Hypertension therapy; SBP -  Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index 
 
 
 
 
 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 +  SBP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
Age 36 (n = 1044) SBP  0.12 (-0.02, 0.26) 0.095 0.12 (-0.02, 0.26) 0.095 0.050 (-0.093, 0.193) 0.491 0.047 (-0.093, 0.188) 0.509 
 HTT  - - 2.01 (-16.59, 20.61) 0.832 2.82 (-15.54, 21.21) 0.762 -2.48 (-20.62, 15.65) 0.788 
Age 43 (n = 1001) SBP  0.11 (-0.05, 0.26) 0.173 0.09 (-0.06, 0.24) 0.224 -0.02 (-0.18, 0.13) 0.758 0.005 (-0.148, 0.157) 0.952 
 HTT  - - 16.33 (5.32, 27.35) 0.004 16.18 (5.34, 27.02) 0.003 11.89 (1.06, 22.73) 0.032 
Age 53 (n = 760) SBP   0.24 (0.10, 0.38) 0.001 0.23 (0.10, 0.37) 0.001 0.17 (0.02, 0.32) 0.027 0.14 (-0.003, 0.289) 0.055 
 HTT  - - 11.85  (6.20, 17.50) <0.001 11.49  (5.84, 17.13) <0.001 9.77  (4.18, 15.35) 0.001 
Age 60-64 (n = 788) SBP   0.21 (0.05, 0.37) 0.012 0.20 (0.04, 0.36) 0.017 - - 0.14 (-0.02, 0.30) 0.082 
 HTT  - - 12.58 (8.56, 16.60) <0.001 - - 8.54 (4.32, 12.75) <0.001 
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Table 4.2i. Regression coefficients (g/m2), 95% confidence intervals and p values estimating the effect of SBP and HTT at 4 time points on 
left ventricular mass indexed to body surface area at 60-64 years (excluding those on HTT). 
 
 
 
 
 
 
 
HTT -  Hypertension therapy; SBP -  Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 +  SBP  at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
Age 36 (n = 1193) SBP   0.16 (0.05, 0.28) 0.006 0.16 (0.05, 0.28) 0.006 0.10 (-0.02, 0.22) 0.089 0.10 (-0.02, 0.21) 0.100 
 HTT  - - - - - - - - 
Age 43 (n = 1209) SBP   0.14 (0.04, 0.25) 0.007 0.14 (0.04, 0.25) 0.007 0.07 (-0.04, 0.18) 0.234 0.07 (-0.04, 0.18) 0.233 
 HTT  - - - - - - - - 
Age 53 (n = 1108) SBP   0.25 (0.17, 0.33) <0.001 0.25 (0.17, 0.33) <0.001 0.22 (0.13, 0.30) <0.001 0.19 (0.11, 0.27) <0.001 
 HTT  - - - - - - - - 
Age 60-64 (n = 1009) SBP   0.21 (0.13, 0.29) <0.001 0.21 (0.13, 0.29) <0.001 - - 0.14 (0.06, 0.22) 0.001 
 HTT  - - - - - - - - 
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Evidence for a sensitive period in midlife 
Faster increases in SBP between 43-53y and 53-60/64y were significantly related to greater 
LVMI with or without adjustment for HTT, T2DM and BMI (Table 4.3), whereas increased rate 
of change in BP between 36-43y was only weakly related to LVMI. The relationship between 
rate of change in SBP between 43-53y was significantly stronger than the other two intervals 
(p = 0.001 for both) and this was essentially unaffected by adjustment for current risk factors. 
 
Table 4.3. Regression coefficients (LVMI unit per unit SD change), 95% confidence 
intervals, and p values for a model showing effect of rate of change in SBP over 3 time 
periods (36-43y), (43-53y) and (53-60 to 64y) on LVMI at age 60-64y. Initial model adjusted 
for sex, age at clinic attendance and clinic attended. Final model also adjusted for BMI, 
T2DM and HTT. 
Period of rate 
of change in 
SBP  
              Adjusted for sex,                               Also adjusted for BMI,                           
       clinic attended and age                          T2DM and current HTT 
β Coefficient 
(95%CI) 
p value β Coefficient 
(95%CI) 
p value 
36y – 43y  1.42 (-0.16, 3.00)  0.078 0.48 (-1.12, 2.08)  0.555 
43y – 53y 5.20 (3.69,6.72) <0.001 3.16 (1.59, 4.73) <0.001 
53y – 60/64y 1.53 (0.06, 3.01)  0.042 1.80 (0.32, 3.28)  0.018 
 
SBP - Systolic blood pressure; BMI - Body mass index, T2DM - Type 2 diabetes mellitus; HTT - Hypertension 
therapy 
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Discussion 
BP from early midlife predicts LVMI and LV remodelling in both men and women and for BP 
at age 53y, this is independent of current BP (BP at age 60-64y). We identified 43-53y as a 
potential sensitive period for the development of poor cardiac structure where rapid rises in 
SBP were particularly detrimental. Those on HTT at all ages had higher LVMI after accounting 
for current SBP, some of this effect could be accounted for by prior higher BP. 
A limited number of studies have investigated the role of high BP in early life on later LV 
structure. Studies in children and young adults from the Bogalusa15-17 and CARDIA18 cohorts 
and Swedish military recruits19 have demonstrated a positive relationship between BP and 
subsequent LVM. Two further studies reported that BP in middle age was positively 
associated with LVM measured two decades later20, 21 but neither study took contemporary 
BP into account and therefore the role of BP tracking could not be excluded (those with earlier 
higher BPs continuing on the same trajectory of BP rise and ending up with higher BP 
compared to their peers). Our findings, based on multiple longitudinal measurements of BP, 
suggest that the effects of earlier adult BP are not entirely due to tracking. Notably, BP at 53y 
was more strongly related to LVMI than BP at 60-64y in a mutually adjusted model. The 
importance of BP at age 53y may be due to the rapid acceleration in BP typically seen around 
this period of life.22 This accords with our findings showing that rapid BP rise between 43-53y 
has the strongest association with subsequent LVMI. Interestingly, one previous study has 
suggested that faster rises in BP were associated with increased LVM, but this conclusion was 
based on measurements over only 2y.23 In contrast we have analysed rate of change in BP 
over a 28y period and have divided the time into segments to identify a particularly sensitive 
period for future LVM. Sensitive periods are times when exposure to particular risk factors 
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may have a greater influence on a subsequent  health outcome than would exposure to the 
same risk factor at a different time.24 Our data suggests that the period between ~ 40–50y 
may be such a period.  
Current guidelines do not take into account changes in BP when determining whether HTT 
should be prescribed,25 even though very rapid rises in BP (e.g. in malignant hypertension) 
are associated with development of acute cardiological, neurological, renal and 
ophthalmological problems.26 Rather, whether BP crosses a threshold is currently of 
paramount importance. Our finding of greater LVMI in those with a rapid rise in BP in the 5th 
decade of life was not just driven by individuals becoming hypertensive but held for those 
whose BP remained in the “normal” range. This suggests a paradigm shift in our evaluation of 
cardiovascular risk due to BP and would necessitate the identification and appropriate 
management of individuals exhibiting sharp rises of BP even within the normal BP range. 
Recent clinical trials have tested whether intervention early in adulthood to prevent the 
development of hypertension has benefits, with mixed results.27, 28  Our finding, that those 
on HTT have higher mean LVMI, even if the BP has been controlled, further highlights the 
importance of intervention before quickly rising/high BP causes a “legacy” of target organ 
damage which may not be fully reversed even if BP is subsequently normalized with 
medication. The current practice in younger individuals of “watching and waiting” until BP 
crosses 140/90 mm Hg may be detrimental to their health as permanent change in LVMI may 
have already occurred before treatment initiation. 
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Strengths and Limitations 
The study members remaining in the Medial Research Council National Survey of Health and 
Development (MRC NSHD) have been found to be representative of native-born adults living 
in England, Scotland, and Wales at the time of data collection at 53y29 and at 60-64y.22 Hence 
our findings are likely to be generalizable to the British-born population. The repeated 
measurements of BP in our study, the longest running birth cohort in the UK, allowed us to 
carry out an analysis investigating the impact of BP tracking and the relative importance of 
rate of change in BP over different periods of the adult life course. 
Missing data are inevitable in studies as long-running as the MRC NSHD.30 Compared to study 
members who attended clinic and had echocardiography, those who had examinations at 
home visits had, on average, greater BMI and higher resting heart rate consistent with 
previous work showing those who attended clinic were healthier than those who had a home 
visit.31 Exclusion of this less healthy group from our analyses could have influenced our 
findings: it is plausible, that if these individuals had undergone echocardiography, the overall 
associations between BP and LVM would have been strengthened. 
BP was not measured in the MRC NSHD prior to 36y, and hence we were unable to assess 
whether there are important earlier-life periods. We are also limited to identifying a sensitive 
period from 3 approximately 10y intervals. Echocardiography was only carried out in the most 
recent round of data collection and hence the possibility of reverse causality, namely that 
increased LVMI in early-life results in raised SBP and increased rate of rise in midlife BP cannot 
be excluded. However, a previous study by Zureik et al,23   demonstrated that change in BP 
preceded change in LVMI, suggesting this is an unlikely explanation of our findings.  
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Conclusions 
Higher BP in midlife predicts subsequent higher LVMI and remodelling, independent of 
current BP for BP at age 53y, with rapid rate of change in the fifth decade playing a key role. 
People on HTT have higher LVMI than untreated individuals, even when accounting for their 
higher BP. Together these observations suggest that exposure to high BP and accelerated rise 
in BP results in irreversible adverse changes in LV structure. Our findings suggest the need for 
trials to re-evaluate current strategies for monitoring and treating BP in younger adults and 
to test the benefits of early identification and treatment of those with rapid rises in BP. 
 
 
 
References 
 
 
 (1)  Danaei G, Ding EL, Mozaffarian D et al. The preventable causes of death in the 
United States: comparative risk assessment of dietary, lifestyle, and metabolic risk 
factors. PLoS Med 2009 April 28;6(4):e1000058. 
 (2)  Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual 
blood pressure to vascular mortality: a meta-analysis of individual data for one 
million adults in 61 prospective studies. Lancet 2002 December 14;360(9349):1903-
13. 
 (3)  Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of 
echocardiographically determined left ventricular mass in the Framingham Heart 
Study. N Engl J Med 1990 May 31;322(22):1561-6. 
166 | P a g e  
 
 (4)  Hammond IW, Devereux RB, Alderman MH, Laragh JH. Relation of blood pressure 
and body build to left ventricular mass in normotensive and hypertensive employed 
adults. J Am Coll Cardiol 1988 October;12(4):996-1004. 
 (5)  Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular 
mass and geometry to morbidity and mortality in uncomplicated essential 
hypertension. Ann Intern Med 1991 March 1;114(5):345-52. 
 (6)  Cuspidi C, Sala C, Negri F, Mancia G, Morganti A. Prevalence of left-ventricular 
hypertrophy in hypertension: an updated review of echocardiographic studies. J 
Hum Hypertens 2012 June;26(6):343-9. 
 (7)  Devereux RB, Pickering TG, Harshfield GA et al. Left ventricular hypertrophy in 
patients with hypertension: importance of blood pressure response to regularly 
recurring stress. Circulation 1983 September;68(3):470-6. 
 (8)  Pletcher MJ, Bibbins-Domingo K, Lewis CE et al. Prehypertension during young 
adulthood and coronary calcium later in life. Ann Intern Med 2008 July 15;149(2):91-
9. 
 (9)  Gray L, Lee IM, Sesso HD, Batty GD. Blood pressure in early adulthood, hypertension 
in middle age, and future cardiovascular disease mortality: HAHS (Harvard Alumni 
Health Study). J Am Coll Cardiol 2011 November 29;58(23):2396-403. 
 (10)  Allen N, Berry JD, Ning H, Van HL, Dyer A, Lloyd-Jones DM. Impact of blood pressure 
and blood pressure change during middle age on the remaining lifetime risk for 
cardiovascular disease: the cardiovascular lifetime risk pooling project. Circulation 
2012 January 3;125(1):37-44. 
 (11)  Berry JD, Dyer A, Cai X et al. Lifetime risks of cardiovascular disease. N Engl J Med 
2012 January 26;366(4):321-9. 
 (12)  Devereux RB, Wachtell K, Gerdts E et al. Prognostic significance of left ventricular 
mass change during treatment of hypertension. JAMA 2004 November 
17;292(19):2350-6. 
 (13)  Bauml MA, Underwood DA. Left ventricular hypertrophy: an overlooked 
cardiovascular risk factor. Cleve Clin J Med 2010 June;77(6):381-7. 
 (14)  Lang RM, Bierig M, Devereux RB et al. Recommendations for chamber quantification: 
a report from the American Society of Echocardiography's Guidelines and Standards 
Committee and the Chamber Quantification Writing Group, developed in 
conjunction with the European Association of Echocardiography, a branch of the 
European Society of Cardiology. J Am Soc Echocardiogr 2005 December;18(12):1440-
63. 
 (15)  Haji SA, Ulusoy RE, Patel DA et al. Predictors of left ventricular dilatation in young 
adults (from the Bogalusa Heart Study). Am J Cardiol 2006 November 1;98(9):1234-7. 
167 | P a g e  
 
 (16)  Toprak A, Wang H, Chen W, Paul T, Srinivasan S, Berenson G. Relation of childhood 
risk factors to left ventricular hypertrophy (eccentric or concentric) in relatively 
young adulthood (from the Bogalusa Heart Study). Am J Cardiol 2008 June 
1;101(11):1621-5. 
 (17)  Urbina EM, Gidding SS, Bao W, Pickoff AS, Berdusis K, Berenson GS. Effect of body 
size, ponderosity, and blood pressure on left ventricular growth in children and 
young adults in the Bogalusa Heart Study. Circulation 1995 May 1;91(9):2400-6. 
 (18)  Gardin JM, Brunner D, Schreiner PJ et al. Demographics and correlates of five-year 
change in echocardiographic left ventricular mass in young black and white adult 
men and women: the Coronary Artery Risk Development in Young Adults (CARDIA) 
study. J Am Coll Cardiol 2002 August 7;40(3):529-35. 
 (19)  Ridderstrale W, Saluveer O, Johansson MC, Bergbrant A, Jern S, Hrafnkelsdottir TJ. 
Consistency of blood pressure and impact on cardiovascular structure over 20 years 
in young men. J Intern Med 2010 March;267(3):295-304. 
 (20)  Strand AH, Gudmundsdottir H, Os I et al. Arterial plasma noradrenaline predicts left 
ventricular mass independently of blood pressure and body build in men who 
develop hypertension over 20 years. J Hypertens 2006 May;24(5):905-13. 
 (21)  Sundstrom J, Lind L, Vessby B, Andren B, Aro A, Lithell H. Dyslipidemia and an 
unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. 
Circulation 2001 February 13;103(6):836-41. 
 (22)  Wills AK, Lawlor DA, Matthews FE et al. Life course trajectories of systolic blood 
pressure using longitudinal data from eight UK cohorts. PLoS Med 2011 
June;8(6):e1000440. 
 (23)  Zureik M, Bonithon-Kopp C, Diebold B, Ducimetiere P, Guize L. Combined effects of 
blood pressure and body mass index on left ventricular structure in middle-aged 
males: cross-sectional and 2-year longitudinal results. J Hypertens 1995 
September;13(9):979-85. 
 (24)  Mishra G, Nitsch D, Black S, De SB, Kuh D, Hardy R. A structured approach to 
modelling the effects of binary exposure variables over the life course. Int J 
Epidemiol 2009 April;38(2):528-37. 
 (25)  Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on 
hypertension management: a European Society of Hypertension Task Force 
document. J Hypertens 2009 November;27(11):2121-58. 
 (26)  Rodriguez MA, Kumar SK, De CM. Hypertensive crisis. Cardiol Rev 2010 
March;18(2):102-7. 
 (27)  Skov K, Julius S, Nesbitt S, Mulvany MJ. Can hypertension be prevented? The Danish 
Hypertension Prevention Project and the Trial of Prevention of Hypertension studies. 
Curr Opin Cardiol 2002 July;17(4):380-4. 
168 | P a g e  
 
 (28)  Julius S, Nesbitt SD, Egan BM et al. Feasibility of treating prehypertension with an 
angiotensin-receptor blocker. N Engl J Med 2006 April 20;354(16):1685-97. 
 (29)  Wadsworth M, Kuh D, Richards M, Hardy R. Cohort Profile: The 1946 National Birth 
Cohort (MRC National Survey of Health and Development). Int J Epidemiol 2006 
February;35(1):49-54. 
 (30)  Kuh D, Pierce M, Adams J et al. Cohort profile: updating the cohort profile for the 
MRC National Survey of Health and Development: a new clinic-based data collection 
for ageing research. Int J Epidemiol 2011 February;40(1):e1-e9. 
 (31)  Pierce M, Silverwood R, Nitsch D et al. Clinical disorders in a post war British cohort 
reaching retirement: evidence from the first national birth cohort study. PLos_ONE. 
In press 2012. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
169 | P a g e  
 
Chapter 5 
 
The effect of midlife blood pressure and midlife 
rise in blood pressure on future cardiac function 
 
 
Introduction   
With an ageing population, and better post myocardial infarction survival, the burden of 
congestive heart failure is increasing and represents a major public health challenge.1 Systolic 
and diastolic dysfunction can both lead to heart failure and may be different ends of the same 
continuum.2, 3 Diastolic dysfunction is common in people over 45 years1 and is a precursor of 
heart failure with preserved ejection fraction (HFPEF).4, 5 Diastolic dysfunction also predicts 
increased cardiovascular and all-cause mortality in those with normal ejection fractions.4, 6 
Systolic heart failure is as common as diastolic heart failure with at least half the patients 
diagnosed with heart failure having a reducing ejection fraction (EF).7 High systolic blood 
pressure (SBP) is an important cause of diastolic dysfunction and while ischaemic heart 
disease is the leading cause of systolic heart failure, hypertension is also a major cause.8 There 
is also evidence that raised antecedent SBP in early and mid-adulthood is associated with 
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increased risk of heart failure9 and elevated risk of cardiovascular mortality independent of 
current blood pressure (BP).10, 11 However, there has been limited work investigating the 
effects of longitudinal changes in BP over adulthood on systolic and diastolic function12, 13 and 
the long-term impact of antihypertensive treatment (HTT) remains uncertain.  
In this chapter we investigate the effect of earlier BP on future cardiac function (i.e. at age 60-
64y) and whether this effect is independent of BP at age 60-64y.  We also investigate the 
effect of HTT from the age of 36y onwards on cardiac function at age 60-64y measured by 
echocardiography. 
 
 
Methods 
The methods have been described in detail in the methods chapter. 
 
Echocardiography 
The following markers of diastolic function were measured in accordance with ASE/EAE 
recommendations – ratio of early (E) to late (A) transmitral Doppler flow (E/A), early (e’) 
myocardial velocity at the mitral valve annulus (average of septal and lateral wall measures) 
e’, E/e’ and ratio of early and late (a’) myocardial velocities at the mitral valve annulus 
(average of septal and lateral wall measures) e’/a’.14 E/e’ was used as the primary measure of 
diastolic function, as advocated by the latest (2009) joint European Society of 
Echocardiography and American Society of Echocardiography guidelines,14 although other 
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measures (E/A, e’ and e’/a’) were also examined. Left atrial volume indexed to body surface 
area (LAVI) was also examined as a marker of chronically elevated left ventricular filling 
pressures.15, 16  
Systolic function was assessed by measuring EF [(using Simpson’s biplane method or by linear 
2D M mode measurements if Simpson’s method was not possible17 as described in the 
methods chapter (chapter 3)]. 
 
Statistical Analysis 
Initially, separate regression models investigated the association between SBP at each of the 
4 ages at which it was measured and measures of cardiac function at 60-64y, with adjustment 
for sex, age at clinic visit and clinic attended. We tested whether these associations were 
linear and whether there was an interaction by gender. There was no gender interaction so 
in subsequent analyses both genders were pooled and adjusted for sex. HTT at the same age 
as BP measurement was then added to models. Additional models assessed whether earlier 
SBP remained predictive once SBP at age 60-64y was also included. Final adjustments were 
made by including BMI and T2DM at age 60-64y and finally left ventricular mass indexed to 
body surface area (LVMI).  
To investigate whether rate of change in SBP at a particular period of midlife was more 
strongly associated with diastolic function, a rate of change in BP model was constructed 
similar to that described in the methods chapter (chapter 3).  
Similar analyses were repeated for diastolic BP (DBP), pulse pressure (PP) and mean arterial 
pressure (MAP). 
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Sensitivity analyses were carried out to assess whether the associations with SBP remained 
unchanged if those on HTT or those who were hypertensive (SBP>=140 mmHg and/or DBP >= 
90mmHg) were excluded. 
 
 
 
 Results 
Characteristics of participants at age 60-64y relevant to this chapter are shown in table 5.1. 
Compared to women, men had a higher mean E/e’ and a larger mean LAVI. e’/a’ was higher 
in women while there were no sex differences for E/A and e’. Mean EF was higher in women 
while s’ was higher in men.  
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Table 5.1. Echocardiographic and cardiac risk factor characteristics of study participants.  
Unless otherwise stated data refer to age 60-64y. 
Variable (at age 60-64y unless stated otherwise) All Men Women 
n Result n Result n Result 
Age, y 1472 63.3 (1.1) 696 63.2 (1.1) 776  63.3 (1.1) 
BMI, kg/m2 1480 27.5 (4.6) 701 27.7 (4.0) 779 27.4 (5.1) 
SBP, mmHg 1478 135.7 (17.9) 701 139.0 (17.7) 777 132.8 (17.7) 
SBP in those on HTT, mmHg 315 137.5 (17.6) 160 139.2 (18.2) 155 135.8 (16.8) 
SBP in those not on HTT, mmHg 1011 135.1 (18.0) 457 138.6 (17.4) 554 132.1 (18.0) 
SBP at age 53y,  mmHg 1393 134.1 (19.1) 657 137.8 (18.9) 736 130.7 (18.7) 
SBP at age 43y, mmHg 1381 121.5 (14.5) 654 123.0 (14.3) 727 120.1 (14.6) 
SBP at age 36y, mmHg 1334 118.3 (14.0) 631 121.3 (14.2) 703 115.6 (13.4) 
DBP, mmHg 1478 77.4 (9.7) 701 79.0 (9.8) 777 75.9 (9.3) 
DBP at age 53y, mm Hg 1393 83.4 (11.9) 657 86.2 (11.9) 736 80.9 (11.3) 
DBP at age 43y, mm Hg 1381 78.5 (11.3) 654 80.9 (11.2) 727  76.3 (10.9) 
DBP at age 36y, mm Hg 1333 76.0 (11.7) 630 77.8 (11.7) 703 74.4 (11.4) 
Heart Rate, bpm 1473 68.5 (11.8) 699 67.2 (12.5) 774  69.7 (11.0) 
LVMI, g/m2 1480 95.7 (26.6) 701  104.1 (27.9) 779 88.1 (22.9) 
E/A 1424 1.0 (0.3) 668 1.0 (0.3) 756 1.0 (0.3) 
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e’, cm/s 1381 8.8 (1.9) 640 8.9 (1.9) 741 8.7 (1.9) 
E/e’ 1354 8.0 (2.1) 681  7.5 (2.1) 727 8.3 (2.1) 
e’/a’ 1358 0.8 (0.2) 624 0.8 (0.2) 734 0.9 (0.2) 
LAVI, ml/m2 1285 20.9 (7.3) 624 21.7 (7.5) 661 20.0 (7.0) 
Ejection Fraction (%) 1453 68.7 (9.7) 687 67.2 (10.1) 766 69.9 (9.2) 
s’ (cm/sec) 1350 7.7 (1.6) 626 8.1 (1.7) 724 7.5 (1.4) 
Antihypertensive medication, n (%) 1332  315 (24) 620 159 (26) 712  156 (22) 
Type 2 Diabetes Mellitus, n (%) 1357  73 (6) 635   37 (6) 722  36 (5) 
Data are mean (SD), or n (%) as appropriate.  
BMI - Body mass index; SBP -Systolic blood pressure; DBP -Diastolic blood pressure; LVMI - Left ventricular mass indexed to body surface area; LAVI - Left atrial volume 
indexed to body surface area 
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The association between SBP at various ages and diastolic function was assessed (Tables 5.2a-
e). 
SBP from 36y onwards was positively associated with increased E/e’ (Table 5.2a). The 
relationship persisted after adjustment for age, sex, clinic attended and current 
HTT/SBP/BMI/presence of T2DM. Analyses were repeated replacing SBP with DBP, MAP or PP 
(Tables 5.2h-j). The relationships of these BP measures with E/e’ were qualitatively broadly 
similar to SBP with DBP/PP/MAP at age 36y positively associated with E/e’ at 60-64y in the 
minimally adjusted model. On full adjustment, DBP from 43y, PP at 60-64y and MAP from 43y 
were positively associated with E/e’.  
From 43y onwards, those on HTT had increased E/e’; this was not affected substantively by 
adjustment for current SBP; regression coefficients were slightly attenuated by adjustment 
for T2DM and BMI, although relationships remained statistically significant (Table 5.2a). We 
also investigated whether the effect of earlier SBP was mediated via left ventricular (LV) 
hypertrophy (LVH) by the inclusion of LVMI in the regression models. This was not the case 
(Table 5.2a). 
We investigated whether relationships between elevated BP in earlier life and E/e’ might be 
driven by inclusion of people who went on to develop hypertension. However, when those 
who were hypertensive at 60-64y (SBP>=140 mmHg and/or DBP >= 90mmHg) were excluded 
from the analysis, the associations remained very similar (Table 5.2f). 
Analyses were also repeated after excluding those on HTT; despite the reduced number of 
individuals in this sub-analysis, SBP from 36y onwards remained positively predictive of E/e’ 
(Table 5.2g). 
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Qualitatively similar findings were observed when the associations between current and 
antecedent SBP and E/A or LAVI were examined, although relationships tended to be weaker. 
Only SBP at 53y was predictive of future E/A, and HTT at any age was unrelated to E/A (Table 
5.2b). SBP at age 53y and HTT at ages 53y and 60-64y were associated with LAVI (Table 5.2c).  
Data relating SBP measured at various ages to e’ and e’/a’ are shown in Tables 2d-e. Overall 
associations were qualitatively similar to those for E/A.  
The associations between DBP, PP and MAP and E/e’ were also examined (Tables 5.2h-j). The 
overall associations were qualitatively similar to those between SBP and E/e’. 
 
The association between SBP at the various ages and systolic function was also examined 
(Tables 5.2k-l). 
SBP was not associated with EF in the minimally adjusted models (Table 5.2k). On further 
adjustment SBP remained unrelated to EF except at age 53y. SBP at age 53y was not 
associated with EF on minimal adjustment or after including HTT in the model. However on 
further adjustment for SBP at 60-64y, the effect size increased slightly and the effect became 
significant (increase in SBP associated with increase in EF i.e. better systolic function). With 
further adjustment for T2DM and BMI at age 60-64y, the effect size marginally increased and 
significance remained.  HTT was not associated with EF. 
 Only SBP at age 36y was associated with s’. Increased SBP at age 36y was associated with 
decreased s’ (i.e. poorer systolic function). This remained the case after the sequential 
adjustments with a marginal attenuation of effect size with the adjustments. Only HTT at age 
53y was associated with s’, with the association being negative (i.e. poorer systolic function). 
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The strength of the effect was similar with sequential adjustments with a marginal increase 
on the addition of T2DM and SBP at age 60-64y and then on the inclusion of LVMI. 
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Table 5.2a. Regression coefficients, 95% confidence intervals and p values estimating the effect of SBP and HTT at 4 time points on E/e’ at 
60-64 years. 
 
HTT - Hypertension treatment; SBP - Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index; LVMI - Left ventricular mass indexed to body surface 
area 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + SBP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 Model 5 
(model 4 + LVMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
 
Age 36y  
 
SBP  
 
0.019  
(0.010, 0.029) 
 
<0.001 
 
0.019 
 (0.010, 0.029) 
 
<0.001 
 
0.012 
 (0.002, 0.021) 
 
0.015 
 
0.012  
(0.003, 0.022) 
 
0.010 
 
0.010 
(0.001, 0.020) 
 
0.038 
(n = 1196) HTT   
 
- - -0.05 (-1.21, 1.11)  0.933 0.10 (-1.04, 1.24) 0.868 -0.09 (-1.21, 1.04) 0.880 -0.07 (-1.19, 1.04) 0.898 
Age 43y  SBP  0.020  
(0.011, 0.028) 
<0.001 0.018  
(0.010, 0.027) 
<0.001 0.009  
(0.000, 0.018) 
 0.049 0.010  
(0.001, 0.018) 
0.031 0.009 
(-0.0001, 0.018) 
0.054 
(n = 1221) HTT 
  
- - 1.46 (0.68, 2.23) <0.001 1.46 (0.68, 2.23) <0.001 1.15 (0.38, 1.93) 0.003 1.00 (0.18, 1.81) 0.017 
Age 53y  SBP  0.024  
(0.018, 0.030) 
<0.001 0.022 
 (0.016, 0.028) 
<0.001 0.015 
(0.008, 0.021) 
<0.001 0.013 
 (0.006, 0.019) 
<0.001 0.010 
(0.003, 0.017) 
0.004 
(n = 1293) HTT  
 
- - 0.77 (0.42, 1.11) <0.001 0.77 (0.43, 1.11) <0.001 0.64 (0.30, 0.98) <0.001 0.55 (0.18, 0.92) 0.003 
Age 60-
64y 
SBP  0.025 
 (0.019, 0.031) 
<0.001 0.025 
 (0.018, 0.031) 
<0.001 - - 0.022  
(0.016, 0.028) 
<0.001 0.021 
(0.014, 0.027) 
<0.001 
(n = 1299) HTT 
  
- - 0.76 (0.49, 1.02) <0.001 - - 0.59 (0.31, 0.86) <0.001 0.43 (0.15, 0.70) 0.003 
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Table 5.2b. Regression coefficients, 95% confidence intervals and p values estimating the effect of SBP and HTT at 4 time points on E/A at 60-
64years. 
 
HTT - Hypertension treatment; SBP - Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index; LVMI - Left ventricular mass indexed to body surface 
area 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + SBP at 60-64y) 
Model 4 
(model 3 +  T2DM + BMI) 
Model 5  
(model 4 + LVMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
 
Age 36y  
 
SBP  
 
0.000070 
 (-0.0012, 0.0013) 
 
0.913 
 
0.000040 
 (-0.0012, 0.0013) 
 
0.950 
 
0.00071  
(-0.0006, 0.0020) 
 
0.282 
 
0.00052 
 (-0.0074, 0.0018) 
 
0.419 
 
0.0007 
(-0.0007, 0.0020) 
 
0.324 
(n = 1267) HTT   
 
- - 0.064  
(-0.096, 0.225) 
0.431 0.051  
(-0.108, 0.210) 
0.529 0.082  
(-0.074, 0.238) 
0.305 0.079 
(-0.080, 0.238) 
0.328 
Age 43y  SBP  0.00010 
 (-0.0010, 0.0013) 
0.858 0.00017 
 (-0.0098, 0.0013) 
0.776 0.0012  
(-0.0001, 0.0024) 
0.052 0.0097 
 (-0.0002, 0.0022) 
0.109 0.0006 
(-0.0007, 0.0018) 
0.362 
(n = 1296) HTT 
  
- - -0.064  
(-0.169, 0.040) 
0.227 -0.066 
 (-0.170, 0.037) 
0.209 -0.025 
 (-0.128, 0.077) 
0.628 -0.020 
(-0.130, 0.090) 
0.719 
Age 53y SBP  -0.0015  
(-0.0023, -0.0007) 
<0.001 -0.0016  
(-0.0024, -0.0008) 
<0.001 -0.00095 
 (-0.0018,  
-0.0007) 
0.035 -0.0067 
 (-0.0015, 0.0002) 
0.131 -0.0007 
(-0.0016, 0.0003) 
0.169 
(n = 1369) HTT 
  
- - 0.032  
(-0.015, 0.078) 
0.180 0.029  
(-0.017, 0.076) 
0.214 0.042  
(-0.004, 0.089) 
0.072 0.038 
(-0.013, 0.088) 
0.143 
Age 60-
64y  
SBP  -0.0021  
(-0.0029, -0.0012) 
<0.001 -0.0020 
 (-0.0029,  
-0.0012) 
<0.001 - - -0.0016  
(-0.0025, -0.0008) 
<0.001 -0.0015 
(-0.0023, -0.0006) 
0.001 
(n = 1375) HTT  - - -0.023  
(-0.059, 0.013) 
0.216 - - 0.0016  
(-0.0350, 0.0382) 
0.933 -0.001 
(-0.039, 0.038) 
0.976 
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Table 5.2c. Regression coefficients (β, ml/m
2
), 95% confidence intervals and p values estimating the effect of SBP and HTT at 4 time points 
on left atrial volume indexed to body surface area at 60-64 years. 
 
HTT - Hypertension treatment; SBP - Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index; LVMI - Left ventricular mass indexed to body surface 
area 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + SBP at 60-64y) 
Model 4 
(model 3 +  T2DM + BMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
 
Age 36y  
 
SBP  
 
0.033 
 (0.001, 0.065) 
 
0.041 
 
0.032 
 (-0.0002, 0.0633) 
 
0.052 
 
0.026  
(-0.007, 0.058) 
 
0.119 
 
0.027 
 (-0.0045, 0.059) 
 
0.093 
(n = 1140) 
 
HTT   - - 3.728 
(-0.563, 8.019) 
0.089 3.890 
(-0.392 8.191) 
0.075 2.785 
(-1.452, 7.021) 
0.197 
Age 43y  SBP  0.033 
 (0.003, 0.062) 
0.029 0.031 
 (0.001, 0.060) 
0.042 0.026  
(-0.005, 0.057) 
0.103 0.027 
 (-0.003, 0.058) 
0.078 
(n = 1164) 
 
HTT 
  
- - 2.830 
(0.210, 5.449) 
0.034 -2.849 
 (0.229, 5.469) 
0.033 1.595 
 (-1.018, 4.208) 
0.231 
Age 53y SBP  0.051 
(0.030, 0.072) 
<0.001 0.043 
(0.022, 0.064) 
<0.001 0.043 
 (0.019, 0.066) 
<0.001 0.036 
 (0.013, 0.059) 
0.002 
(n = 1189) 
 
HTT 
  
- - 2.333 
(1.119,3.547) 
<0.001 2.336 
(1.120, 3.552) 
<0.001 1.872 
(0.650, 3.094) 
0.003 
Age 60-64y  SBP  0.024 
(0.002, 0.046) 
0.033 0.021 
 (-0.0005, 0.043) 
0.056 - - 0.012 
(-0.010, 0.034) 
0.297 
(n = 1248) HTT  - - 1.728 
(0.822, 2.632) 
<0.001 - - 1.093 
(0.166, 0.345) 
0.021 
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Table 5.2d. Regression coefficients, 95% confidence intervals and p values estimating the effect of SBP and HTT at 4 time points on e’ at 60-
64 years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HTT - Hypertension treatment; SBP - Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index; LVMI - Left ventricular mass indexed to body surface 
area 
 
 
 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + SBP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
Model 5 
(model 4 + LVMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
Age 36y 
 (n = 1227) 
SBP  -0.008 
 (-0.017, 0.000) 
0.061 -0.008  
(-0.017, 0.000) 
0.062 -0.003 
 (-0.011, 0.006) 
0.540 -0.004 
 (-0.012, 0.005) 
0.418 -0.003 
 (-0.012, 0.006) 
0.566 
 HTT  - - -0.026 
 (-1.094, 1.042) 
0.962 -0.133  
(-1.190, 0.924) 
0.805 0.005 
 (-1046, 1.056) 
0.993 0.005  
(-1.037, 1.047) 
0.992 
Age 43y 
 (n = 1255) 
SBP  -0.007  
(-0.015, 0.001) 
0.082 -0.006  
(-0.014, 0.002) 
0.115 0.002  
(-0.007, 0.010) 
0.718 0.001 
 (-0.008, 0.009) 
0.900 -0.0002 
 (-0.009, 0.008) 
0.959 
 HTT  - - -0.794 
 (-1.511, -0.076) 
0.030 -0.769  
-(1.479, -0.060) 
0.034 -0.602 
 (-1.313, 0.109) 
0.097 -0.393 
 (-1.158, 0.371) 
0.313 
Age 53y 
 (n = 1329) 
SBP  -0.013 
 (-0.018, -0.007) 
<0.001 -0.012 
 (-0.017, -0.006) 
<0.001 -0.006  
(-0.012, -0.000) 
0.038 -0.005  
(-0.011, 0.0001) 
0.092 -0.004 
 (-0.010, 0.003) 
0.276 
 HTT  - - -0.284  
(-0.601, 0.033) 
0.079 -0.284  
(-0.599, 0.030) 
0.076 -0.234 
 (-0.551, 0.083) 
0.148 -0.190  
(-0.532, 0.153) 
0.278 
Age 60-64y  
(n = 1335) 
SBP  -0.018 
 (-0.024, -0.012) 
<0.001 -0.017  
(-0.023, -0.011) 
<0.001 - - -0.016 
 (-0.021, -0.010) 
<0.001 -0.014 
 (-0.020, -0.008) 
<0.001 
 HTT  - - -0.271  
(-0.517, -0.026) 
0.030 - - -0.162  
(-0.041, 0.089) 
0.206 -0.081 ( 
-0.341, 0.179) 
0.541 
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Table 5.2e. Regression coefficients, 95% confidence intervals and p values estimating the effect of SBP and HTT at 4 time points on e’/a’ at 
60-64 years. 
HTT - Hypertension treatment; SBP - Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index; LVMI - Left ventricular mass indexed to body surface 
area 
 
 
 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + SBP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
Model 5 
(model 4 + LVMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
Age 36y  SBP  -0.0004 
 (-0.0015, 0.0006) 
0.437 -0.00044  
(-0.0015, 0.0006) 
0.414 0.00033  
(-0.0007, 0.0014) 
0.540 0.00018 
 (-0.00086, 0.00123) 
0.735 0.0003 
(-0.0008, 0.0013) 
0.643 
(n = 1209) HTT  - - 0.044 
 (-0.086, 0.173) 
0.508 0.028  
(-0.099, 0.156) 
0.661 0.054 
 (-0.071, 0.180) 
0.398 0.052  
(-0.073, 0.177) 
0.413 
Age 43y  SBP  -0.00047  
(-0.0014, 0.0005) 
0.328 -0.00040 
 (-0.0014, 0.0006) 
0.409 0.00070  
(-0.0003, 0.0017) 
0.167 0.0053 
 (-0.0005, 0.0015) 
0.292 0.0005  
(-0.0006, 0.0015) 
0.374 
(n = 1255) HTT  - - -0.090 
 (-0.177, -0.003) 
0.042 -0.087 
 (-0.172, -0.001) 
0.047 -0.052 
 (-0.137, 0.033) 
0.229 -0.029  
(-0.121, 0.063) 
0.537 
Age 53y SBP  -0.0017  
(-0.0023, -0.0010) 
<0.001 -0.0017 
 (-0.0024, -0.0010) 
<0.001 -0.00099  
(-0.0017, -0.0003) 
0.008 -0.00072 
 (-0.0015, 0.0001) 
0.051 -0.0006 
 (0.0014, 0.0001) 
0.105 
(n = 1308) HTT  - - 0.0057  
(-0.0333, 0.0447) 
0.774 0.0061  
(-0.0326, 0.0449) 
0.756 0.020 
 (-0.018, 0.059) 
0.300 0.029 
 (-0.012, 0.070) 
0.168 
Age 60-
64y  
SBP  -0.0023 
 (-0.0030, -0.0016) 
<0.001 -0.0022  
(-0.0029, -0.0015) 
<0.001 - - -0.0018 
 (-0.0025, -0.0011) 
<0.001 -0.0018 
(-0.0025, -0.0010) 
<0.001 
(n = 1314) HTT  - - -0.017  
(-0.047, 0.013) 
0.265 - - 0.006 
 (-0.003, 0.037) 
0.688 0.007 
 (-0.025, 0.038) 
0.676 
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Table 5.2f. Regression coefficients, 95% confidence intervals and p values estimating the effect of SBP and HTT at 4 time points on E/e’ at 60-
64 years excluding those who were hypertensive (SBP>=140 mmHg and/or DBP >= 90mmHg). 
 
HTT - Hypertension treatment; SBP - Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index; LVMI - Left ventricular mass indexed to body surface 
area 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + SBP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 Model 5 
(model 4 + LVMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
 
Age 36y  
 
SBP  
 
0.017  
(0.0056, 0.0285) 
 
0.004 
 
0.017 
 (0.0056, 0.0285) 
 
0.004 
 
0.0082 
 (-0.0034, 0.0197) 
 
0.165 
 
0.0083  
(-0.0031, 0.0198) 
 
0.153 
 
0.0079 
(-0.0040, 0.0199) 
 
0.194 
(n = 1064) HTT   
 
- - 1.14 (-0.36, 2.64) 0.136 1.23 (-0.24, 2.70) 0.101 0.93 (-0.53,2.39) 0.212 0.91 (-0.55, 2.36) 0.222 
Age 43y  SBP  0.014  
(0.017, 0.026) 
0.026 0.012  
(0.0002, 0.0245) 
0.046 -0.000093  
(-0.012, 0.012) 
0.988 0.0016  
(-0.011, 0.014) 
0.803 0.0033 
(-0.0095, 0.0162) 
0.610 
(n = 1012) HTT 
  
- - 2.06 (1.06,3.06) <0.001 1.97(0.99, 2.95) <0.001 1.68 (0.70, 2.67) 0.001 1.62 (0.60, 2.63) 0.002 
Age 53y  SBP  0.028  
(0.015, 0.040) 
<0.001 0.027 
 (0.015, 0.039) 
<0.001 0.013 
(0.0035, 0.0265) 
0.044 0.013 
 (-0.0048, 0.0257) 
0.059 0.014 
(0.003, 0.027) 
0.045 
(n = 769) HTT  
 
- - 0.66 (0.17, 1.14) 0.008 0.57(0.096, 1.053) 0.019 0.52 (0.04, 1.00) 0.034 0.36 (-0.16, 0.88) 0.174 
Age 60-
64y 
SBP  0.036 
 (0.023, 0.049) 
<0.001 0.034 
 (0.021, 0.047) 
<0.001 - - 0.029 
(0.016, 0.042) 
<0.001 0.028 
(0.014, 0.042) 
<0.001 
(n = 802) HTT 
  
- - 0.94 (0.60, 1.28) <0.001 - - 0.67 (0.32, 1.02) <0.001 0.58 (0.21, 0.95) 0.002 
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Table 5.2g. Regression coefficients, 95% confidence intervals and p values estimating the effect of SBP and HTT at 4 time points on E/e’ at 
60-64 years excluding those who were on HTT. 
 
HTT - Hypertension treatment; SBP - Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index; LVMI - Left ventricular mass indexed to body surface 
area 
 
 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + SBP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 Model 5 
(model 4 + LVMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
 
Age 36y  
 
SBP  
 
0.020  
(0.011, 0.029) 
 
<0.001 
 
0.020  
(0.011, 0.029) 
 
<0.001 
 
0.012 
 (0.0025, 0.0215) 
 
0.013 
 
0.012  
(0.0029, 0.0217) 
 
0.010 
 
0.011 
(0.0014, 0.0211) 
 
0.025 
(n = 1205 ) HTT   
 
- - - - - - - - - - 
Age 43y  SBP  0.019 
(0.011, 0.028) 
<0.001 0.019 
(0.011, 0.028) 
<0.001 0.010  
(0.00082, 0.01822) 
 0.032 0.010  
(0.0014, 0.0186) 
0.023 0.010 
(0.00083, 0.01906) 
0.032 
(n = 1217 ) HTT 
  
- - - - - - - - - - 
Age 53y  SBP  0.020  
(0.013, 0.026) 
<0.001 0.020  
(0.013, 0.026) 
<0.001 0.012 
(0.0050, 0.0192) 
0.001 0.010 
 (0.0033, 
0.0175) 
0.004 0.0086 
(0.0012, 0.0161) 
0.024 
(n = 1113) HTT  
 
- - - - - - - - - - 
Age 60-
64y 
SBP  0.026 
 (0.020, 0.033) 
<0.001 0.026 
 (0.020, 0.033) 
<0.001 - - 0.024  
(0.017, 0.030) 
<0.001 0.024 
(0.017, 0.031) 
<0.001 
(n = 1030) HTT 
  
- - - - - - - - - - 
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Table 5.2h. Regression coefficients, 95% confidence intervals and p values estimating the effect of DBP and HTT at 4 time points on E/e’ at 
60-64 years. 
 
 
HTT - Hypertension treatment; DBP - Diastolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index; LVMI - Left ventricular mass indexed to body 
surface area 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + DBP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 Model 5 
(model 4 + LVMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
 
Age 36y  
 
DBP  
 
0.018  
(0.0054, 0.0302) 
 
0.005 
 
0.018 
 (0.0054, 0.0302) 
 
0.005 
 
0.012 
 (-0.0007, 0.0246) 
 
0.064 
 
0.011  
(-0.0011, 0.0238) 
 
0.074 
 
0.010 
(-0.0026, 0.0236) 
 
0.116 
(n = 1215) HTT   
 
- - -0.029 
 (-1.187, 1.129) 
0.961 0.046 
(-1.106, 1.197) 
0.938 -0.124 
(-1.261,1.012) 
0.830 -0.150 
(-1.281, 0.981) 
0.795 
Age 43y  DBP  0.023  
(0.011, 0.036) 
<0.001 0.021  
(0.0082, 0.0333) 
0.001 0.016 
(0.0028, 0.0284) 
0.017 0.013 
(0.00062, 0.0259) 
0.040 0.014 
(0.00081, 0.0279) 
0.038 
(n = 1242) HTT 
  
- - 1.421 
(0.618, 2.224) 
0.001 1.389 
(0.589, 2.189) 
0.001 1.059 
(0.264, 1.854) 
0.009 0.904 
 (0.078, 1.731) 
0.032 
Age 53y  DBP  0.032  
(0.022, 0.042) 
<0.001 0.028 
 (0.019, 0.038) 
<0.001 0.022 
(0.012, 0.033) 
<0.001 0.017 
 (0.0067, 0.0279) 
0.001 0.017 
(0.0060, 0.0284) 
0.003 
(n = 1265) HTT  
 
- - 0.859 
 (0.515, 1.203) 
<0.001 0.858 
(0.515, 1.202) 
<0.001 0.696  
(0.0351, 1.040) 
<0.001 0.575 
 (0.206, 0.944) 
0.002 
Age 60-
64y 
DBP  0.029 
(0.018, 0.041) 
<0.001 0.027 
(0.016, 0.039) 
<0.001 - - 0.025 
(0.013, 0.036) 
<0.001 0.022 
(0.010, 0.034) 
<0.001 
(n = 1331) HTT 
  
- - 0.788 
(0.016, 0.039) 
<0.001 - - 0.588 
(0.321, 0.855) 
<0.001 0.440 
(0.010, 0.034) 
<0.001 
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Table 5.2i. Regression coefficients, 95% confidence intervals and p values estimating the effect of PP and HTT at 4 time points on E/e’ at 60-
64 years. 
 
HTT - Hypertension treatment; PP - Pulse pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index; LVMI - Left ventricular mass indexed to body surface area 
 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + PP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 Model 5 
(model 4 + LVMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
 
Age 36y  
 
PP  
 
0.016  
(0.0033, 0.0279) 
 
0.013 
 
0.016 
 (0.0033, 0.0279) 
 
0.013 
 
0.010 
 (-0.0019, 0.0227) 
 
0.097 
 
0.011  
(-0.0009, 0.0234) 
 
0.069 
 
0.0099 
(-0.0027, 0.0224) 
 
0.123 
(n = 1215) HTT   
 
- - 0.122 
 (-1.033, 1.277) 
0.835 0.203 
(-0.935, 1.341) 
0.727 0.027  
(-1.100,1.153) 
0.962 -0.005  
(-1.125, 1.115) 
0.993 
Age 43y  PP  0.016  
(0.0043, 0.0270) 
0.007 0.016 
(0.0047, 0.0273) 
0.006 0.0054 
(-0.0062, 0.0170) 
0.364 0.0075 
(-0.0040, 0.0190) 
0.199 0.0067 
(-0.0054, 0.0188) 
0.278 
(n = 1242) HTT 
  
- - 1.587 
(0.787, 2.386) 
<0.001 1.548 
(0.762, 2.334) 
<0.001 1.231 
(0.447, 2.016) 
0.002 0.904 
 (0.078, 1.731) 
0.032 
Age 53y  PP  0.024 
(0.016, 0.033) 
<0.001 0.021 
 (0.012, 0.030) 
<0.001 0.013 
(0.0038, 0.022) 
0.006 0.011 
 (0.0022, 0.0204) 
0.015 0.0091 
(-0.0004, 0.0186) 
0.059 
(n = 1265) HTT  
 
- - 0.890 
 (0.545, 1.235) 
<0.001 0.877 
(0.536, 1.22) 
<0.001 0.714  
(0.371, 1.057) 
<0.001 0.620  
(0.254, 0.986) 
0.001 
Age 60-
64y 
PP  0.030 
(0.022, 0.038) 
<0.001 0.028 
(0.020, 0.036) 
<0.001 - - 0.025 
(0.013, 0.036) 
<0.001 0.024 
(0.016, 0.033) 
<0.001 
(n = 1331) HTT 
  
- - 0.749 
(0.490, 1.009) 
<0.001 - - 0.025 
(0.017, 0.033) 
<0.001 0.427 
(0.147, 0.707) 
0.003 
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Table 5.2j. Regression coefficients, 95% confidence intervals and p values estimating the effect of MAP and HTT at 4 time points on E/e’ at 
60-64 years. 
 
HTT - Hypertension treatment; MAP – Mean arterial blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index; LVMI - Left ventricular mass indexed to body 
surface area 
 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + MAP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 Model 5 
(model 4 + LVMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
 
Age 36y  
 
MAP  
 
0.022  
(0.010, 0.034) 
 
<0.001 
 
0.022 
 (0.010, 0.034) 
 
<0.001 
 
0.013 
 (0.0004, 0.0252) 
 
0.044 
 
0.013  
(0.0005, 0.0251) 
 
0.041 
 
0.012 
(-0.0012, 0.0246) 
 
0.076 
(n = 1215) HTT   
 
- - -0.029 
 (-1.187, 1.129) 
0.961 0.046 
(-1.106, 1.197) 
0.938 -0.092  
(-1.221,1.037) 
0.873 0.91 (-0.55, 2.36) 0.222 
Age 43y  MAP  0.026 
(0.014, 0.038) 
<0.001 0.024  
(0.012, 0.036) 
<0.001 0.015 
(0.0024, 0.0266) 
0.019 0.013 
(0.0015, 0.0254) 
0.027 0.014 
(0.0011, 0.0267) 
0.033 
(n = 1242) HTT 
  
- - 1.407 
(0.606, 2.207) 
0.001 1.370 
(0.579, 2.161) 
0.001 1.058 
(0.269, 1.846) 
0.009 0.904 
 (0.078, 1.731) 
0.032 
Age 53y  MAP  0.033  
(0.025, 0.042) 
<0.001 0.030 
 (0.021, 0.038) 
<0.001 0.021 
(0.011, 0.030) 
<0.001 0.017 
 (0.0070, 0.0261) 
0.001 0.016 
(0.0056, 0.0258) 
0.002 
(n = 1265) HTT  
 
- - 0.797 
 (0.453, 1.142) 
<0.001 0.800 
(0.458, 1.141) 
<0.001 0.658  
(0.315, 1.001) 
<0.001 0.547 
(0.179, 0.914) 
0.004 
Age 60-
64y 
MAP  0.035 
(0.025, 0.044) 
<0.001 0.033 
(0.023, 0.042) 
<0.001 - - 0.030 
(0.020, 0.039) 
<0.001 0.028 
(0.018, 0.038) 
<0.001 
(n = 1331) HTT 
  
- - 0.755 
(0.496, 1.015) 
<0.001 - - 0.573 
(0.307, 0.838) 
<0.001 0.432 
(0.152, 0.712) 
0.003 
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Table 5.2k. Regression coefficients, 95% confidence intervals and p values estimating the effect of SBP and HTT at 4 time points on ejection 
fraction at 60-64 years. 
 
HTT - Hypertension treatment; SBP – Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index; LVMI - Left ventricular mass indexed to body surface 
area 
 
 
 
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + SBP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 Model 5 
(model 4 + LVMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
 
Age 36y  
 
SBP  
0.0018 
(-0.041, 0.045) 
0.936 0.0028 
(-0.040, 0.046) 
0.898 0.0067 
(-0.038, 0.051) 
0.766 0.0077 
(-0.037, 0.052) 
0.733 0.0081 
(-0.037, 0.053) 
0.723 
(n = 1193) HTT   
 
- - -2.321 
(-7.734, 3.091) 
0.400 -2.400 
(-7.818, 3.017) 
0.385 -2.27 
(-7.700, 3.159) 
0.412 -2.263 
(-7.700, 3.169) 
0.414 
Age 43y  SBP  0.0000006 
(-0.040, 0.040) 
1.000 -0.00066 
(-0.041, 0.039) 
0.974 0.0034 
(-0.039, 0.046) 
0.874 0.0040 
(-0.038, 0.046) 
0.854 0.0037 
(-0.039, 0.047) 
0.865 
(n = 1228) HTT 
  
- - 0.984 
(-2.606, 4.574) 
0.591 0.983 
(-2.609, 4.574) 
0.592 1.275 
(-2.354, 4.904) 
0.491 0.759 
(-2.943, 4.460) 
0.688 
Age 53y  SBP  0.021 
(-0.0077, 0.0490) 
0.153 0.025 
(-0.0040, 0.0542) 
0.091 0.035 
(0.0029, 0.0664) 
0.032 0.038 
(0.0065, 0.0704) 
0.019 0.038 
(0.0056, 0.0705) 
0.022 
(n = 1248) HTT  
 
- - -1.131 
(-2.786, 0.525) 
0.180 -1.157 
(-2.812, 0.498) 
0.170 -0.826 
(-2.512, 0.860) 
0.337 -0.783 
(-2.493, 0.928) 
0.370 
Age 60-
64y 
SBP  -0.0060 
(-0.035, 0.235) 
0.692 -0.0064 
(-0.036, 0.231) 
0.669 - - -0.0038 
(-0.034, 0.026) 
0.804 -0.0055  
(-0.036, 0.025) 
0.721 
(n = 1309) HTT 
  
- - 0.307 
(-0.933, 1.548) 
0.627 - - 0.526 
(-0.758, 1.809) 
0.422 0.473 
(-0.831, 1.776) 
0.477 
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Table 5.2l. Regression coefficients, 95% confidence intervals and p values estimating the effect of SBP and HTT at 4 time points on s’ at 60-64 
years. 
 
HTT - Hypertension treatment; SBP – Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index; LVMI - Left ventricular mass indexed to body surface 
area
Variable  Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + HTT) 
Model 3 
(model 2 + SBP at 60-64y) 
Model 4 
(model 3 + T2DM + BMI) 
 Model 5 
(model 4 + LVMI) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
 
Age 36y  
 
SBP  
-0.0125 
(-0.0196, -0.0054) 
0.001 -0.0124 
(-0.0195, -0.0053) 
0.001 -0.0118 
(-0.0191, -0.0044) 
0.002 -0.0115 
(-0.0189, -0.0042) 
0.002 -0.0113 
(-0.0189, -0.0037) 
0.004 
(n = 1223) HTT   
 
- - -0.203 
(-1.095, 0.689) 
0.655 -0.214 
(-1.107, 0.678) 
0.638 -0.260 
(-1.153, 0.634) 
0.569 -0.241 
(-1.121, 0.639) 
0.591 
Age 43y  SBP  -0.0046 
(-0.0111, 0.0019) 
0.169 -0.0044 
(-0.0110, 0.0021) 
0.183 -0.0030 
(-0.0099, 0.0039) 
0.397 -0.0028 
(-0.0097, 0.0042) 
0.433 -0.0032 
(-0.0105, 0.00410 
0.391 
(n = 1242) HTT 
  
- - -0.241 
(-0.838, 0.357) 
0.429 -0.234 
(-0.832, 0.364) 
0.443 -0.320 
(-0.923, 0.284) 
0.299 -0.369 
(-1.000, 0.261) 
0.251 
Age 53y  SBP  -0.0018 
(-0.0065, 0.0028) 
0.446 -0.00082 
(-0.0055, 0.0039) 
0.732 0.00074 
(-0.0044, 0.0059) 
0.777 0.00025 
(-0.0049, 0.0054) 
0.925 0.0011 
(-0.0043, 0.0066) 
0.691 
(n = 1276) HTT  
 
- - -0.311 
(-0.579, -0.042) 
0.023 -0.309 
(-0.578, -0.041) 
0.024 -0.335 
(-0.608, -0.063) 
0.016 -0.339 
(-0.630, -0.047) 
0.023 
Age 60-
64y 
SBP  -0.0042 
(-0.0090, 0.0005) 
0.081 -0.0041 
(-0.0089, 0.0007) 
0.092 - - -0.0047 
(-0.0096, 0.0001) 
0.055 -0.0039 
(-0.0090, 0.0011) 
0.129 
(n = 1343) HTT 
  
- - -0.074 
(-0.277, 0.129) 
0.476 - - -0.114 
(-0.324, 0.095) 
0.284 -0.063 
(-0.284, 0.157) 
0.574 
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We looked to see whether there was a sensitive period when rate of change in SBP had the 
most influence on cardiac function. For diastolic function, increased rate of rise in SBP at all 
age periods (36-43y, 43-53y and 53-60/64y) was associated with increased E/e’ (Table 5.3a), 
although the relationship was strongest over the period 43-53y. Increased rates of rise in SBP 
over the age periods 43-53y and 53-60/64y were also significantly associated with decreased 
E/A (Table 5.3b), while rate of rise in the 43-53y period was also associated with increased 
LAVI (Table 5.3c).  
The associations between rate of change in SBP and future e’ (Table 5.3d) and e’/a’ (Table 
5.3e) were similar to those between rate of SBP change and E/A. 
 
When the associations between rate of change in SBP and systolic function were examined, 
only rate of change in SBP over 43y-53y was positively associated with EF (i.e. better systolic 
function) in the fully adjusted model. In the minimally adjusted model, the effect size was less 
and the effect was marginally non-significant (p = 0.058). The effect sizes were much smaller 
and non-significant for rate of change between 36-43y. There was a reversal of association 
for rate of change in SBP over 53y-60/64y (i.e. the coefficients were negative indicating worse 
systolic function); however the associations were just non-significant.  
Rate of change in SBP was not associated with s’.  
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Table 5.3a. Regression coefficients (β, E/e’ unit per unit SD change), 95% confidence intervals, and p values for a model showing effect of 
rate of change in SBP over 3 time periods (36-43y), (43-53y) and (53-60/64y) on E/e’ at age 60-64y. Initial model adjusted for sex, age at 
clinic attendance and clinic attended. Final model also adjusted for BMI, T2DM and HTT. 
Period of rate of change 
in SBP 
                               Adjusted for sex,                                                              Also adjusted for BMI,                           
                         clinic attended and age                                                        T2DM and current HTT 
β (95%CI) p value β (95%CI) p value 
36y – 43y 
 
0.22 (0.09, 0.34) 0.001 0.14 (0.01, 0.27) 0.032 
43y – 53y 0.37 (0.25, 0.49) 
 
<0.001 0.23 (0.11, 0.36) <0.001 
53y – 60/64y 
 
0.25 (0.13, 0.37) <0.001 0.28 (0.16, 0.40) <0.001 
 
SBP – Systolic blood pressure; BMI – body mass index; T2DM – type 2 diabetes mellitus; HTTT – hypertension treatment 
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Table 5.3b. Regression coefficients (β, E/A unit per unit SD change), 95% confidence intervals, and p values for a model showing effect of 
rate of change in SBP over 3 time periods (36-43y), (43-53y) and (53-60/64y) on E/A at age 60-64y. Initial model adjusted for sex, age at 
clinic attendance and clinic attended. Final model also adjusted for BMI, T2DM and HTT. 
Period of rate of 
change in SBP 
                                        Adjusted for sex,                                                                    Also adjusted for BMI,                           
                                 clinic attended and age                                                              T2DM and current HTT 
β Coefficient (95%CI)       p value          β Coefficient   (95%CI)      p value 
36y – 43y 
 
0.003 (-0.014, 0.021) 0.703 0.001 (-0.016, 0.019) 0.879 
43y – 53y 
 
-0.032 (-0.049, -0.016) <0.001 -0.025 (-0.042, -0.008) 0.005 
53y – 60/64y 
 
-0.033 (-0.049, -0.016) <0.001 -0.026 (-0.042, -0.009) 0.002 
 
SBP – Systolic blood pressure; BMI – body mass index; T2DM – type 2 diabetes mellitus; HTTT – hypertension treatment 
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Table 5.3c. Regression coefficients (β, LAVI unit per unit SD change), 95% confidence intervals, and p values for a model showing effect of 
rate of change in SBP over 3 time periods (36-43y), (43-53y) and (53-60/64y) on left atrial volume indexed to body surface area at age 60-
64y. Initial model adjusted for sex, age at clinic attendance and clinic attended. Final model also adjusted for BMI, T2DM and HTT. 
Period of rate of 
change in SBP 
                                        Adjusted for sex,                                                                    Also adjusted for BMI,                           
                                 clinic attended and age                                                              T2DM and current HTT 
β Coefficient (95%CI)       p value          β Coefficient   (95%CI)      p value 
36y – 43y 
 
0.330 (-0.125, 0.785) 0.155 0.260 (-0.207, 0.728) 0.274 
43y – 53y 
 
0.893 (0.453, 1.333) <0.001 0.605 (0.151, 1.059) 0.009 
53y – 60/64y 
 
-0.026 (-0.451, 0.399) 0.904 -0.141 (-0.570, 0.287) 0.518 
 
LAVI – left atrial volume indexed to body surface area; SBP – Systolic blood pressure; BMI – body mass index; T2DM – type 2 diabetes mellitus; HTTT – hypertension 
treatment 
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Table 5.3d. Regression coefficients, 95% confidence intervals, and p values for a model showing effect of rate of change in SBP over 3 time 
periods (36-43y), (43-53y) and (53-60/64y) on e’ at age 60-64y. Initial model adjusted for sex, age at clinic attendance and clinic attended. 
Final model also adjusted for BMI, T2DM and HTT. 
Period of rate of 
change in SBP 
                                        Adjusted for sex,                                                                    Also adjusted for BMI,                           
                                 clinic attended and age                                                              T2DM and current HTT 
β Coefficient (95%CI)       p value          β Coefficient   (95%CI)      p value 
36y – 43y -0.07 (-0.19, 0.05) 0.232 -0.05 (-0.17, 0.07) 0.443 
43y – 53y 
 
-0.21 (-0.32, -0.10) <0.001 -0.14 (-0.26, -0.02) 0.021 
53y – 60/64y -0.23 (-0.34, -0.12) <0.001 -0.22 (-0.33, -0.11) <0.001 
 
SBP – Systolic blood pressure; BMI – body mass index; T2DM – type 2 diabetes mellitus; HTTT – hypertension treatment 
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Table 5.3e. Regression coefficients, 95% confidence intervals, and p values for a model showing effect of rate of change in SBP over 3 time 
periods (36-43y), (43-53y) and (53-60/64y) on e’/a’ at age 60-64y. Initial model adjusted for sex, age at clinic attendance and clinic 
attended. Final model also adjusted for BMI, T2DM and HTT. 
Period of rate of 
change in SBP 
                                        Adjusted for sex,                                                                    Also adjusted for BMI,                           
                                 clinic attended and age                                                              T2DM and current HTT 
β Coefficient (95%CI)       p value          β Coefficient   (95%CI)      p value 
36y – 43y 
 
-0.0030 (-0.017, 0.011) 0.675 -0.0039 (-0.018, 0.011) 0.596 
43y – 53y 
 
-0.035 (-0.048, -0.021) <0.001 -0.025 (-0.039, -0.011) <0.001 
53y – 60/64y 
 
-0.033 (-0.046, -0.019) <0.001 -0.028 (-0.041, -0.014) <0.001 
  
     SBP – Systolic blood pressure; BMI – body mass index; T2DM – type 2 diabetes mellitus; HTTT – hypertension treatment 
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Table 5.3f. Regression coefficients, 95% confidence intervals, and p values for a model showing effect of rate of change in SBP over 3 time 
periods (36-43y), (43-53y) and (53-60/64y) on ejection fraction at age 60-64y. Initial model adjusted for sex, age at clinic attendance and 
clinic attended. Final model also adjusted for BMI, T2DM and HTT. 
Period of rate of 
change in SBP 
                                        Adjusted for sex,                                                                    Also adjusted for BMI,                           
                                 clinic attended and age                                                              T2DM and current HTT 
β Coefficient (95%CI)       p value          β Coefficient   (95%CI)      p value 
36y – 43y 
 
0.0015 (-0.6114, 0.6144) 0.996 0.0786 (-0.5541, 0.7113) 0.807 
43y – 53y 
 
0.5788 (-0.0199, 1.1776) 0.058 0.7507 (0.1235, 1.3778) 0.019 
53y – 60/64y 
 
-0.5310 (-1.1105, 0.0485) 0.072 -0.5197 (-1.1142, 0.0748) 0.087 
  
     SBP – Systolic blood pressure; BMI – body mass index; T2DM – type 2 diabetes mellitus; HTTT – hypertension treatment 
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Table 5.3g. Regression coefficients, 95% confidence intervals, and p values for a model showing effect of rate of change in SBP over 3 time 
periods (36-43y), (43-53y) and (53-60/64y) on s’ at age 60-64y. Initial model adjusted for sex, age at clinic attendance and clinic attended. 
Final model also adjusted for BMI, T2DM and HTT. 
Period of rate of 
change in SBP 
                                        Adjusted for sex,                                                                    Also adjusted for BMI,                           
                                 clinic attended and age                                                              T2DM and current HTT 
β Coefficient (95%CI)       p value          β Coefficient   (95%CI)      p value 
36y – 43y 
 
-0.014 (-0.116, 0.088) 0.793 0.015 (-0.090, 0.119) 0.784 
43y – 53y 
 
0.054 (-0.042, 0.150) 0.273 0.066 (-0.035, 0.167) 0.198 
53y – 60/64y 
 
-0.057 (-0.153, 0.039) 0.248 -0.084 (-0.181, 0.014) 0.093 
  
     SBP – Systolic blood pressure; BMI – body mass index; T2DM – type 2 diabetes mellitus; HTTT – hypertension treatment 
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Discussion 
BP from early midlife predicted worse diastolic function at age 60-64y. This effect was 
independent of current BP; extended across the whole range of BP; and was not limited to 
people with hypertension, or those who went on to develop hypertension at the time when 
diastolic function was assessed. Further, we found that rapid rises in SBP between 43-53y and 
53-60/64y were particularly influential in determining subsequent diastolic function. Since 
the rise in BP in the UK population typically begins to accelerate around the fourth decade of 
life until it slows again in later life,18 we suggest that the period 40-60y may represent a 
sensitive period when rise in BP adversely influences future development of diastolic 
dysfunction. Finally, we found that HTT from early mid-life was associated with impaired 
diastolic function even when the effect of current BP was accounted for.  
SBP and HTT were not consistently associated with EF. However, increased SBP at age 36y 
and HTT at 53y were associated with decreased s’ (i.e. poorer systolic function). Rate of 
change in SBP was not consistently related to systolic function.  
I will initially discuss the diastolic function findings and then the systolic function findings.  
There has been limited work in the past on relating antecedent BP with future diastolic 
function. Arnlov et al reported that higher SBP and DBP at the age of 50y were associated 
with decreased E/A measured 20y later in the Swedish Uppsala cohort.19 Hypertension is 
thought to cause diastolic dysfunction via impaired LV relaxation and reduced LV 
compliance.20 Ultimately the elevated filling pressures associated with severe diastolic 
dysfunction can lead to HFPEF21, 22 or pulmonary oedema.23 Interestingly, Lee et al reported 
that higher BP and BMI in midlife were predictive of incident heart failure in later life in the 
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Framingham study.9 Our data suggest that that this relationship may be mediated at least in 
part via increased diastolic dysfunction.  
Effective management of diastolic dysfunction remains unclear as there have been few trials 
that have focused on this (as opposed to heart failure with decreased ejection 
fraction/systolic dysfunction) and the trials which have been done have demonstrated 
minimal benefit with conventional heart failure medication.24, 25 This has led to the treatment 
of comorbidities/determinants of diastolic dysfunction (e.g. HTT) becoming a cornerstone of 
management of these patients.26 Controlling BP is a class 1 recommendation from the  
American College of Cardiology and American Heart Association for the prevention of diastolic 
heart failure,27 and large trials like ALLHAT and HYVET demonstrated the benefits of treating 
hypertension  in terms of decreased incidence of new heart failure and heart failure 
admissions.28, 29 In our cohort we found that from the age of 43y onwards, exposure to HTT 
was associated with worse diastolic function at age 60-64y (even if the BP had normalized 
with HTT). A possible explanation of this finding is that initiation of treatment was delayed 
too long to prevent irreversible damage at an earlier stage of life. If this is true, individuals at 
risk, for example, those with faster rises in BP, even within the so-called normal range, may 
need to be treated earlier.  Another possible explanation is that although the BP was 
controlled when measured at the clinic visit, it remained poorly controlled at other times 
leading to worse diastolic function in these individuals on HTT.  
Elevated BP is associated with LVH and this could contribute to impaired diastolic function. 
However, adjustment for LVMI had only modest effects on associations between antecedent 
BP and diastolic function and it seems that this relationship is largely independent of 
increased LVMI. Some cross-sectional studies have found PP to be the best predictor of 
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diastolic function,30, 31 but we found relatively similar associations between antecedent SBP, 
DBP, PP and MAP and diastolic function. 
E/e’ had a more consistent relationship with BP and from an earlier age than some of the 
other measures of diastolic function. The reason for this may be that E/e’ may be less load 
dependent and is likely to be more accurate across a range of severity of diastolic 
impairment.32 E/A suffers from pseudonormalization as discussed below and in the methods 
chapter (chapter 3),  and as such, the associations with previous BP may not be as strong. The 
other advantages of focussing on E/e’ have been discussed in the methods chapter (chapter 
3). 
Few studies have related earlier BP or BP over time with later systolic function and the studies 
that have investigated this have demonstrated differing associations. Johnson et al showed 
that sustained higher SBP over a 5 year period among young adults (21-24y old at follow up), 
was associated with increased fractional shortening,33 while Bjorklund et al showed that, over 
a 20y period (initial contact at age 50y), study members with sustained hypertension had the 
same follow-up EF as those with normal BP.34 In our analyses, SBP was not associated with EF 
except at age 53y. However for SBP at age 53y, initial models were non-significant and it was 
only on adding SBP at 60-64y and on further adjustment that the effect size increased and 
significance was achieved.  This may represent an artefact or it may imply that SBP at age 53y 
is associated with better systolic function (possibly an early compensatory response) when 
the effects of SBP, T2DM and BMI at age 60-64y are accounted for. If this is the case it would 
be difficult to explain why the effect is not seen before adjustment.  
While the association of SBP at age 53y with EF was positive, that of SBP at 36y with s’ was 
negative i.e. poorer systolic function. There was a marginal decrease in effect size through 
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sequential adjustments and it is interesting that only SBP at age 36y demonstrated this 
association. It is possible that increase in early BP causes a subtle decline in long axis function 
and it is important to note that s’ does not measure the same aspect of systolic function that 
EF does. Long axis systolic function is closely linked to long axis diastolic function35-40 and if 
systolic and diastolic function are 2 ends of the same continuum,2, 3 a decrease in s’ may 
reflect impending systolic dysfunction (as measured by an impending decrease in EF) in 
individuals with coexisting diastolic dysfunction. It is less clear why this association is not seen 
with the later SBP measures.   
HTT at age 53y was associated with poorer systolic function in terms of decreased s’. It is 
possible that age 53y (and the period 43-53y; discussed below) may represent a sensitive 
period for systolic function. As mentioned previously, s’ and EF are not analogous measures 
of systolic function, and as such, the differing effects of SBP and HTT at different times on EF 
and s’ may represent differing responses of radial and longitudinal contractility to SBP.  
Rate of change in SBP over the 43y-53y period was associated with an increase in EF in the 
fully adjusted model while the effect was just non-significant in the minimally adjusted model. 
It is possible that the effects of BMI, T2DM and HTT at age 60-64y need to be excluded before 
the effect of rate of change in SBP on EF is revealed. As seen with SBP at age 53y, the increase 
in EF may reflect and initial compensatory change due to increased afterload.  
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Strengths and limitations 
General strengths and limitations relevant to this chapter have been previously discussed in 
the blood pressure-cardiac structure chapter (chapter 4).   
We utilized tissue Doppler as our primary measure of diastolic function; this has the 
advantage that it can distinguish normal diastolic function from pseudonormalization.41 
Pseudonormalization will tend to attenuate relationships between antecedent BP and 
diastolic function assessed by E/A, and probably accounts for the generally weaker 
relationships seen using this measure of diastolic function.  
Ideally we would have liked to interrogate further measures of systolic function (e.g. 
fractional shortening and wall stress relationships); however this was not possible due to the 
constraints of time. 
Echocardiography was only carried out in the last round of data collection; hence the 
possibility of cardiac dysfunction preceding the rise in BP cannot be excluded.  
 
Conclusions 
BP from the age of 36y is associated with diastolic function in people aged 60-64y 
independently of current BP (E/e’); faster increases in BP in midlife are particularly 
detrimental. People on HTT have more adverse diastolic function even when current BP is 
taken into account suggesting that early risk factor modification may be important to prevent 
the adverse effects of BP on diastolic function. The associations between BP and systolic 
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function were less consistent although increased SBP at age 36y was associated with 
decreased s’ at age 60-64y while HTT at age 53y was associated with decreased s’. 
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Chapter 6 
 
 
The relationship between adult life course body 
mass index and overweight and left ventricular 
mass 
 
 
Introduction 
The World Health Organization predicts that 2.3 billion adults will be overweight by the 
middle of this decade and that more than 700 million adults will be obese.1 The trend to 
overweight is starting at younger ages now with 10% of school-age children estimated to be 
overweight with this figure rising to more than 30% for the Americas.2 
Previously published work on the Medical Research Council National Survey of Health and 
Development (MRC NSHD) cohort has shown that median body weight and body mass index 
(BMI) rise over the life course (Figure 6.1) and the earlier an individual becomes overweight, 
the greater is their BMI in the future (Figure 6.2).3 
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Figure 6.1. Median BMI and interquartile range (continuous line) and % of individuals 
overweight (BMI >25 Kg/m2) (broken line) in men and women at each age in adulthood.3 
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Figure 6.2. Observed mean BMI trajectories in men and women by age at which 
participant first became overweight. Shaded areas are 95% confidence intervals.3 
 
 
A variety of changes to left ventricular (LV) structure occur with increased BMI and obesity.4 
Many cross-sectional studies in adults in their twenties to fifties have shown that obesity is 
independently associated with LV hypertrophy (LVH),5-8 while others have shown increases in 
LV mass (LVM) correspond to increased BMI only if there are no associated comorbidities (e.g. 
hypertension, diabetes, coronary artery disease).9-11 Earlier studies in the literature from the 
1980s and 1990s, focussed on the relationship between cavity size and increased BMI and 
suggested LV dilation was associated with obesity.12-14 However these studies were carried 
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out in small numbers of heart failure patients in whom the underlying aetiology of the heart 
failure itself may have played a greater role in determining LV cavity dimensions.10, 11 More 
recent studies from the last decade, looking at larger cohorts of people of varying ages free 
from comorbidities, have demonstrated that overweight and obese individuals have a greater 
prevalence of LVH, increased LV cavity size and LV wall thickness compared to age-matched 
normal-weight controls.10, 11, 15-17 
The effect of duration of overweight and obesity on cardiac structure has not been extensively 
explored in the literature. Alpert et al showed that increased duration of morbid obesity was 
associated with increased LVM indexed to height and with LV cavity size (duration of morbid 
obesity ranging from 5y to 28y)13 but others have been unable to demonstrate an association 
between duration of obesity and cardiac structure.17  
There is also evidence that obesity affects cardiac function. Obesity has been associated with 
diastolic dysfunction18 and heart failure with preserved ejection fraction (HFpEF).19 Increased 
LVM as a result of increased weight, leading to diastolic dysfunction, may be a putative 
mechanism of HFpEF in these patients.20, 21 However, some studies have shown that the 
diastolic dysfunction associated with obesity is independent of LV geometry.5 Data relating 
BMI and systolic function have shown inconsistent relationships.17, 22 They are discussed more 
fully in the BMI-cardiac function chapter (chapter 7). 
The aim of this chapter is to investigate the effect of adult BMI and prolonged overweight on 
cardiac structure as measured by echocardiography at age 60-64y based on longitudinal data 
derived from the MRC NHSD birth cohort. 
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Methods 
The majority of relevant methods have been described previously in the methods chapter 
(chapter 3).   
 
Statistical Analysis 
Initially, separate regression models investigated the association between BMI at each of the 
6 ages at which it was measured and LVM indexed to body surface area (BSA): LVMI-BSA with 
adjustment for sex, age at clinic visit and clinic attended. We tested whether these 
associations were linear and whether they were different for men and women. There was no 
gender interaction so in subsequent analyses both genders were pooled and adjusted for sex. 
Subsequent adjustments were made for systolic blood pressure (SBP) and type 2 diabetes 
mellitus (T2DM) at age 60-64y and then for BMI at age 60-64y. Similar analyses were also 
carried out replacing LVMI-BSA with LVM indexed to height raised to the power 2.7 – LVMI-
ht2.7 and with relative wall thickness (RWT). 
In a similar series of models to those described above, BMI was replaced by overweight at 
each age. We then estimated the effect of age at first overweight [variable construction 
described in the methods chapter (chapter 3)] on cardiac structure. We tested for linearity 
across categories and then for deviation from linearity. Estimates from the categorical 
variable model and estimated marginal means are presented. 
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Results 
General characteristics of the study population as relevant to this chapter are shown in Table 
6.1. The correlation between mean BMI (combined for men and women) at the different ages 
is depicted in Table 6.2. A high degree of tracking is demonstrated with high correlations 
between BMI measured at adjacent ages with decreasing correlation with greater ages 
differences. Weaker correlations are seen with ages 20y and 26y.   The increase in mean BMI 
with age is depicted in Figure 6.3. 
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Table 6.1. Echocardiographic and cardiac risk factor characteristics of study participants. Unless otherwise stated data refer to age 60-64y. 
 
Variable (At age 60-64y unless 
stated otherwise) 
Combined Men Women 
n(%) Mean (SD) n(%) Mean (SD) n(%) Mean (SD) 
      
Age at echo (y) 1472 63.3 (1.1) 696 63.2 (1.1) 776  63.3 (1.1) 
IVSD (cm) 1480 1.1 (0.2) 701  1.1 (0.2) 779  1.0 (0.2) 
LVPWTD (cm) 1480 1.0 (0.2) 701  1.0 (0.2) 779  0.9 (0.2) 
RWT 1480 0.4 (0.1) 701  0.4 (0.1) 779  0.4 (0.1) 
LVM  (g) 1480 181.3 (59.3) 701  209.2 (60.3) 779  156.1 (45.6) 
LVMI-BSA  (g/m2) 1480 95.7 (26.6) 701  104.1 (27.9) 779 88.1 (22.9) 
LVMI-ht2.7 (g/m2.7) 1480 44.2 (13.2) 701 46.1 (13.7) 779 42.4 (12.6) 
BMI (Kg/m2) 1480 27.5 (4.6) 701 27.7 (4.0) 779 27.4 (5.1) 
Overweight  (%) 1009 (68)  514 (73)  495 (64)  
Not overweight 465  185  280  
BMI at age 53y (Kg/m2) 1411 26.8 (4.4) 660 27.0 (3.7) 751 26.8 (4.9) 
Overweight at age 53y 891 (63)  456 (69)  435 (58)  
Not overweight at age 53y 517  202  315  
BMI at age 43y (Kg/m2) 1400 24.9 (3.7) 664 25.2 (3.1) 736 24.6 (4.1) 
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Overweight at age 43y 592 (42)  337 (51)  255 (35)  
Not overweight at age 43y 794  323  471  
BMI at age 36y (Kg/m2) 1341 23.6 (3.3) 631 24.3 (2.9) 710 23.0 (3.4) 
Overweight at age 36y 384 (29)  238 (38)  146 (21)  
Not overweight at age 36y 924  384  540  
BMI at age 26y (Kg/m2) 1307 22.5 (2.8) 616 23.0 (2.7) 691 22.0 (2.9) 
Overweight at age 26y 199 (15)  122 (20)  77 (11)  
Not overweight at age 26y 1057  480  577  
BMI at age 20y (Kg/m2) 1225 22.0 (2.6) 570 22.4 (2.3) 655 21.6 (2.8) 
Overweight at age 20y 134 (11)  75 (13)  59 (9)  
Not overweight at age 20y 1021  484  537  
SBP (mm Hg) 1478 135.7 (17.9) 701 139.0 (17.7) 777 132.8 (17.7) 
DBP (mm Hg) 1478 77.4 (9.7) 701 79.0 (9.8) 777 75.9 (9.3) 
T2DM 1357  635  722  
     Diabetic              73 (6)            37 (6)          36 (5)  
IVSD - Interventricular septal thickness in diastole; LVPWTD - Left ventricular posterior wall thickness in diastole; RWT - Relative wall thickness; LVM - Left ventricular mass; 
LVMI-BSA - Left ventricular mass indexed to body surface area; LVMI-ht2.7 - Left ventricular mass indexed to height raised to the power 2.7; BMI - Body mass index; SBP -
Systolic blood pressure; DBP - Diastolic blood pressure; T2DM - Type 2 diabetes mellitus
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Table 6.2. Correlation between mean body mass indexes (combined for both sexes) at 
different ages. 
 
 BMI at 
60-64y 
BMI at 53y BMI at 43y BMI at 36y  BMI at 26y  BMI at 20y 
BMI at 60-64y 1.0000      
BMI at 53y 0.8607 1.0000     
BMI at 43y 0.7819 0.8530 1.0000    
BMI at 36y 0.7033 0.7680 0.8481 1.0000   
BMI at 26y 0.5475 0.6194 0.6924 0.7453 1.0000  
BMI at 20y 0.4461 0.5015 0.5727 0.6387 0.7781 1.0000 
                                                  
 BMI – body mass index 
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Figure 6.3. Combined mean Body mass index (BMI) for men and women (+/- 1 standard 
deviation) at different ages (20-60/64y) demonstrating a steady increase in mean BMI 
with increasing age.  
 
 
 
The effect of BMI at different ages on LVMI-BSA, LVMI-ht2.7 and RWT is presented in Tables 
6.3a-c.  
Increased BMI from the age of 20y onwards was associated with greater LVMI-BSA in a 
minimally adjusted model, and on inclusion of SBP and T2DM at age 60-64y, the estimates 
were generally only slightly attenuated (Table 6.3a). When BMI at age 60-64y was included in 
models, the effect of BMI at prior ages was reduced, although less so for ages 26y and 43y 
with the associations becoming non-significant for ages 20y and 36y.  
 
Increased BMI from the age of 20y onwards was associated with greater LVMI-ht2.7 in a 
minimally adjusted model and these relationships were only minimally attenuated following 
inclusion of the potential mediators, SBP and T2DM (at age 60-64y) (Table 6.3b). When BMI 
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at age 60-64y was included, effects of earlier BMI were reduced, but as for LVMI-BSA, BMI at 
26y and 43y remained associated with LVMI- ht2.7. 
 
Higher BMI from age 43y onwards was associated with greater RWT (Table 6.3c); this 
remained the case when SBP and T2DM at age 60-64y were included in the model. A similar, 
although weaker, association was observed with BMI at age 26y which was attenuated after 
adjustment for SBP and T2DM. On including BMI at age 60-64y, the associations changed from 
positive to negative and also became non-significant except at age 36y.  
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Table 6.3a. Regression coefficients, 95% confidence intervals and p values estimating the effect of BMI at different ages on LVM indexed to 
body surface area at age 60-64y. Models adjusted for age, sex and clinic attended and then for systolic blood pressure and type 2 diabetes 
mellitus at age 60-64y and then for body mass index at age 60-64y. 
 
 
SBP - Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + BMI at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1133) 1.27 (0.71, 1.82) <0.001 1.14 (0.58, 1.69) <0.001 0.45 (-0.16, 1.07) 0.148 
26 (n=1203) 1.77 (1.28, 2.27) <0.001 1.58 (1.08, 2.08) <0.001 0.92 (0.32, 1.52) 0.003 
36 (n = 1236) 1.54 (1.11, 1.96) <0.001 1.33 (0.90, 1.77) <0.001 0.59 (-0.02, 1.20) 0.060 
43 (n = 1289) 1.46 (1.10, 1.82) <0.001 1.40 (0.93, 1.87) <0.001 1.28 (0.90, 1.65) <0.001 
53 (n = 1282) 0.80 (0.20, 1.40) 0.009 1.04 (0.74, 1.35) <0.001 0.64 (0.01, 1.28) 0.046 
60-64 (n = 1353) 1.17 (0.89, 1.45) <0.001 0.99 (0.70, 1.28) <0.001 - - 
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Table 6.3b. Regression coefficients, 95% confidence intervals and p values estimating the effect of BMI at different ages on LVM indexed to 
ht2.7 at age 60-64y. Models adjusted for age, sex and clinic attended and then for systolic blood pressure and type 2 diabetes mellitus at age 
60-64y and then for body mass index at age 60-64y. 
 
SBP - Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 +  SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + BMI at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1133) 1.17 (0.89, 1.45) <0.001 1.08 (0.800, 1.36) <0.001 0.21 (-0.08, 0.51) 0.152 
26 (n=1203) 1.50 (1.25, 1.74) <0.001 1.37 (1.12, 1.62) <0.001 0.45 (0.16, 0.73) 0.002 
36 (n = 1236) 1.42 (1.21, 1.63) <0.001 1.30 (1.08, 1.51) <0.001 0.24 (-0.05, 0.54) 0.100 
43 (n = 1289) 1.37 (1.19, 1.54) <0.001 1.27 (1.09, 1.45) <0.001 0.38 (0.09, 0.66) 0.010 
53 (n = 1304) 1.20 (1.06, 1.35) <0.001 1.12 (0.97, 1.26) <0.001 0.29 (-0.01, 0.59) 0.058 
60-64 (n = 1353) 1.23 (1.10, 1.37) <0.001 1.14 (1.00, 1.28) <0.001 - - 
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Table 6.3c. Regression coefficients, 95% confidence intervals and p values estimating the effect of BMI at different ages on relative wall 
thickness at age 60-64y. Models adjusted for age, sex and clinic attended and then for systolic blood pressure and type 2 diabetes mellitus 
at age 60-64y and then for body mass index at age 60-64y 
 
 
 
 
 
 
 
 
 
 
 
SBP - Systolic blood pressure; T2DM - Type 2 diabetes mellitus; BMI - Body mass index
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 +  SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + BMI at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1131) 0.00082  
(-0.00110, 0.00274) 
0.403 0.00071 
(-0.00123, 0.00265) 
0.473 -0.00121 
 (-0.00337, 0.00096) 
0.275 
26 (n=1201) 0.00174 
(-0.00002, 0.00348) 
0.050 0.00140 
 (-0.00037, 0.00317) 
0.121 -0.00065 
 (-0.00278, 0.00149) 
0.552 
36 (n = 1234) 0.00087 
(-0.00061, 0.00236) 
0.248 0.00052  
(-0.00100, 0.00205) 
0.502 -0.00285 
(-0.00500, -0.00071) 
0.009 
43 (n = 1287) 0.00183 
(0.00057, 0.00310) 
0.005 0.00152  
(0.00021, 0.00284) 
0.023 -0.00131  
(-0.00343, 0.00081) 
0.227 
53 (n = 1302) 0.00216  
(0.00110, 0.00322) 
<0.001 0.00190  
(0.00080, 0.00300) 
0.001 -0.00003  
(-0.00231, 0.00225) 
0.980 
60-64 (n = 1351) 0.00244 
(0.00144, 0.00343) 
<0.001 0.00209 
(0.00106, 0.00312) 
<0.001 - - 
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The effect of being overweight (BMI >=25 kg/m2) at different ages on future LVMI-BSA, LVMI-
ht2.7 and RWT is presented in Tables 6.4a-c. 
Overweight from the age of 20y onwards was predictive of increased LVMI-BSA in a minimally 
adjusted model with the effect size weakest at 20y and strongest at 60-64y (Table 6.4a). When 
SBP and T2DM at age 60-64y were included, the effect of overweight was slightly reduced 
with overweight at age 20y becoming non-significant. When overweight at 60-64y was 
included in the model, coefficients were generally halved but remained positive and 
overweight at age 26y and 43y were independently associated with increased LVMI-BSA. 
The overall pattern of association between overweight and LVMI- ht2.7 was qualitatively 
similar to that between overweight and LVMI-BSA (Table 6.4b). Overweight from the age of 
20y onwards was associated with greater LVMI-ht2.7 in all the models and at all ages. There 
was a slight reduction in effect size with successive adjustment for SBP and T2DM at 60-64y 
and then for overweight at 60-64y.  
Increased RWT was seen with overweight from age 43y onwards and was strongest at age 60-
64y in a minimally adjusted model and on inclusion of SBP and T2DM at age 60-64y (Table 
6.4c). When overweight at 60-64y was included in the model, the associations were almost 
completely explained.  
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Table 6.4a. Regression coefficients (g/m2), 95% confidence intervals and p values estimating the effect of being overweight at different ages 
on LVM indexed to body surface area at age 60-64y. Models adjusted for age, sex and clinic attended and then for systolic blood pressure 
and type 2 diabetes mellitus at age 60-64y and then for being overweight at age 60-64y. 
 
SBP - Systolic blood pressure; T2DM - Type 2 diabetes mellitus 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 +SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + overweight at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1070) 5.12 (0.54, 9.70) 0.028 4.12 (-0.43, 8.67) 0.076 1.94 (-2.63, 6.51) 0.404 
26 (n=1156) 9.93 (5.98, 13.88) 0.001 8.40 (4.43, 12.37) <0.001 5.55 (1.52, 9.58) 0.007 
36 (n = 1204) 6.67 (3.47, 9.87) <0.001 5.38 (2.16, 8.60) 0.001 2.33 (-1.05, 5.70) 0.176 
43 (n = 1276) 8.14 (5.34, 10.94) <0.001 6.79 (3.95, 9.62) <0.001 3.71 (0.58, 6.85) 0.020 
53 (n = 1302) 8.94 (6.17, 11.70) <0.001 7.54 (4.76, 10.32) <0.001 3.22 (-0.31, 6.75) 0.074 
60-64 (n = 1349) 10.99 (8.15, 13.83) <0.001 9.42 (6.52, 12.31) <0.001 - - 
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Table 6.4b. Regression coefficients (g/m2.7), 95% confidence intervals and p values estimating the effect of being overweight at different 
ages on LVM indexed to ht2.7 at age 60-64y. Models adjusted for age, sex and clinic attended and then for systolic blood pressure and type 2 
diabetes mellitus at age 60-64y and then for being overweight at age 60-64y. 
 
 
 
 
 
 
 
 
 
 
SBP - Systolic blood pressure; T2DM - Type 2 diabetes mellitus 
 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 +SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + overweight at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1070) 6.10 (3.74, 8.46) <0.001 5.42 (3.11, 7.74) <0.001 3.31 (1.06, 5.57) 0.004 
26 (n=1156) 8.74 (6.74, 10.75) <0.001 7.76 (5.77, 9.76) <0.001 5.23 (3.26, 7.19) <0.001 
36 (n = 1204) 7.01 (5.39, 8.63) <0.001 6.23 (4.61, 7.85) <0.001 3.54 (1.89, 5.19) <0.001 
43 (n = 1276) 7.83 (6.43, 9.23) <0.001 6.995 (5.585, 8.405) <0.001 4.16 (2.63, 5.70) <0.001 
53 (n = 1302) 8.25 (6.86, 9.63) <0.001 7.41 (6.03, 8.80) <0.001 3.45 (1.71, 5.18) <0.001 
60-64 (n = 1349) 9.83 (8.43, 11.24) <0.001 8.92 (7.50, 10.34) <0.001 - - 
224 | P a g e  
 
Table 6.4c. Regression coefficients, 95% confidence intervals and p values estimating the effect of being overweight at different ages on 
relative wall thickness at age 60-64y. Models adjusted for age, sex and clinic attended and then for systolic blood pressure and type 2 
diabetes mellitus at age 60-64y and then for being overweight at age 60-64y. 
 
SBP - Systolic blood pressure; T2DM - Type 2 diabetes mellitus 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 +SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + overweight at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1068) 0.0068 (-0.0092, 0.0227) 0.405 0.0057(-0.0102, 0.0217) 0.481 0.0008 (-0.0153, 0.0169) 0.923 
26 (n=1154) 0.0059 (-0.0079, 0.1973) 0.402 0.0036 (-0.0104, 0.0175) 0.681 -0.0020 (-0.0163, 0.0123) 0.784 
36 (n = 1202) 0.0067 (-0.0044, 0.0177) 0.237 0.0047 (-0.0065, 0.0158) 0.415 -0.00054 (-0.0124, 0.0113) 0.929 
43 (n = 1274) 0.0129 (0.0031, 0.0227) 0.010 0.0105 (0.00052, 0.02042) 0.039 0.0042 (-0.0069, 0.0152) 0.458 
53 (n = 1300) 0.0135 (0.0037, 0.0233) 0.007 0.0104 (0.00044, 0.02034) 0.041 0.00059 (-0.0121, 0.0132) 0.927 
60-64 (n = 1347) 0.0230 (0.0130, 0.0330) <0.001 0.0190 (0.0088, 0.0292) <0.001 - - 
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The effect of age at first overweight on future LVMI-BSA, LVMI-ht2.7 and RWT is presented in 
Tables 6.5a-c and Figures 6.4a-c.  
There was an overall significant linear trend of increase in LVMI-BSA with earlier age at first 
overweight with the greatest effect in those overweight at 26y (Table 6.5a, Figure 6.4a). The 
trend seemed to start at age 26y with some levelling off at ages 20y and 36y. The test for 
deviation from a linear trend was borderline significant (p= 0.0492). The trend was 
maintained when SBP and T2DM at age 60-64y were included in the model. When BMI at age 
60-64y was included in the model, the coefficients were reduced by varying extents at the 
different ages at first overweight, with the effect at some of the ages becoming non-
significant and with the overall linear trend also becoming non-significant.  
The relationship between age at first overweight and LVMI-ht2.7 (Table 6.5b, Figure 6.4b) was 
qualitatively similar to that between age at first overweight and LVMI-BSA where the trend 
of increasing LVMI- ht2.7 with earlier age at first overweight levelled off at the younger ages. 
The test for deviation from linear trend was significant (p = 0.0013). When BMI at age 60-64y 
was included in the final model, nearly all the coefficients for different ages at first overweight 
became non-significant while the overall test for linear trend was also non-significant.  
In a minimally adjusted model, there was an overall weaker linear trend of increase in RWT 
with earlier age at first overweight (Table 6.5c, Figure 6.4c). The coefficient at age 26y was 
non-significant and the coefficients for age 36y and later were similar in magnitude. The test 
for deviation from linear trend was non-significant (p = 0.1327). In contrast to LVMI, the 
trend for linearity became non-significant on the addition of SBP and T2DM at age 60-64y to 
the model, as the effects were slightly attenuated. When BMI at age 60-64y was included in 
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the model, the effects were attenuated with reversal of association at earlier ages (the 
coefficients became negative for ages 20y to 36y although they were non-significant). 
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Table 6.5a. Regression coefficients (g/m2), 95% confidence intervals and p values estimating the effect of age at first overweight on LVM 
indexed to body surface area at 60-64 years in men and women. 
 
 
 
 
 
 
 
 
 
SBP - Systolic blood pressure; T2DM - Type 2 Diabetes mellitus; BMI - Body mass index 
 
Age at first 
diagnosis of 
overweight 
(years) 
Model 1 
(age sex, clinic) 
Model 2 
(Model 1 + SBP at 60-64y + T2DM) 
Model 3 
(Model 2 + BMI at 60-64y) 
 
 
β (95%CI) p value 
for 
overall 
linear 
trend 
β (95%CI) p value 
for 
overall 
linear 
trend 
β (95%CI) p value 
for 
overall 
linear  
trend 
20 15.18 (8.04, 22.32)  
 
 
<0.001 
12.42 (5.18, 19.66)  
 
 
<0.001 
5.76 (-4.85, 16.37)  
 
 
0.222 
26 20.64 (12.54, 28.75) 16.76 (8.46, 25.06) 10.78 (-0.06, 21.61) 
36 13.05 (6.87, 19.22) 11.03 (4.76, 17.30) 6.33 (-1.99, 14.65) 
43 14.43 (8.42, 20.44) 12.18 (6.06, 18.30) 8.73 (1.41, 16.05) 
53 10.16 (4.78, 15.55) 8.71 (3.25, 14.17) 6.10 (-0.14, 12.34) 
60-64 6.57 (-0.51, 13.66) 5.59 (-1.49, 12.68) 3.65 (-3.78, 11.08) 
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Figure 6.4a. Estimated marginal means in men and women of left ventricular mass indexed to body surface area (g/m2) for different ages at 
first overweight and for never overweight for model 1 (above). 
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Table 6.5b. Regression coefficients (g/m2.7), 95% confidence intervals and p values estimating the effect of age at first overweight on LVM 
indexed to ht2.7 at 60-64 years in men and women. 
 
 
 
 
 
 
 
 
 
SBP - Systolic blood pressure; T2DM - Type 2 Diabetes mellitus; BMI - Body mass index 
 
 
 
Age at first 
diagnosis of 
overweight 
(years) 
Model 1 
(age sex, clinic) 
Model 2 
(Model 1 + SBP at 60-64y + T2DM) 
Model 3 
(Model 2 + BMI at 60-64y) 
 
 
β (95%CI) p value 
for 
overall 
linear 
trend 
β (95%CI) p value 
for 
overall 
linear 
trend 
β (95%CI) p value 
for 
overall 
linear 
trend 
20 15.36 (11.85, 18.87)  
 
 
<0.001 
13.81 (10.26, 17.36)  
 
 
<0.001 
2.59 (-2.50, 7.67)  
 
 
0.248 
26 17.29 (13.30, 21.28) 15.14 (11.07, 19.21) 5.06 (-0.14, 10.25) 
36 12.03 (8.99, 15.07) 10.96 (7.88, 14.03) 3.04 (-0.95, 7.03) 
43 11.35 (8.40, 14.32) 10.20 (7.20, 13.21) 4.39 (0.89, 7.90) 
53 8.12 (5.47, 10.77) 7.37 (4.70, 10.05) 2.99 (-0.01, 5.98) 
60-64 5.53 (2.05, 9.02) 5.08 (1.60, 8.55) 1.80 (-1.77, 5.36) 
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Figure 6.4b. Estimated marginal means in men and women of left ventricular mass indexed to ht2.7 (g/m2.7) for different ages at first 
overweight and for never overweight for model 1 (above). 
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Table 6.5c. Regression coefficients, 95% confidence intervals and p values estimating the effect age at first overweight on relative wall 
thickness at 60-64 years in men and women. 
 
 
 
 
 
 
 
 
 
SBP - Systolic blood pressure; T2DM - Type 2 Diabetes mellitus; BMI - Body mass index 
 
 
Age at first 
diagnosis of 
overweight 
(years) 
Model 1 
(age sex, clinic) 
Model 2 
(Model 1 + SBP at 60-64y + T2DM) 
Model 3 
(Model 2 + BMI at 60-64y) 
 
 
β (95%CI) p value 
for 
overall 
linear 
trend 
β (95%CI) p value 
for 
overall 
linear 
trend 
β (95%CI) p value 
for 
overall 
linear 
trend 
20 0.031 (0.0061, 0.0560)  
 
 
0.037 
0.024 (-0.0008, 0.0498)  
 
 
0.187 
-0.0106 (-0.0476, 0.0264)  
 
 
0.136 
26 0.012 (-0.017, 0.040) 0.0021 (-0.069, 0.0311) -0.0295 (-0.0673, 0.0083) 
36 0.025 (0.0038, 0.0471) 0.020 (-0.0025, 0.04150 -0.0052 (-0.0342, 0.0238) 
43 0.028 (0.0070, 0.0491) 0.020 (-0.0011, 0.0417) 0.0022 (-0.0234, 0.0258) 
53 0.025 (0.0058, 0.0435) 0.018 (-0.0014, 0.0369) 0.0039 (-0.0179, 0.0258) 
60-64 0.027 (0.0022, 0.0518) 0.023 (-0.0022, 0.0473) 0.0122 (-0.0137, 0.0381) 
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Figure 6.4c. Estimated marginal means in men and women of relative wall thickness for different ages at first overweight and for never 
overweight for model 1 (above). 
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Discussion 
We found that increased BMI from the age of 20y onwards was associated with increased 
LVMI-BSA/LVMI-ht2.7 in minimally adjusted models and after adjustment for SBP and T2DM. 
There was some evidence that the effect of prior BMI on LVMI remained even after 
adjustment for BMI at age 60-64y, with the effects at ages 26y and 43y being significantly 
independently associated with increased LVMI. This pattern of persistent adverse effect of 
prior overweight was replicated when BMI at different ages was replaced with overweight at 
different ages. Earlier age at first overweight was associated with greater LVMI in a minimally 
adjusted model and when SBP and T2DM at age 60-64y were included.  
BMI and overweight appeared to be less strongly associated with RWT. Positive associations 
were present only from age 43y onwards in minimally adjusted models and when SBP and 
T2DM at age 60-64y were included. In a minimally adjusted model, earlier age at first 
overweight was associated with greater RWT. 
Demonstrating an association between earlier adult BMI and overweight and later cardiac 
structure is an important step forward in understanding the effect prolonged exposure to 
overweight and elevated BMI have on the heart. While research has shown that earlier 
overweight can lead to long-lasting detrimental effects on cardiac function, there is far less 
work relating longitudinal measures of BMI to future cardiac structure.4, 12, 13  
Current BMI (BMI at age 60-64y) did not explain the total effect of prior BMI, and in particular 
BMI at ages 26y to 43y remained associated with LVMI-BSA. It is possible that these ages 
represent a sensitive period for weight gain, the effect of which on cardiac structure is not 
entirely due to tracking (earlier increased BMI associated with later increased BMI). When we 
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consider the effect of overweight we see that there may be additional evidence for a sensitive 
period as overweight at ages 26y and 43y is associated with increased LVMI-BSA even when 
current overweight (overweight at 60-64y) is accounted for. If we put this in the context of 
the overall results, the interpretation may rather be that BMI/overweight from age 26y 
onwards has an effect over and above BMI/overweight at age 60-64y. It is also worth noting 
in this context, that this is the same time period that there is accelerated weight gain in our 
cohort (especially for women) (Figure 6.1).  
It is difficult to disentangle the role of tracking of BMI from persistent exposure in these 
analyses. When the age at first overweight analyses are examined, we see that on inclusion 
of BMI at 60-64y, the linear trend for earlier age of first overweight being associated with 
increased LVMI becomes non-significant. The test for deviation from linear trend is significant 
for both LVMI outcomes (LVMI-BSA and LVM-ht2.7) indicating that a non-linear trend may be 
present. This may reflect that high BMI/overweight at younger ages is due to higher muscle 
mass, while increased BMI/overweight at older ages represents fat mass.  
 
The loss of significance when BMI at age 60-64y was included in the models may indicate that 
there is sufficient tracking of BMI for BMI at 60-64y to encompass the effect of previous BMI 
history (Table 6.2).  However, it is important to note that this was not always the case. Due to 
the presence of BMI tracking, it is impossible to clearly differentiate whether length of 
overweight is more important than overweight at 60-64y. 
From a preventive Cardiology viewpoint preventing overweight at an early stage should be 
warranted based on our findings especially since it is easier to stop people becoming 
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overweight or to reduce small amount of weight rather than to lose large amounts of weight 
when obese.23  
 
Our analyses showed similar associations for both LVMI outcomes. In the setting of significant 
obesity, LVMI-BSA can be lower than normal as BSA increases more than LV weight.8, 24, 25 
Allometric indexation is felt by some to be the optimal correction factor as it minimizes gender 
differences in cardiac geometry.26 In this context it is interesting that there were no major 
differences in our results when using LVMI-BSA and LVMI-ht2.7 except for the fully-adjusted 
overweight-LVMI models where the associations with LVMI- ht2.7 were more consistent on 
inclusion of overweight at 60-64y. This may be due to falsely-low LVMI-BSA due to greater 
increases in BSA in these overweight individuals as discussed above. 
Overall however, it is possible that while the majority of our cohort are overweight at 60-64y, 
there may not be enough obesity [n = 286 (19%)] or morbid obesity [n = 98 (7%)] to skew all 
the LVMI-BSA results.  
Compared to the associations with LVMI, associations of BMI and overweight with RWT were 
manifest at only older ages. Given the weaker strength of the associations, overweight at 60-
64y may be more influential than age at first overweight. It is also possible that increased BMI 
affects RWT through a mechanism of “accumulated insult” i.e. only sustained elevated BMI 
over a period of time can affect RWT.  
When BMI at 60-64y is included in the model, there is a reversal of the association, which may 
support BMI at 60-64y being more important than previous BMI history. However the reversal 
of effect is only significant at age 36y and the overall linear trend is non-significant. This may 
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reflect that while tracking of BMI occurs, it is possible that elevated BMI at 36y is 
independently reflective of earlier increased BMI and it is this accumulated increased BMI 
that is associated with changes in RWT. Alternatively it could be artefact or it could imply that 
greater increase in BMI is associated with a greater propensity to eccentric remodelling or LV 
chamber dilation.  
In contrast to LVMI, the linear trend of earlier age at first overweight being associated with 
increased RWT, became non-significant when SBP and T2DM at age 60-64y were included in 
the model. This may imply that LV geometry (LVG) i.e. RWT is affected differently by increased 
BMI than is LVMI. SBP and T2DM may capture the effect of changes in BMI on RWT. An 
alternative explanation may be that increased BMI causes increased SBP or incidence of T2DM 
and these secondary increases lead to increased RWT. A third possibility is that, the 
association may have become non-significant after inclusion of SBP and T2DM, due to a 
weaker initial association with RWT (compared to LVMI) rather than due to substantial 
confounding. We should also remember that only SBP at age 60-64y has been included in the 
model and not SBP history. It is also worth noting that the linear trend for RWT in the 
minimally adjusted model (model 1) is weaker than the corresponding linear trends for both 
LVMI outcomes. This may imply that there is less evidence of a cumulative effect of 
overweight on RWT.  
 
Strengths and limitations 
Generalization to the UK population and the issue of missing data have been discussed in 
previous chapters.  
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The heights and weights recorded at ages 20 and 26y were self-reported. Although collected 
at the respective ages (and thus not subject to recall bias) they were not measured by trained 
staff in a controlled environment unlike at the other years, this may have introduced some 
reporting bias if people have a tendency to under-report their weight or over-estimate their 
height.27 However, the former bias may be less problematic at 20y and 26y as most study 
members had normal BMIs at those ages.    
The imbalance between energy intake and expenditure is an important factor in weight gain 
and the development of obesity as is total energy intake.28-30 While some have shown that 
exercise and physical activity is associated with maintenance of a normal body weight,31, 32 
this area is more controversial with some studies not demonstrating such a relationship.33, 34 
In our cohort diet diaries and a questionnaire relating to physical activity have been collected, 
while objective measurements of physical activity were captured using Actiheart devices 
(CamNtech Ltd, Cambridge, UK). These data could not be incorporated in this work as they 
were unavailable at the time of analysis. 
While body composition data had been collected in the last round of data collection this was 
not available at the time of my analyses and as such could not be incorporated. The addition 
of such data would have better elucidated the role of fat distribution in the body, possibly 
highlighting any gender differences. 
Echocardiography was only carried out in the last round of data collection. As such, with no 
baseline echocardiography, the possibility of increased LVMI or RWT being a pre-existing 
diagnosis cannot be excluded. Reverse causality (prior cardiac structural abnormalities 
leading directly or indirectly to decreased exercise capacity and increased BMI and 
overweight in the future) also cannot be excluded. 
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Conclusions 
Higher BMI and overweight from the age of 20y onwards is associated with increased LVMI 
when aged 60-64y. The earlier the diagnosis of overweight, the greater the increase in 
LVMI/RWT at age 60-64y. Current BMI/overweight captures some of the effects of previous 
BMI/overweight history on future LVM and RWT. These finding indicate that earlier weight 
reduction and achieving optimal BMI levels may prevent a future increase in LVM.  
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Chapter 7 
 
The relationship between adult life course BMI, 
overweight and age at first diagnosis of 
overweight and future cardiac function 
 
 
 
Introduction 
The prevalence of overweight individuals and obesity is rising with 300 million adults 
diagnosed with obesity at the turn of the 21st century.1, 2 Increased body mass index (BMI) is 
associated with increased risk of congestive heart failure.3 A variety of mechanisms have been 
proposed to link adiposity to cardiac dysfunction, including chronically increased workload,4 
direct lipotoxic5 or adverse metabolic effects on cardiomyocyte function,6 indirect effects via 
hypertension, dyslipidaemia, diabetes or chronic inflammation4, 7 or effects on right 
ventricular function, including those due to the consequences of sleep apnoea.4 There is also 
evidence that increased obesity is associated with diastolic dysfunction8 and heart failure with 
preserved ejection fraction (HFPEF).9 Nevertheless, there is still considerable uncertainty 
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regarding the effects of adiposity on cardiac function in the absence of heart failure and there 
is no firm pathological evidence of an obesity-induced cardiomyopathy.12  Some studies have 
shown that estimates of systolic function [ejection fraction (EF), midwall fractional 
shortening] are either unchanged in obese individuals10 or show a hyperdynamic pattern.11 
The adverse effect of obesity on diastolic function, may be mediated through an alteration in 
left ventricular (LV) filling indices secondary to an increase in LV mass (LVM).12, 13 However, 
some studies have also shown that the diastolic dysfunction associated with obesity is 
independent of LV geometry.14 The effect of the duration of obesity on diastolic function is 
even more controversial. Early work from the mid-1980s to mid-1990s seemed to show a 
relationship between increased duration of obesity and diastolic dysfunction, 15-17 but later 
studies from the middle of the last decade onwards do not bear out this association.18, 19 All 
these studies have been limited by small sample sizes and duration of obesity was subject to 
recall bias.  
The aim of this chapter is to investigate the effect of adult BMI and prolonged overweight on 
cardiac function as measured by echocardiography at age 60-64y based on longitudinal data 
derived from the NHSD birth cohort. 
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Methods 
The majority of relevant methods have been described previously in the methods chapter 
(chapter 3).    
 
Statistical Analysis 
Initially, separate regression models investigated the association between BMI at each of the 
6 ages at which it was measured and measures of cardiac function [E/e’, E/A, e’, e’/a’, left 
atrial volume indexed to body surface area (LAVI), ejection fraction (EF) and s’ (measures 
having been defined in the methods chapter – chapter 3)]. Adjustments were initially made 
for sex, age at clinic visit and clinic attended. Subsequent adjustments were made for systolic 
blood pressure (SBP) and presence of type 2 diabetes mellitus (T2DM) at age 60-64y and then 
for left ventricular mass indexed to body surface area (LVMI). The final model also included 
BMI at age 60-64y. We tested whether these associations were linear and whether they were 
different for men and women. There was no gender interaction so in subsequent analyses 
both genders were pooled and adjusted for sex. 
In similar models to those above, BMI was replaced by overweight at each age and then by 
age at first overweight (variable derivation described in detail in methods chapter). Serial 
adjustments as described above were made with the final model in the series looking at the 
effect of overweight at the different ages also including overweight at age 60-64y (instead of 
BMI at age 60-64y). 
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Results 
General characteristics of the study population relevant to his chapter are shown in Table 7.1. 
The pattern of increase in mean BMI over time and tracking have been graphically 
depicted/tabulated in the chapter on BMI-cardiac structure (chapter 6).  
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Table 7.1. Echocardiographic and cardiac risk factor characteristics of study participants. 
Unless otherwise stated data refer to age 60-64y. 
 
Variable 
 (At age 60-64y unless stated 
otherwise) 
Combined Men Women 
 
n(%) 
 
Mean (SD) 
 
n(%) 
 
Mean (SD) 
 
n(%) 
 
Mean (SD) 
Age at echo (y) 1472 63.3 (1.1) 696 63.2 (1.1) 776  63.3 (1.1) 
E/A 1424 1.0 (0.3) 668 1.0 (0.3) 756 1.0 (0.3) 
e’ 1381 8.8 (1.9) 640 8.9 (1.9) 741 8.7 (1.9) 
E/e’ 1354 8.0 (2.1) 681  7.5 (2.1) 727 8.3 (2.1) 
e’/a’ 1358 0.8 (0.2) 624 0.8 (0.2) 734 0.9 (0.2) 
LAVI (ml/m2) 1285 20.9 (7.3) 624 21.7 (7.5) 661 20.0 (7.0) 
Ejection Fraction (%) 1453 68.7 (9.7) 687 67.2 (10.1) 766 69.9 (9.2) 
s’ (cm/sec) 1350 7.7 (1.6) 626 8.1 (1.7) 724 7.5 (1.4) 
BMI (Kg/m2) 1480 27.5 (4.6) 701 27.7 (4.0) 779 27.4 (5.1) 
Overweight  1009 (68)  514 (73)  495 (64)  
Not overweight 465  185  280  
BMI at age 53y (Kg/m2) 1411 26.8 (4.4) 660 27.0 (3.7) 751 26.8 (4.9) 
Overweight at age 53y 891 (63)  456 (69)  435 (58)  
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Not overweight at age 53y 517  202  315  
BMI at age 43y (Kg/m2) 1400 24.9 (3.7) 664 25.2 (3.1) 736 24.6 (4.1) 
Overweight at age 43y 592 (42)  337 (51)  255 (35)  
Not overweight at age 43y 794  323  471  
BMI at age 36y (Kg/m2) 1341 23.6 (3.3) 631 24.3 (2.9) 710 23.0 (3.4) 
Overweight at age 36y 384 (29)  238 (38)  146 (21)  
Not overweight at age 36y 924  384  540  
BMI at age 26y (Kg/m2) 1307 22.5 (2.8) 616 23.0 (2.7) 691 22.0 (2.9) 
Overweight at age 26y 199 (15)  122 (20)  77 (11)  
Not overweight at age 26y 1057  480  577  
BMI at age 20y (Kg/m2) 1225 22.0 (2.6) 570 22.4 (2.3) 655 21.6 (2.8) 
Overweight at age 20y 134 (11)  75 (13)  59 (9)  
Not overweight at age 20y 1021  484  537  
SBP  (mm Hg) 1478 135.7 (17.9) 701 139.0 (17.7) 777 132.8 (17.7) 
DBP (mm Hg) 1478 77.4 (9.7) 701 79.0 (9.8) 777 75.9 (9.3) 
T2DM 1357  635  722  
     Diabetic              73 (6)            37 (6)          36 (5)  
LAVI - Left atrial volume indexed to body surface area; BMI - Body mass index; SBP - Systolic blood pressure; DBP - Diastolic blood pressure; T2DM - Type 2 
diabetes mellitus 
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The effect of BMI at different ages on diastolic function is presented in Tables 7.2a-e. 
In a minimally adjusted model, increased BMI from the age of 26y was associated with 
increased E/e’ i.e. worse diastolic function (Table 7.2a). When SBP and T2DM at age 60-64y 
were included there was marginal attenuation of the effect and the association held from age 
26y onwards.  The association remained from 36y onwards when LVMI was included in the 
model, and in addition, the regression coefficient for age 20y became negative. When BMI at 
60-64y was included in the final model, the coefficients also became negative at ages 26y and 
53y with increasing BMI at age 20y associated with significantly decreased E/e’ i.e. better 
diastolic function. 
 
In a minimally adjusted model, increased BMI from 20y was associated with decreased E/A 
i.e. worse diastolic function (Table 7.2b). This was also the case on adjusting for SBP and T2DM 
at age 60-64y and LVMI. The effect sizes did not change much with these sequential 
adjustments. On adding in BMI at 60-64y, the β coefficients from 26y onwards became 
positive, although all were small and none was significant.  
 
When the association between BMI at different ages and e’ was examined, a negative 
association was seen from age 36y onwards in the minimally adjusted model (i.e. increased 
BMI associated with worse diastolic function) (Table 7.2c). This was also the case on 
adjustment for SBP and T2DM at age 60-64y and LVMI with a marginal attenuation of the 
effect sizes. On including BMI at age 60-64, the associations became positive (i.e. better 
diastolic function) but none was significant.  
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The associations between BMI at different ages and e’/a’ (Table 7.2d) were somewhat 
qualitatively similar to those between BMI and E/e’. In a minimally adjusted model, increased 
BMI from age 26y onwards was associated with decreased e’/a’ i.e. worse diastolic function. 
This was the case from age 36y onwards on addition of SBP and T2DM at age 60-64y and when 
LVMI was included in the model. There was a small decrease in effect sizes on these sequential 
adjustments. When BMI at age 60-64y was included, the coefficients became positive (i.e. 
better diastolic function) and were significant at ages 20y and 26y.  
 
The effect of BMI at different ages on LAVI was also examined (Table 7.2e) with increased BMI 
from the age of 20y onwards associated with greater LAVI in a minimally adjusted model and 
on inclusion of SBP and T2DM at age 60-64y. This was the case from age 26y onwards when 
LVMI was also included in the model with some attenuation of effect. When BMI at age 60-
64y was also included there was a varying degree of attenuation of the effect at the different 
ages and increased BMI at age 36y remained associated with greater LAVI.   
 
The effect of BMI at different ages on systolic function was also examined (Tables 7.2f-g).  
In a minimally adjusted model, increased BMI at age 26y was associated with a decrease in EF 
i.e. worse systolic function (Table 7.2f). This association remained on further adjustments 
with a small increase in the magnitude of the effect with these adjustments.  
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In a minimally adjusted model, increased BMI at age 43y was associated with increased s’ i.e. 
better systolic function (Table 7.2g). This association remained when SBP and T2DM at age 
60-64y were included in the model and on inclusion of LVMI. Although the effect size 
continued to increase slightly with each round of adjustment, the association became non-
significant when BMI at age 60-64y was included. The effect sizes for the associations 
between BMI at age 53y and s’ were similar in the 4 models (minimally adjusted and then 
subsequent adjustments as described above). However, while 3 of the models showed non-
significant associations, increased BMI at age 53y was associated with increased s’ when the 
minimally adjusted model was also adjusted for SBP and T2DM at age 60-64y. 
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Table 7.2a. Regression coefficients, 95% confidence intervals and p values estimating the effect of body mass index at different ages on E/e’ 
at age 60-64y. Models adjusted for age, sex and clinic attended. Subsequent adjustments made for systolic blood pressure and presence of 
type 2 diabetes mellitus at age 60-64y, left ventricular mass indexed to body surface area and body mass index at age 60-64y. 
 
SBP- Systolic blood pressure; T2DM – Type 2 diabetes mellitus, LVMI - Left ventricular mass indexed to body surface area; BMI - Body mass index 
 
 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + BMI at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1146) 0.0087 
 (-0.0370, 0.0544) 
0.708 0.0037 
(-0.0416, 0.0489) 
0.874 -0.0065 
(-0.0540, 0.0409) 
0.787 -0.0726 
(-0.1247, -0.0206) 
0.006 
26 (n=1213) 0.0617 
 (0.0209, 0.1026) 
0.003 0.046 
(0.0057, 0.0871) 
0.025 0.0238 
(-0.0191, 0.0667) 
0.277 -0.0480 
(-0.0985, 0.0026) 
0.063 
36 (n = 1250) 0.0876 
 (0.0530, 0.1222) 
<0.001 0.0718 
(0.0367, 0.1068) 
<0.001 0.0590 
(0.0222, 0.0958) 
0.002 0.00048 
(-0.0507, 0.0517) 
0.985 
43 (n = 1296) 0.0894  
(0.0601, 0.1187) 
<0.001 0.0724 
(0.0425, 0.1022) 
<0.001 0.0674 
(0.0357, 0.0992) 
<0.001 0.0083 
(-0.0423, 0.0591) 
0.748 
53 (n = 1311) 0.0805  
(0.0558, 0.1053) 
<0.001 0.0658 
(0.0406, 0.0910) 
<0.001 0.0570 
(0.0304, 0.0837) 
<0.001 -0.0058 
(-0.0609, 0.0493) 
0.836 
60-64 
 (n = 1367) 
0.0862 
 (0.0633, 0.1091) 
<0.001 0.0694 
(0.0462, 0.0927) 
<0.001 0.0642 
(0.0395, 0.0889) 
<0.001 - - 
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Table 7.2b. Regression coefficients, 95% confidence intervals and p values estimating the effect of body mass index at different ages on E/A 
at age 60-64y. Models adjusted for age, sex and clinic attended. Subsequent adjustments made for systolic blood pressure and presence of 
type 2 diabetes mellitus at age 60-64y, left ventricular mass indexed to body surface area and body mass index at age 60-64y. 
 
SBP- Systolic blood pressure; T2DM – Type 2 diabetes mellitus, LVMI - Left ventricular mass indexed to body surface area; BMI - Body mass index 
 
 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + BMI at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1205) -0.0081 
 (-0.0142, -0.0021) 
0.009 -0.0086 
(-0.0147, -0.0026) 
0.005 -0.0075 
(-0.0140, -0.0010) 
0.023 -0.00024 
(-0.0074, 0.0069) 
0.947 
 
26 (n=1279) -0.0077 
 (-0.0132, -0.0023) 
0.006 -0.0080 
(-0.0135, -0.0024) 
0.005 -0.0066 
(-0.01252, -0.00061) 
0.031 0.0043 
(-0.0027, 0.0113) 
0.229 
36 (n = 1321) -0.0114 
 (-0.0160, -0.0067) 
<0.001 -0.0115 
(-0.0163, -0.0068) 
<0.001 -0.0103 
(-0.0154, -0.0052) 
<0.001 0.00079 
(-0.00626, 0.00785) 
0.826 
43 (n = 1373) -0.0114 
 (-0.0153, -0.0074) 
<0.001 -0.0117 
(-0.0158, -0.0076) 
<0.001 -0.0106 
(-0.0151, -0.0062) 
<0.001 0.0012 
(-0.0058, 0.0082) 
0.743 
53 (n = 1387) -0.0097 
 (-0.0130, -0.0064) 
<0.001 -0.0100 
(-0.0135, -0.0066) 
<0.001 -0.0097 
(-0.0134, -0.0060) 
<0.001 0.0017 
(-0.0059, 0.0093) 
0.661 
60-64  
(n = 1444) 
-0.0115 
(-0.0145, -0.0084) 
<0.001 -0.0113 
(-0.0144, -0.0081) 
<0.001 -0.0110 
(-0.0143, -0.0075) 
<0.001 - - 
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Table 7.2c. Regression coefficients, 95% confidence intervals and p values estimating the effect of body mass index at different ages on e’ at 
age 60-64y. Models adjusted for age, sex and clinic attended. Subsequent adjustments made for systolic blood pressure and presence of 
type 2 diabetes mellitus at age 60-64y, left ventricular mass indexed to body surface area and body mass index at age 60-64y. 
 
SBP- Systolic blood pressure; T2DM – Type 2 diabetes mellitus, LVMI - Left ventricular mass indexed to body surface area; BMI - Body mass index 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + BMI at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1178) -0.0080 
 (-0.0500, 0.0336) 
0.707 -0.0115 
(-0.0531, 0.0300) 
0.587 -0.0014 
(-0.0450, 0.0423) 
0.951 0.0408 
(-0.0076, 0.0891) 
0.098 
26 (n=1249) -0.0298 
 (-0.0668, 0.0072) 
0.114 -0.0267 
(-0.0640, 0.0105) 
0.159 -0.0120 
(-0.0513, 0.0273) 
0.548 0.0432 
(-0.0034, 0.0897) 
0.069 
36 (n = 1283) -0.0516 
 (-0.0832, -0.0200) 
0.001 -0.0484 
(-0.0807, -0.0161) 
0.003 -0.0373 
(-0.0713, -0.0034) 
0.031 0.0082 
(-0.0392, 0.0557) 
0.734 
43 (n = 1331) -0.0521 
 (-0.0789, -0.0253) 
<0.001 -0.0504 
(-0.0780, -0.0228) 
<0.001 -0.0431 
(-0.0725, -0.0137) 
0.004 0.0086 
(-0.0385, 0.0558) 
0.719 
53 (n = 1348) -0.0471 
 (-0.0696, -0.0245) 
<0.001 -0.0452 
(-0.0684, -0.0219) 
<0.001 -0.0350 
(-0.0597, -0.0103) 
0.006 0.0292 
(-0.0215, 0.0800) 
0.259 
60-64  
(n = 1406) 
-0.0592 
 (-0.0802, -0.0382) 
<0.001 -0.0530 
(-0.0746, -0.0315) 
<0.001 -0.0467 
(-0.0697, -0.0237) 
<0.001 - - 
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Table 7.2d. Regression coefficients, 95% confidence intervals and p values estimating the effect of body mass index at different ages on e’/a’ 
at age 60-64y. Models adjusted for age, sex and clinic attended. Subsequent adjustments made for systolic blood pressure and presence of 
type 2 diabetes mellitus at age 60-64y, left ventricular mass indexed to body surface area and body mass index at age 60-64y. 
 
SBP- Systolic blood pressure; T2DM – Type 2 diabetes mellitus, LVMI - Left ventricular mass indexed to body surface area; BMI - Body mass index 
 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + BMI at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20  
(n=1158) 
-0.00089 
 (-0.00594, 0.00416) 
0.730 -0.00102 
(-0.00603, 0.00400) 
0.691 -0.00031 
(-0.00561, 0.00498) 
0.907 0.00790 
(0.00210, 0.01369) 
0.008 
26 
 (n=1227) 
-0.00506  
(-0.00959,-0.00053) 
0.029 -0.00429 
(-0.00884, 0.00027) 
0.065 -0.00286 
(-0.00772, 0.00200) 
0.248 0.00745 
(0.00176, 0.01314) 
0.010 
36 
 (n = 1263) 
-0.00921 
 (-0.01305, -0.00537) 
<0.001 -0.00844 
(-0.01235, -0.00453) 
<0.001 -0.00786 
(-0.01199, -0.00374) 
<0.001 0.00165 
(-0.00407, 0.00737) 
0.572 
43 
 (n = 1310) 
-0.00901 
 (-0.01226, -0.00575) 
<0.001 -0.00851 
(-0.01185, -0.00516) 
<0.001 -0.00824 
(-0.01184, -0.00465) 
<0.001 0.00260 
(-0.00314, 0.00834) 
0.374 
53 
 (n = 1326) 
-0.00902 
 (-0.01175, -0.00629) 
<0.001 -0.00856 
(-0.01136, -0.00575) 
<0.001 -0.00812 
(-0.01111, -0.00513) 
<0.001 0.00101 
(-0.00513, 0.00715) 
0.747 
60-64  
(n = 1383) 
-0.01032 
 (-0.01286, -0.00778) 
<0.001 -0.00942 
(-0.01202, -0.00682) 
<0.001 -0.00928 
(-0.01207, -0.00649) 
<0.001 - - 
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Table 7.2e. Regression coefficients, 95% confidence intervals and p values estimating the effect of body mass index at different ages on left 
atrial volume indexed to body surface area at age 60-64y. Models adjusted for age, sex and clinic attended. Subsequent adjustments made 
for systolic blood pressure and presence of type 2 diabetes mellitus at age 60-64y, left ventricular mass indexed to body surface area and 
body mass index at age 60-64y. 
 
SBP- Systolic blood pressure; T2DM – Type 2 diabetes mellitus, LVMI - Left ventricular mass indexed to body surface area; BMI - Body mass index 
 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + BMI at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1075) 0.276 (0.117, 0.435) 0.001 0.270 (0.109, 0.430) 0.001 0.148 (-0.016, 0.313) 0.077 0.018 (-0.165, 0.200) 0.847 
26 (n=1142) 0.449 (0.306, 0.591) <0.001 0.445 (0.300, 0.590) <0.001 0.282 (0.132, 0.431) <0.001 0.161 (-0.017, 0.338) 0.076 
36 (n = 1176) 0.495 (0.372, 0.618) <0.001 0.488 (0.361, 0.614) <0.001 0.340 (0.211, 0.470) <0.001 0.310 (0.132, 0.488) 0.001 
43 (n = 1219) 0.363 (0.259, 0.467) <0.001 0.358 (0.250, 0.466) <0.001 0.227 (0.116, 0.338) <0.001 0.161 (-0.010, 0.333) 0.066 
53 (n = 1236) 0.289 (0.199, 0.379) <0.001 0.285 (0.192, 0.379) <0.001 0.166 (0.070, 0.262) 0.001 0.021 (-0.171, 0.213) 0.830 
60-64 (n = 1287) 0.286 (0.202, 0.370) <0.001 0.276 (0.189, 0.362) <0.001 0.173 (0.084, 0.263) <0.001 - - 
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Table 7.2f. Regression coefficients, 95% confidence intervals and p values estimating the effect of body mass index at different ages on 
ejection fraction at age 60-64y. Models adjusted for age, sex and clinic attended. Subsequent adjustments made for systolic blood pressure 
and presence of type 2 diabetes mellitus at age 60-64y, left ventricular mass indexed to body surface area and body mass index at age 60-
64y. 
 
SBP- Systolic blood pressure; T2DM – Type 2 diabetes mellitus, LVMI - Left ventricular mass indexed to body surface area; BMI - Body mass index 
 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + BMI at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1123) -0.16 (-0.38, 0.05) 0.137 -0.15 (-0.37, 0.06) 0.163 -0.19 (-0.41, 0.04) 0.100 -0.18 (-0.43, 0.06) 0.142 
26 (n=1194) -0.23 (-0.43, -0.04) 0.017 -0.23 (-0.42, -0.03) 0.023 -0.24 (-0.44, -0.05) 0.016 -0.34 (-0.58, -0.10) 0.005 
36 (n = 1224) -0.09 (-0.25, 0.07) 0.279 -0.06 (-0.23, 0.10) 0.450 -0.09 (-0.26, 0.08) 0.304 -0.10 (-0.34, 0.14) 0.396 
43 (n = 1279) -0.07 (-0.21, 0.07) 0.355 -0.05 (-0.19, 0.10) 0.505 -0.08 (-0.23, 0.07) 0.274 -0.07 (-0.30, 0.17) 0.585 
53 (n = 1293) -0.04 (-0.16, 0.08) 0.516 -0.02 (-0.14, 0.10) 0.769 -0.03 (-0.16, 0.09) 0.627 0.07 (-0.19, 0.32) 0.599 
60-64 (n = 1343) -0.05 (-0.16, 0.06) 0.418 -0.04 (-0.15, 0.08) 0.517 -0.05 (-0.17, 0.06) 0.371 - - 
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Table 7.2g. Regression coefficients, 95% confidence intervals and p values estimating the effect of body mass index at different ages on s’ at 
age 60-64y. Models adjusted for age, sex and clinic attended. Subsequent adjustments made for systolic blood pressure and presence of 
type 2 diabetes mellitus at age 60-64y, left ventricular mass indexed to body surface area and body mass index at age 60-64y. 
 
SBP- Systolic blood pressure; T2DM – Type 2 diabetes mellitus, LVMI - Left ventricular mass indexed to body surface area; BMI - Body mass index 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + BMI at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1156) 0.019 (-0.017, 0.054) 0.300 0.019 (-0.017, 0.055) 0.308 0.021 (-0.016, 0.058) 0.261 0.015 (-0.026, 0.056) 0.482 
26 (n=1223) 0.023 (-0.009, 0.054) 0.154 0.025 (-0.0073, 0.0571) 0.129 0.031 (-0.0023, 0.0646) 0.068 0.031 (-0.008, 0.071) 0.123 
36 (n = 1260) 0.208 (-0.006, 0.048) 0.131 0.023 (-0.0046, 0.0514) 0.101 0.022 (-0.0069, 0.0511) 0.136 0.0064 (-0.034, 0.047) 0.759 
43 (n = 1307) 0.025 (0.002, 0.048) 0.032 0.029 (0.0053, 0.0529) 0.017 0.028 (0.0031, 0.0529) 0.028 0.038 (-0.0021, 0.0779) 0.063 
53 (n = 1324) 0.017 (-0.003, 0.036) 0.089 0.021 (0.0008, 0.0408) 0.042 0.019 (-0.002, 0.040) 0.083 0.022 (-0.021, 0.064) 0.325 
60-64 (n = 1383) 0.010 (-0.008, 0.028) 0.280 0.013 (-0.0053, 0.0317) 0.162 0.012 (-0.0070, 0.0320) 0.210 - - 
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The effect of overweight (BMI>=25 kg/m2) at different ages on cardiac function is presented 
in Tables 7.3a-3g.  
Overweight from the age of 26y onwards was associated with increased E/e’ i.e. worse 
diastolic function in a minimally adjusted model (Table 7.3a); this remained the case when 
SBP and T2DM at age 60-64y were included and the association held from the age of 36y 
onwards when LVMI was included in the model. There was a minor attenuation in effect with 
each successive adjustment. When overweight at age 60-64y was included in the models 
there was further attenuation of the effects and only overweight at 43y was associated with 
increased E/e’.  
 
The associations between overweight and E/A were qualitatively similar to that between 
overweight and E/e’. The only difference was that in the final model, when overweight at 60-
64y was included, only overweight at 53y remained associated with decreased E/A. 
Overweight at 43y was marginally non-significant in the final model (Table 7.3b). 
 
Overweight from the age of 36y onwards was associated decreased e’ i.e. poorer diastolic 
function in a minimally adjusted model (Table 7.3c); this was also the case when SBP and 
T2DM at age 60-64y and LVMI were included with minimal changes in effect sizes with these 
adjustments. In a fully adjusted model including overweight at 60-64y, only overweight at 43y 
was associated with e’ with a near-halving of effect size. 
The association between overweight and e’/a’ (Table 7.3d) mirrored that between overweight 
and e’.  
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In a minimally adjusted model, overweight from 20y onwards was associated with increased 
LAVI (Table 7.3e); this was also the case on inclusion of SBP and T2DM at age 60-64y. When 
LVMI was included, there was some attenuation of the effect and the associations held from 
age 26y onwards. In a fully-adjusted model, there was further attenuation of the effect and 
only overweight at age 43y remained associated with increased LAVI.  
 
Overweight at ages 26y and 36y was associated with decreased EF i.e. worse systolic function 
in a minimally adjusted model (Table 7.3f). These associations remained on further 
adjustments [except when SBP and T2DM at age 60-64y were added into the overweight at 
age 26y model where it was borderline non-significant (p = 0.05)].  
 
Overweight at different ages was not associated with s’ (Table 7.3g). The associations with 
overweight at age 43y came the closest to significance (positive association i.e. better systolic 
function). 
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Table 7.3a. Regression coefficients, 95% confidence intervals and p values estimating the effect of overweight  at different ages on E/e’ at 
age 60-64y. Models adjusted for age, sex and clinic attended. Subsequent adjustments made for systolic blood pressure and presence of 
type 2 diabetes mellitus at age 60-64y, left ventricular mass indexed to body surface area and overweight  at age 60-64y. 
 
SBP- Systolic blood pressure; T2DM – Type 2 diabetes mellitus, LVMI - Left ventricular mass indexed to body surface area 
 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + overweight at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1085) 0.325 (-0.054, 0.705) 0.093 0.286 (-0.088, 0.659) 0.133 0.217 (-0.178, 0.613) 0.281 0.085 (-0.313, 0.482) 0.675 
26 (n=1168) 0.523 (0.201, 0.844) 0.001 0.409 (0.090, 0.729) 0.012 0.267 (-0.075, 0.609) 0.126 0.117 (-0.231, 0.466) 0.508 
36 (n = 1218) 0.474 (0.219, 0.729) <0.001 0.353 (0.098, 0.609) 0.007 0.315 (0.046, 0.583) 0.022 0.169 (-0.113, 0.451) 0.241 
43 (n = 1286) 0.587 (0.362, 0.813) <0.001 0.456 (0.230, 0.681) <0.001 0.492 (0.253, 0.730) <0.001 0.312 (0.050, 0.575) 0.020 
53 (n = 1309) 0.491 (0.259, 0.723) <0.001 0.350 (0.119, 0.581) 0.003 0.261 (0.020, 0.502) 0.034 -0.087 (-0.388, 0.215) 0.573 
60-64 (n = 1362) 0.887 (0.655, 1.119) <0.001 0.710 (0.476, 0.943) <0.001 0.603 (0.357, 0.849) <0.001 - - 
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Table 7.3b. Regression coefficients, 95% confidence intervals and p values estimating the effect of overweight at different ages on E/A at 
age 60-64y. Models adjusted for age, sex and clinic attended. Subsequent adjustments made for systolic blood pressure and presence of 
type 2 diabetes mellitus at age 60-64y, left ventricular mass indexed to body surface area and overweight at age 60-64y. 
 
SBP- Systolic blood pressure; T2DM – Type 2 diabetes mellitus, LVMI - Left ventricular mass indexed to body surface area 
 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 +  overweight at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1143) -0.049 (-0.099, 0.001) 0.056 -0.049 (-0.099, 0.001) 0.055 -0.058 (-0.1112, -0.0041) 0.035 -0.037 (-0.091, 0.017) 0.179 
26 (n=1233) -0.051 (-0.093, -0.008) 0.019 -0.051 (-0.093, -0.008) 0.020 -0.046 (-0.093, 0.001) 0.053 -0.019 (-0.066, 0.028) 0.430 
36 (n = 1288) -0.061 (-0.094, -0.027) <0.001 -0.058 (-0.093, -0.024) 0.001 -0.056 (-0.093, -0.020) 0.003 -0.028 (-0.067, 0.010) 0.148 
43 (n = 1361) -0.078 (-0.108, -0.048) <0.001 -0.076 (-0.107, -0.045) <0.001 -0.067 (-0.100, -0.034) <0.001 -0.035 (-0.071, 0.001) 0.058 
53 (n = 1385) -0.086 (-0.117, -0.055) <0.001 -0.081 (-0.112, -0.050) <0.001 -0.084 (-0.117, -0.051) <0.001 -0.046 (-0.087, -0.004) 0.031 
60-64 
 (n = 1439) 
-0.101 (-0.132, -0.070) <0.001 -0.095 (-0.126, -0.063) <0.001 -0.093 (-0.127, -0.059) <0.001 - - 
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Table 7.3c. Regression coefficients, 95% confidence intervals and p values estimating the effect of overweight at different ages on e’ at age 
60-64y. Models adjusted for age, sex and clinic attended. Subsequent adjustments made for systolic blood pressure and presence of type 2 
diabetes mellitus at age 60-64y, left ventricular mass indexed to body surface area and overweight at age 60-64y. 
 
SBP- Systolic blood pressure; T2DM – Type 2 diabetes mellitus, LVMI - Left ventricular mass indexed to body surface area 
 
 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 +  overweight at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1114) -0.220 (-0.560, 0.120) 0.204 -0.229 (0.568, 0.109) 0.184 -0.190 (-0.548, 0.168) 0.297 -0.076 (-0.436, 0.284) 0.678 
26 (n=1201) -0.170 (-0.461, 0.120) 0.251 -0.142 (-0.435, 0.151) 0.341 -0.085 (-0.398, 0.228) 0.593 0.056 (-0.262, 0.374) 0.729 
36 (n = 1251) -0.383 (-0.614, -0.153) 0.001 -0.349 (-0.581, -0.116) 0.003 -0.326 (-0.572, -0.080) 0.009 -0.191 (-0.449, 0.067) 0.147 
43 (n = 1321) -0.461 (-0.667, -0.255) <0.001 -0.428 (-0.636, -0.220) <0.001 -0.438 (-0.659, -0.218) <0.001 -0.261 (-0.504, -0.018) 0.036 
53 (n = 1346) -0.482 (-0.692, -0.271) <0.001 -0.420 (-0.632, -0.208) <0.001 -0.364 (-0.586, -0.141) <0.001 -0.093 (-0.372, 0.186) 0.514 
60-64 
 (n = 1401) 
-0.714 (-0.926, -0.503) <0.001 -0.629 (-0.844, -0.414) <0.001 -0.560 (-0.788, -0.333) <0.001 - - 
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Table 7.3d. Regression coefficients, 95% confidence intervals and p values estimating the effect of overweight at different ages on e’/a’ at 
age 60-64y. Models adjusted for age, sex and clinic attended. Subsequent adjustments made for systolic blood pressure and presence of 
type 2 diabetes mellitus at age 60-64y, left ventricular mass indexed to body surface area and overweight at age 60-64y. 
 
SBP- Systolic blood pressure; T2DM – Type 2 diabetes mellitus, LVMI - Left ventricular mass indexed to body surface area 
 
 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + overweight at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1095) -0.031 (-0.073, 0.010) 0.136 -0.031 (-0.072, 0.009) 0.131 -0.032 (-0.075, 0.012) 0.154 -0.011 (-0.055, 0.032) 0.612 
26 (n=1180) -0.028 (-0.064, 0.007) 0.120 -0.023 (-0.059, 0.128) 0.209 -0.018 (-0.057, 0.020) 0.349 0.0062 (-0.033, 0.045) 0.753 
36 (n = 1232) -0.054 (-0.083, -0.026) <0.001 -0.048 (-0.076, -0.019) 0.001 -0.051 (-0.081, -0.021) 0.001 -0.026 (-0.058, 0.005) 0.103 
43 (n = 1300) -0.074 (-0.099, -0.049) <0.001 -0.068 (-0.093, -0.043) <0.001 -0.070 (-0.097, -0.043) <0.001 -0.040 (-0.070, -0.011) 0.008 
53 (n = 1324) -0.081 (-0.107, -0.056) <0.001 -0.072 (-0.098, -0.047) <0.001 -0.073 (-0.100, -0.046) <0.001 -0.031 (-0.065, 0.0033) 0.076 
60-64 
 (n = 1378) 
-0.104 (-0.130, -0.079) <0.001 -0.093 (-0.119, -0.067) <0.001 -0.092 (-0.120, -0.064) <0.001 - - 
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Table 7.3e. Regression coefficients, 95% confidence intervals and p values estimating the effect of overweight at different ages on left atrial 
volume indexed to body surface area at age 60-64y. Models adjusted for age, sex and clinic attended. Subsequent adjustments made for 
systolic blood pressure and presence of type 2 diabetes mellitus at age 60-64y, left ventricular mass indexed to body surface area and 
overweight at age 60-64y. 
 
SBP- Systolic blood pressure; T2DM – Type 2 diabetes mellitus, LVMI - Left ventricular mass indexed to body surface area 
 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 +  overweight at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1019) 1.938 (0.677, 3.198) 0.003 1.900 (0.637, 3.162) 0.003 1.246 (-0.051, 2.543) 0.060 0.807 (-0.503, 2.116) 0.227 
26 (n=1097) 2.619 (1.522, 3.717) <0.001 2.601 (1.488, 3.714) <0.001 1.493 (0.331, 2.655) 0.012 1.073 (-0.112, 2.259) 0.076 
36 (n = 1147) 2.421 (1.528, 3.314) <0.001 2.285 (1.377, 3.193) <0.001 1.392 (0.459, 2.325) 0.003 0.928 (-0.057, 1.914) 0.065 
43 (n = 1208) 2.514 (1.728, 3.300) <0.001 2.407 (1.603, 3.210) <0.001 1.552 (0.729, 2.375) <0.001 1.087 (0.181, 1.993) 0.019 
53 (n = 1235) 2.430 (1.627, 3.232) <0.001 2.340 (1.526, 3.155) <0.001 1.606 (0.775, 2.437) <0.001 0.883 (-0.160, 1.927) 0.097 
60-64  
(n = 1283) 
2.823 (2.001, 3.645) <0.001 2.738 (1.898, 3.578) <0.001 1.803 (0.940, 2.667) <0.001 - - 
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Table 7.3f. Regression coefficients, 95% confidence intervals and p values estimating the effect of overweight at different ages on ejection 
fraction at age 60-64y. Models adjusted for age, sex and clinic attended. Subsequent adjustments made for systolic blood pressure and 
presence of type 2 diabetes mellitus at age 60-64y, left ventricular mass indexed to body surface area and overweight at age 60-64y. 
 
SBP- Systolic blood pressure; T2DM – Type 2 diabetes mellitus, LVMI - Left ventricular mass indexed to body surface area 
 
 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 +  overweight at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1060) -0.057 (-1.820, 1.707) 0.950 0.0078 (-1.769, 1.785) 0.993 -0.0046 (-1.8028, 1.7937) 0.996 -0.140 (-1.969, 1.689) 0.881 
26 (n=1147) -1.602 (-3.126, -0.077) 0.040 -1.540 (-3.082, 0.002) 0.050 -1.568 (-3.125, -0.011) 0.048 -1.879 (-3.476, -0.283) 0.021 
36 (n = 1192) -1.575 (-2.789, -0.361) 0.011 -1.401 (-2.633, -0.169) 0.026 -1.524 (-2.770, -0.277) 0.017 -1.963 (-3.276, -0.649) 0.003 
43 (n = 1266) -0.335 (-1.414, 0.744) 0.543 -0.276 (-1.375, 0.822) 0.622 -0.451 (-1.568, 0.667) 0.429 -0.779 (-2.015, 0.457) 0.216 
53 (n = 1291) -0.277 (-1.364, 0.811) 0.618 -0.118 (-1.219, 0.984) 0.834 -0.168 (-1.287, 0.951) 0.768 -0.846 (-2.262, 0.571) 0.242 
60-64 (n = 1339) 0.525 (-0.586, 1.636) 0.354 0.562 (-0.576, 1.699) 0.333 0.483 (-0.678, 1.644) 0.414 - - 
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Table 7.3g. Regression coefficients, 95% confidence intervals and p values estimating the effect of overweight at different ages on s’ at age 
60-64y. Models adjusted for age, sex and clinic attended. Subsequent adjustments made for systolic blood pressure and presence of type 2 
diabetes mellitus at age 60-64y, left ventricular mass indexed to body surface area and overweight at age 60-64y. 
 
SBP- Systolic blood pressure; T2DM – Type 2 diabetes mellitus, LVMI - Left ventricular mass indexed to body surface area 
 
 
 
 
 
Age (years) Model 1 
(age sex, clinic) 
 
Model 2 
(Model 1 + SBP and T2DM at 60-64y) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 +  overweight at 60-64y) 
 β (95%CI) p value β (95%CI) p value β (95%CI) p value β (95%CI) p value 
20 (n=1094) 0.019 (-0.273, 0.311) 0.897 0.024 (-0.270, 0.318) 0.874 0.046 (-0.259, 0.352) 0.767 0.052 (-0.258, 0.362) 0.741 
26 (n=1176) -0.023 (-0.271, 0.225) 0.855 -0.021 (-0.275, 0.232) 0.870 0.047 (-0.221, 0.316) 0.730 0.061 (-0.214, 0.335) 0.664 
36 (n = 1230) -0.035 (-0.233, 0.163) 0.729 -0.021 (-0.223, 0.181) 0.841 0.006 (-0.205, 0.217) 0.956 -0.005 (-0.228, 0.217) 0.964 
43 (n = 1297) 0.149 (-0.026, 0.324) 0.095 0.175 (-0.005, 0.354) 0.056 0.138 (-0.049, 0.326) 0.148 0.195 (-0.014, 0.403) 0.067 
53 (n = 1322) 0.092 (-0.087, 0.271) 0.312 0.119 (-0.063, 0.302) 0.199 0.097 (-0.092, 0.285) 0.315 0.160 (-0.079, 0.400) 0.189 
60-64  
(n = 1378) 
-0.067 (-0.249, 0.114) 0.467 -0.038 (-0.224, 0.148) 0.690 -0.054 (-0.248, 0.139) 0.581 - - 
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There was an overall significant linear trend of increase in E/e’ (i.e. implying worse diastolic 
function) with earlier age at first overweight (Table 7.4a, Figure 7.1a). The test for deviation 
from linear trend was non-significant (p = 0.3757).This was maintained when SBP, T2DM and 
LVMI at age 60-64y were included in the model with some attenuation of effect at each round 
of adjustment. When BMI at 60-64y was included in the model, regression coefficients for 
each of the ages became negative (i.e. indicating better diastolic function). However, the 
overall test for linear trend was non–significant.  
 
There was an overall significant linear trend of decreased E/A (i.e. implying worse diastolic 
function) with earlier age at first overweight in all models (Table 7.4b, Figure 7.1b). The test 
for deviation from linear trend was significant (p = 0.0145).There was an attenuation of the 
trend when BMI at age 60-64y as included in the model but the trend remained.  
 
When the association between age at first overweight and e’ was investigated, there was an 
overall significant linear trend demonstrating greater decrease in e’ (i.e. implying worse 
diastolic function) the earlier age at first overweight, in the minimally adjusted model (Table 
7.4c, Figure 7.1c). The test for deviation from linear trend was significant (p = 0.0374).The 
linear trend remained on inclusion of SBP, T2DM and LVMI at age 60-64y. The trend was 
substantially attenuated and became non-significant when BMI at 60-64y was included. The 
coefficient at age 26y became positive (i.e. implying better diastolic function) although it was 
non-significant.  
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There was an overall significant linear trend of decrease in e’/a’ (i.e. implying worse diastolic 
function) with earlier age at first overweight (Table 7.4d, Figure 7.1d). The test for deviation 
from linear trend was significant (p = 0.0002). This was maintained when SBP, T2DM and LVMI 
at age 60-64y were included in the model. The coefficients were attenuated when BMI at 60-
64y was included in the model and the overall linear trend became non-significant.  
 
There was an overall significant linear trend of increase in LAVI with earlier age at first 
overweight (Table 7.4e, Figure 7.1e). The test for deviation from linear trend was non-
significant (p = 0.0924). This was maintained when SBP, T2DM and LVMI at age 60-64y were 
included in the model. There was only a small change in the regression coefficients when BMI 
at age 60-64y was included and the overall linear trend just became non-significant.  
 
There was no significant overall linear trend between EF and age at first overweight in any of 
the models (Table 7.4f, Figure 7.1f). The test for deviation from linear trend was non-
significant (p = 0.5422). The regression coefficient for age at first overweight at 43y was 
significant on adjusting for SBP and T2DM at age 60-64y and when LVMI was included in the 
model, but was non-significant in the minimally and fully adjusted models. The test for 
deviation from linear trend was non-significant (p = 0.1919). Similarly, there was no 
relationship between s’ and age at first overweight (Table 7.4g, Figure 7.1g).  
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Table 7.4a. Regression coefficients, 95% confidence intervals and p values estimating the effect of age at first overweight on E/e’ at 60-64 
years in men and women. 
SBP - Systolic blood pressure; T2DM - Type 2 Diabetes mellitus; LVMI - Left ventricular mass indexed to body surface area; BMI - Body mass index 
 
 
 
 
Age at first 
diagnosis of 
being 
overweight 
(years) 
Model 1 
(age sex, clinic) 
Model 2 
(Model 1 + SBP at 60-64y + T2DM) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + BMI at 60-64y) 
 
 
Β (95%CI) p value 
for 
overall 
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
20 0.965 (0.369, 1.562)  
 
 
<0.001 
0.828 (0.224, 1.432)  
 
 
<0.001 
0.573 (-0.059, 1.205)  
 
 
0.002 
-0.650 (-1.540, 0.239)  
 
 
0.387 
26 1.288 (0.647, 1.930) 1.065 (0.400, 1.730) 0.826 (0.116, 1.535) -0.286 (-1.193, 0.622) 
36 1.008 (0.496, 1.519) 0.839 (0.318, 1.360) 0.796 (0.259, 1.333) -0.081 (-0.779, 0.618) 
43 0.792 (0.124, 1.025) 0.639 (0.139, 1.140) 0.581 (0.065, 1.096) -0.060 (-0.668, 0.548) 
53 0.575 (0.124, 1.025) 0.466 (0.008, 0.923) 0.234 (-0.234, 0.702) -0.237 (-0.761, 0.286) 
60-64 0.444 (-0.139, 1.027) 0.351 (-0.233, 0.936) 0.213 (-0.394, 0.820) -0.143 (-0.771, 0.485) 
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Figure 7.1a. Estimated marginal means in men and women of E/e’ for different ages at first overweight and for never overweight for model 
1 (above). 
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Table 7.4b. Regression coefficients, 95% confidence intervals and p values estimating the effect of duration of age at first diagnosis of being 
persistently overweight on E/A at 60-64 years in men and women. 
SBP - Systolic blood pressure; T2DM - Type 2 Diabetes mellitus; LVMI - Left ventricular mass indexed to body surface area; BMI - Body mass index 
 
 
Age at first 
diagnosis of 
being 
overweight 
(years) 
Model 1 
(age sex, clinic) 
Model 2 
(Model 1 + SBP at 60-64y + T2DM) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + BMI at 60-64y) 
 
 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall 
linear  
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
20 -0.194 (-0.273, -0.115)  
 
 
<0.001 
-0.188 (-0.268, -0.109)  
 
 
<0.001 
-0.181 (-0.267, 0.095)  
 
 
<0.001 
-0.170 (-0.295, -0.046)  
 
 
0.020 
26 -0.123 (-0.208, -0.039) -0.115 (-0.203, -0.028) -0.117 (-0.215, -0.018) -0.108 (-0.235, 0.019) 
36 -0.150 (-0.218, -0.083) -0.141 (-0.210, -0.072) -0.126 (-0.200, -0.052) -0.119 (-0.216, -0.021) 
43 -0.162 (-0.228, -0.096) -0.149 (-0.216, -0.083) -0.136 (-0.208, -0.064) -0.131 (-0.217, -0.045) 
53 -0.116 (-0.176, -0.056) -0.104 (-0.165, 0.043) -0.094 (-0.159, -0.030) -0.090 (-0.164, -0.017) 
60-64 -0.088 (-0.165, -0.010) -0.077 (-0.154, 0.001) -0.057 (-0.141, 0.026) -0.054 (-0.142, 0.033) 
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Figure 7.1b. Estimated marginal means in men and women of E/A for different ages at first overweight and for never overweight for model 
1 (above). 
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Table 7.4c. Regression coefficients, 95% confidence intervals and p values estimating the effect of duration of age at first diagnosis of being 
persistently overweight on e’ at 60-64 years in men and women. 
SBP - Systolic blood pressure; T2DM - Type 2 Diabetes mellitus; LVMI - Left ventricular mass indexed to body surface area; BMI - Body mass index 
 
 
 
Age at first 
diagnosis of 
being 
overweight 
(years) 
Model 1 
(age sex, clinic) 
Model 2 
(Model 1 + SBP at 60-64y + T2DM) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + BMI at 60-64y) 
 
 
β (95%CI) p value 
for 
overall 
linear  
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall 
linear  
trend 
β (95%CI) p value 
for 
overall 
linear  
trend 
20 -0.745 (-1.264, 0.226)  
 
 
<0.001 
-0.710 (-1.237, -0.183)  
 
 
0.001 
-0.377 (-0.917, 0.163)  
 
 
0.005 
-0.115 (-0.906, 0.677)  
 
 
0.843 
 
 
26 -0.635 (-1.206, -0.064) -0.579 (-1.170, 0.012) -0.406 (-1.040, 0.228) 0.043 (-0.772, 0.859) 
36 -0.977 (-1.427, -0.526) -0.898 (-1.357, -0.440) -0.877 (-1.354, -0.401) -0.524 (-1.149, 0.101) 
43 -0.755 (-1.189, -0.321) -0.661 (-1.103, -0.176) -0.639 (-1.098, -0.181) -0.383 (-0.926, 0.161) 
53 -0.672 (-1.070, -0.275) -0.580 (-0.983, -0.176) -0.435 (-0.849, -0.021) -0.245 (-0.712, 0.222) 
60-64 -0.485 (-1.000, 0.030) -0.407 (-0.923, 0.110) -0.377 (-0.017, 0.163) -0.234 (-0.797, 0.329) 
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Figure 7.1c. Estimated marginal means in men and women of e’ for different ages at first overweight and for never overweight for model 1 
(above). 
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Table 7.4d. Regression coefficients, 95% confidence intervals and p values estimating the effect of duration of age at first diagnosis of being 
persistently overweight on e’/a’ at 60-64 years in men and women. 
SBP - Systolic blood pressure; T2DM - Type 2 Diabetes mellitus; LVMI - Left ventricular mass indexed to body surface area; BMI - Body mass index 
 
 
 
Age at first 
diagnosis of 
being 
overweight 
(years) 
Model 1 
(age sex, clinic) 
Model 2 
(Model 1 + SBP at 60-64y + T2DM†) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + BMI at 60-64y) 
 
 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
20 -0.135 (-0.198, -0.073)  
 
 
<0.001 
-0.124 (-0.187, -0.061)  
 
 
<0.001 
-0.125 (-0.193, -0.058)  
 
 
<0.001 
-0.059 (-0.155, 0.038)  
 
 
0.416 
26 -0.082 (-0.151, -0.013) -0.062 (-0.133, 0.009) -0.064 (-0.143, 0.014) -0.004 (-0.105, 0.096) 
36 -0.162 (-0.216, -0.107) -0.146 (-0.201, -0.090) -0.156 (-0.215, -0.097) -0.109 (-0.185, -0.032) 
43 -0.135 (-0.187, -0.083) -0.117 (-0.170, -0.064) -0.124 (-0.180, -0.068) -0.090 (-0.156, -0.023) 
53 -0.101 (-0.149, -0.052) -0.084 (-0.132, -0.035) -0.083 (-0.134, -0.032) -0.057 (-0.1145, 0.0001) 
60-64 -0.087 (-0.150, -0.025) -0.075 (-0.137, -0.012) -0.075 (-0.142, 0.009) -0.056 (-0.126, 0.013) 
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Figure 7.1d. Estimated marginal means in men and women of e’/a’ for different ages at first overweight and for never overweight for model 
1 (above). 
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Table 7.4e. Regression coefficients, 95% confidence intervals and p values estimating the effect of duration of age at first diagnosis of being 
persistently overweight on left atrial volume indexed to body surface area at 60-64 years in men and women. 
SBP - Systolic blood pressure; T2DM - Type 2 Diabetes mellitus; LVMI - Left ventricular mass indexed to body surface area; BMI - Body mass index index 
 
 
 
Age at first 
diagnosis of 
being 
overweight 
(years) 
Model 1 
(age sex, clinic) 
Model 2 
(Model 1 + SBP at 60-64y + T2DM) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + BMI at 60-64y) 
 β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
20 5.458 (3.556, 7.361)  
 
 
<0.001 
5.485 (3.553, 7.417)  
 
 
<0.001 
3.625 (1.622, 5.627)  
 
 
<0.001 
3.703 (0.755, 6.651)  
 
 
0.070 
26 4.965 (2.857, 7.073) 4.944 (2.753, 7.135) 2.434 (0.104, 4.764) 2.504 (-0.529, 5.538) 
36 4.127 (2.412, 5.842) 4.087 (2.330, 5.845) 2.865 (1.083, 4.648) 2.921 (0.564, 5.278) 
43 3.317 (1.647, 4.987) 3.375 (1.663, 5.087) 2.282 (0.537, 4.028) 2.323 (0.244, 4.402) 
53 2.189 (0.706, 3.671) 2.284 (0.776, 3.791) 1.450 (-0.072, 2.971) 1.481 (-0.271, 3.232) 
60-64 2.917 (1.028, 4.806) 3.005 (1.106, 4.905) 2.346 (0.395, 4.297) 2.369 (0.311, 4.428) 
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Figure 7.1e. Estimated marginal means in men and women of left atrial volume indexed to body surface area (ml/m2) for different ages at 
first overweight and for never overweight for model 1 (above). 
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Table 7.4f. Regression coefficients (% Ejection Fraction), 95% confidence intervals and p values estimating the effect of age at first diagnosis 
of being persistently overweight on Ejection Fraction at 60-64 years in men and women. 
SBP - Systolic blood pressure; T2DM - Type 2 Diabetes mellitus; LVMI - Left ventricular mass indexed to body surface area; BMI - Body mass index 
Age at first 
diagnosis of 
being 
overweight 
(years) 
Model 1 
(age sex, clinic) 
Model 2 
(Model 1 + SBP at 60-64y + T2DM) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + BMI at 60-64y) 
 
 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
20 -1.290 (-4.049, 1.470)  
 
 
0.344 
-1.142 (-3.967, 1.682)  
 
 
0.416 
-1.051 (-3.909, 1.806)  
 
 
0.394 
-2.122 (-6.302, 2.057)  
 
 
0.152 
26 -0.128 (-3.259, 3.003) 0.119 (-3.120, 3.357) 0.264 (-3.023, 3.551) -0.694 (-4.966, 3.578) 
36 -0.081 (-2.472, 2.309) 0.109 (-2.351, 2.570) -0.095 (-2.608, 2.418) -0.852 (-4.163, 2.459) 
43 2.287 (-0.045, 4.619) 2.484 (0.090, 4.877) 2.575 (0.136, 5.014) 2.020 (-0.887, 4.927) 
53 1.103 (-0.997, 3.204) 1.294 (-0.852, 3.440) 1.442 (-0.733, 3.617) 1.019 (-1.468, 3.506) 
60-64 1.762 (-1.030, 4.553) 1.862 (-0.956, 4.679) 1.904 (-0.926, 4.733) 1.593 (-1.373, 4.559) 
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Figure 7.1f. Estimated marginal means in men and women of ejection fraction (%) for different ages at first overweight and for never 
overweight for model 1 (above). 
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Table 7.4g. Regression coefficients, 95% confidence intervals and p values estimating the effect of duration of age at first diagnosis of being 
persistently overweight on s’ at 60-64 years in men and women. 
SBP - Systolic blood pressure; T2DM - Type 2 Diabetes mellitus; LVMI - Left ventricular mass indexed to body surface area; BMI - Body mass index 
 
 
 
 
Age at first 
diagnosis of 
being 
overweight 
(years) 
Model 1 
(age sex, clinic) 
Model 2 
(Model 1 + SBP at 60-64y + T2DM) 
Model 3 
(Model 2 + LVMI) 
Model 4 
(Model 3 + BMI at 60-64y) 
 
 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
β (95%CI) p value 
for 
overall  
linear 
trend 
20 0.218 (-0.249, 0.684)  
 
 
0.313 
0.230 (-0.247, 0.707)  
 
 
0.281 
0.200 (-0.291, 0.691)  
 
 
0.261 
-0.009 (-0.713, 0.695)  
 
 
0.833 
26 0.001 (-0.519, 0.521) 0.023 (-0.523, 0.570) 0.228 (-0.359, 0.815) 0.043 (-0.697, 0.782) 
36 -0.008 (-0.411, 0.395) 0.008 (-0.404, 0.421) 0.060 (-0.360, 0.481) -0.086 (-0.636, 0.464) 
43 0.347 (-0.041, 0.734) 0.352 (-0.045, 0.749) 0.266 (-0.138, 0.669) 0.158 (-0.321, 0.638) 
53 0.030 (-0.326, 0.387) 0.025 (-0.340, 0.389) 0.071 (-0.295, 0.438) -0.007 (-0.420, 0.406) 
60-64 -0.111 (-0.571, 0.349) -0.111 (-0.575, 0.353) -0.047 (-0.522, 0.428) -0.107 (-0.603, 0.390) 
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Figure 7.1g. Estimated marginal means in men and women of s’ for different ages at first overweight and for never overweight for model 1 
(above). 
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Discussion 
We found that previous BMI/overweight and earlier age at first overweight were all 
associated with poorer subsequent diastolic function. However the relationships were 
complex and varied. Increased BMI from the twenties onwards was associated with diastolic 
dysfunction at age 60-64y. On adding in BMI at 60-64y, the association reversed and for ages 
20y and 26y increased BMI was associated with poorer diastolic function (when measured in 
terms of E/e’ and e’/a’). Overweight from the age of 26y (E/e’ and E/A) or 36y onwards (e’ 
and e’/a’) was associated with poorer diastolic function at 60-64y. In fully adjusted models, 
overweight at 43y (E/e’, e’/a’ and e’) and overweight at 53y (E/A) were associated with 
decreased diastolic function. On examining the effect of age at first overweight, we found 
that earlier age at first overweight was associated with worse diastolic function (E/e’, E/A, e’ 
and e’/a’). When BMI at age 60-64y was included, the overall linear trend remained significant 
for E/A only.  
When the effects of BMI/overweight on LAVI were examined it was found that increased BMI 
and overweight from age 20y onwards were associated with increased LAVI in minimally 
adjusted models. Earlier age at first overweight was associated with increased LAVI in 
preliminary models.  
  
When systolic function was examined it was found that increased BMI at age 26y was 
associated with poorer EF in fully adjusted models, while increased BMI at age 43y was 
associated with higher s’ in preliminary models. Only EF had associations with overweight, 
with overweight at ages 26y and 36y associated with poorer systolic function on full 
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adjustment. Overall, associations between age at first overweight and EF or s’ did not reach 
significance. 
 
The trends of becoming overweight and obesity have reached epidemic proportions and are 
occurring at all ages including childhood and young adulthood.20-23 Once weight is gained and 
individuals become overweight, it is very difficult to permanently return to a normal weight.24  
Therefore, determining the implications of long-term overweight on cardiac structure is 
important.  
In the literature to date, there has been a focus on the cardiac effects of morbid obesity,25, 26 
and on those awaiting surgical interventions for morbid obesity, with post-gastroplasty 
weight loss being associated with better diastolic function.17 However the effect of morbid 
obesity on LVM may not be the same as that of being slightly overweight. We have moved 
the focus away from morbid obesity in our work to look at the effects of unit increases in BMI 
and of the effect of being overweight (BMI >= 25 Kg/m2). Our work tallies with cross sectional 
work showing that increased BMI is associated with diastolic dysfunction27 and also agrees 
with work done by Arnlov et al who showed that greater BMI at an earlier age can predict 
worse diastolic function at a later age (at 50y and 70y respectively in his cohort).28  
It was interesting to note that when BMI at 60-64y was added to models looking at the 
predictive power of earlier BMI on future diastolic function, greater BMI in the twenties 
seemed to be associated with a “protective” effect on future diastolic function. A similar 
reversal of association to a “protective” effect was also seen when BMI at age 60-64y was 
added to the age at first overweight-E/e’ model, although this association was non-significant. 
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Reasons for these observations are speculative but it may be that this reversal of effect occurs 
because those with higher BMIs in their twenties have greater muscle mass rather than fat 
mass and that increased lean body mass is protective. Another explanation could be that the 
period between 20y-64y is a sensitive period for the relationship between BMI and diastolic 
function with change in BMI over this period being the determining factor on future diastolic 
function i.e. for a given BMI at age 20y, greater subsequent weight gain is associated with 
increased diastolic dysfunction. Of course, a third possible explanation is that this is an over-
adjustment in the statistical models.  
When BMI at age 60-64y was included in the age at first overweight models, the linear trend 
to worse diastolic function with earlier age at first overweight only remained for E/A. It is 
difficult to explain why this is, especially in light of the pseudonormalization issues known to 
be a problem with E/A. It is possible that BMI at age 60-64y may play a defining role in cardiac 
haemodynamics and accounting for it may allow E/A to reflect true diastolic function status. 
It may however also be the case, that including BMI at age 60-64y is an over-adjustment for 
the E/A models or it may be a chance finding. Another explanation could be that non-linear 
trends exist for the other measures in the final models, especially for those measures where 
the deviation from linear trend was significant.  
Overall, when final adjustments were made by including BMI or overweight at 60-64y to the 
models, the associations at earlier ages in most cases became non-significant. This is likely to 
be due to tracking of BMI (and hence also of overweight) in the NSHD cohort31 with individuals 
who had higher BMI in early adulthood having higher BMI throughout the 44y period of 
measurement [Table 7.5; initially shown in BMI-structure chapter (chapter 6), reprinted 
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below]. BMI at age 60-64y may be able to “capture” the previous BMI history and is thus 
significant in these models at the cost of previous BMI levels. 
 
Table 7.5. Correlation between mean body mass indexes (combined for both sexes) at 
different ages. 
 BMI at 
60-64y 
BMI at 
53y 
BMI at 
43y 
BMI at 
36y  
BMI at 
26y  
BMI at 
20y 
BMI at 60-64y 1.0000      
BMI at 53y 0.8607 1.0000     
BMI at 43y 0.7819 0.8530 1.0000    
BMI at 36y 0.7033 0.7680 0.8481 1.0000   
BMI at 26y 0.5475 0.6194 0.6924 0.7453 1.0000  
BMI at 20y 0.4461 0.5015 0.5727 0.6387 0.7781 1.0000 
                                                    
BMI – body mass index 
 
 
It is therefore very difficult to separate effects of age at first overweight and current BMI (at 
age 60-64y). To be better able to answer this question, we would need to study general 
patterns of overweight across the life course including more trajectories where individuals 
are overweight in early life and become normal weight by 60-64 years. However, in the 
Medical Research Council National Survey of Health and Development, few people lost 
weight and or reduced weight categories i.e. from obese to overweight and overweight to 
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normal weight and previous analyses in our cohort have shown that such analyses lack 
power.31  
 
The few studies that have attempted to quantify the effects of duration of obesity 
(increased duration of obesity associated with decreased EF but not with tissue Doppler 
markers of systolic or diastolic function) have included small numbers and have been based 
on recalled weights and hence the risk factor is prone to recall bias.16, 18 While there has 
been inconsistent evidence in the literature on whether duration of obesity affects cardiac 
function,19 our work shows that earlier age at first overweight is associated with poorer 
diastolic function but not with systolic function.  
 
An important finding was that all the relations between BMI, overweight and age at first 
overweight all held on the inclusion of LVMI. This indicates that the deleterious effects of 
increased BMI and being overweight on future diastolic function were independent of 
diastolic dysfunction caused by a BMI-associated increase in LVMI described in earlier 
chapters.  
While we showed consistent associations with diastolic function, BMI, overweight and age 
at first overweight were not consistently related to systolic function. This is in keeping with 
most recent work on the topic,18, 19 although not so much with older work.16, 17 
Mechanistically, being overweight is more likely to affect cardiac haemodynamics through 
volume expansion, hypertension and increased cardiac output, alterations which in turn 
lead to diastolic rather than systolic dysfunction.32-34   However, what was interesting to note 
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was that increased BMI and overweight at age 26y were both associated with worse EF in all 
models, including those with BMI/overweight at age 60-64y. It is difficult to say why BMI 
and overweight, at only age 26y, have this association – it may be a sensitive period – more 
work is needed to answer this.  
Increased BMI at age 43y was associated with increased s’ (i.e. better systolic function) in 
preliminary models and of all the overweight-s’ models, those relating to overweight at age 
43y were the closest to being significant. These results may indicate that BMI and 
overweight at age 43y is a sensitive period for s’. However, unlike EF, the s’ associations 
indicate better systolic function with increased BMI. This may be an artefact or it may 
indicate that overall systolic function should not be estimated on the basis of one measure. 
Another explanation could be that the change in s’ indicates a subtle change in long axis 
function (possibly an initial compensatory increase in systolic contractility) which cannot be 
captured by EF. It is also worth noting that the associations between EF and BMI/overweight 
at age 26y were not repeated for s’; this may reflect that BMI/overweight affect radial and 
longitudinal systolic contraction differently.  
 
Strengths and limitations 
Generalization to the UK population and the issue of missing data have been discussed in 
previous chapters. Strengths and limitations with regard to anthropometry and diastolic 
function measures have been discussed previously in the BMI-structure chapter (chapter 6) 
and in the methods chapter (chapter 3).  
289 | P a g e  
 
Echocardiography was only carried out in the last round of data collection. As such, with no 
baseline echocardiography, the possibility of diastolic dysfunction being a pre-existing 
diagnosis cannot be excluded. Reverse causality (prior diastolic dysfunction causing 
decreasing exercise capacity and increased BMI and overweight in the future) cannot be 
excluded. 
  
 
Conclusions 
Higher BMI and overweight from the age of 20y onwards is associated with poorer diastolic 
function at age 60-64y. The earlier the age at first overweight, the worse diastolic function is 
at age 60-64y. Current BMI/overweight accounts for most of the effects of previous 
BMI/overweight history on future diastolic function, although whether the effects of excess 
adiposity are reversible cannot be addressed by these data. Nevertheless these findings are 
consistent with an emphasis on weight reduction as early as possible in adult life to prevent 
a future deterioration in diastolic function. 
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Chapter 8 
Conclusion 
 
In this thesis I have investigated the role of adult blood pressure (BP) and body mass index 
(BMI) histories over 28y and 44y periods of adult life respectively on cardiac structure and 
function at age 60-64y. I have shown that previous measures of BP provide additional 
information above and beyond current BP levels, for BMI the significance of earlier measures 
of BMI independent of current BMI is less clear cut but it is evident that earlier adiposity is 
associated with more adverse LV mass and diastolic function. I provide evidence that sensitive 
periods may exist when the impact of these RFs on cardiac structure and function is 
particularly marked and that rate of change in BP in midlife may adversely affect left 
ventricular (LV) mass (LVM) in later life. I have also shown that anti-hypertensive treatment 
(HTT) at various ages is associated with detrimental effects on cardiac structure, and function 
after accounting for differences in BP; I interpret that as probably reflecting a legacy effect of 
irreversible damage due to exposures occurring prior to the initiation of HTT.  
In this chapter I will synthesize some of the common questions and themes that have arisen 
in the previous chapters. I will also comment on possible areas of future research. 
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An important finding in this work was that previous measures of BMI and BP were associated 
with current cardiac structure and function. While serial adjustments often attenuated, and 
by implication may therefore partially explain the effect of previous measures, previous high 
BP and elevated BMI were associated with adverse cardiac structure and function, even when 
additional RFs e.g.  type 2 diabetes mellitus (T2DM) were included in the model.  If elevated 
current RFs levels are taken to be representative of earlier elevated RFs levels these findings 
could be interpreted as providing support for earlier intervention to prevent later cardiac 
changes occurring. This cannot be definitively proved in the context of our study (i.e. it is not 
a randomized clinical trial looking at intervention), but at least for BP, our data suggest the 
timing of intervention during a sensitive period may be crucial given HTT was not associated 
with normalization of cardiac structure or function.  
Overall, the similarity of the patterns of associations between BP and BMI at earlier ages and 
cardiac structure and function in the minimally adjusted models (increases in BP/BMI 
associated with detriments to cardiac structure and function) was striking. Studies examining 
epigenetic modifications and modification of cardiac myocyte structure and cardiac fibrosis 
might be informative on this issue. 
 
Further research 
Some areas of future research have already been highlighted earlier in this chapter and in the 
analysis chapters. Other areas of possible future research will be discussed in this section. 
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While we do not have BP measures prior to age 36y, we do have earlier BMI measures 
including anthropometric measures taken at birth. Investigating the influence of birth weight 
and childhood growth on these echocardiographic outcomes is an area for future research.  
Electrocardiograms (ECGs) were recorded on study members during the last round of data 
collection and at immediately prior visits. We could correlate our echocardiographic LV 
hypertrophy (LVH) findings with electrocardiographically diagnosed LVH and also attempt to 
address the possibility of reverse causality using ECG-defined LVH at early time points. It 
would also be of interest to elucidate life course determinants of ECG-diagnosed LVH and its 
progression.  
Pulse wave analysis, pulse wave velocity and carotid intima media thickness measures were 
also collected in the last round of data collection. These findings can be correlated with the 
echocardiographic findings to determine the role of central as opposed to brachial BP in cross-
sectional analyses, and also to obtain a broader picture of the effect of adult life course RF 
history on the cardiovascular system as a whole.  
Investigating the effect of duration of type 2 diabetes mellitus and incorporating measures of 
physical activity, diet and other measures of systolic function [as described in the methods 
chapter (chapter 3)] are planned to be carried out in the future. 
 
Implications of the findings 
Our findings demonstrate the importance of knowing previous BP and BMI histories and rate 
of change in BP even within the “normal” BP range. Developing a life course risk assessment 
approach for patients would be the logical extrapolation of our work. This would raise the 
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possibility of screening from very young ages allied to intervention in asymptomatic people. 
Both these measures would be controversial from the cost and risk-benefit points of view. 
Certain questions would need to be answered. We would need to qualify what is a 
“dangerous” or significant rise in the echocardiographic outcome measure and use that to 
determine what would constitute a “dangerous” rise in longitudinal BP or BMI measures. We 
would also need to determine how frequently patients would need to be screened (especially 
those who are asymptomatic and with “normal” BP and BMI levels) to pick up “dangerous” 
rises in RF levels. Ultimately, we would need to relate life course RF measurements to hard 
cardiovascular end points (e.g. death, myocardial infarction, stroke and heart failure). A 
comparison of current risk assessment practice against a life course approach to risk 
determination using a randomised clinical trial (RCT) is required. However, achieving hard end 
points in a randomised clinical trial would be difficult with a life course methodology, as by 
definition, “life course” covers a substantial period of time. Softer end points, which are 
independently associated with cardiovascular morbidity and mortality (such as those we have 
used e.g. LVH and E/e’) may need to be used to enable a shorter length of study. It would be 
possible to carry out an RCT using life course methodology if the study population were 
elderly and had detailed past medical records. However, the older the participants, the less 
the likelihood of availability of detailed records from early life. 
A variety of other measures of physical function (grip strength, balance tests, bone 
densitometry etc.), mental health (cognitive function tests etc.), genetics (telomere length 
measurement), lung function and a variety of blood tests (kidney function, coagulation, 
hormone levels) have been assessed in the last round of data collection, with some of these 
tests having also been conducted in previous rounds. Integrating our findings with the results 
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of these other tests will give an in-depth and broad-spanning picture of life course 
determinants of both healthy and unhealthy ageing and help to identify possible common 
aetiological/mechanistic pathways and targets of correctly-timed intervention. 
Future rounds of research where we look again at the cardiac structure and function of study 
members would be warranted. Harder end-points (as discussed above) would be more 
prevalent and would, for example, allow a better understanding of the seriousness of having 
a fast rising BP at a young age.  
 
Our work has provided a number of interesting new findings and using a similar approach to 
other RFs and echocardiographic outcomes in our study will provide further information 
about the life course effects of RFs on cardiac structure and function. The more widespread 
the adoption of the life course approach in Cardiology, the better understanding we will get 
of earlier-life risk factors and how to intervene more effectively at an earlier stage of disease.  
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